0001437749-24-010119.txt : 20240329 0001437749-24-010119.hdr.sgml : 20240329 20240329171757 ACCESSION NUMBER: 0001437749-24-010119 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FITLIFE BRANDS, INC. CENTRAL INDEX KEY: 0001374328 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41803 FILM NUMBER: 24804831 BUSINESS ADDRESS: STREET 1: 5214 S. 136TH STREET CITY: OMAHA STATE: NE ZIP: 68137 BUSINESS PHONE: 402-884-1894 MAIL ADDRESS: STREET 1: 5214 S. 136TH STREET CITY: OMAHA STATE: NE ZIP: 68137 FORMER COMPANY: FORMER CONFORMED NAME: BOND LABORATORIES, INC. DATE OF NAME CHANGE: 20060831 10-K 1 ftlf20231231_10k.htm FORM 10-K ftlf20231231_10k.htm
0001374328 FITLIFE BRANDS, INC. false --12-31 FY 2023 false false false false 17 50 162 107 113 71 0.01 0.01 10,000 10,000 0 0 0.01 0.01 60,000 60,000 4,598 4,598 4,507 4,507 1 1 3 2 1 1 42 8.21 8.21 0 0.70 11.55 5 3 5 5 0 0 00013743282023-01-012023-12-31 iso4217:USD 00013743282023-06-30 xbrli:shares 00013743282024-03-28 thunderdome:item 00013743282023-12-31 00013743282022-12-31 0001374328ftlf:TermLoansMember2023-12-31 0001374328ftlf:TermLoansMember2022-12-31 iso4217:USDxbrli:shares 00013743282022-01-012022-12-31 0001374328ftlf:CommonStockOutstandingMember2022-12-31 0001374328us-gaap:CommonStockMember2022-12-31 0001374328us-gaap:TreasuryStockCommonMember2022-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001374328us-gaap:RetainedEarningsMember2022-12-31 0001374328us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2022-12-31 0001374328ftlf:CommonStockOutstandingMember2023-01-012023-12-31 0001374328us-gaap:CommonStockMember2023-01-012023-12-31 0001374328us-gaap:TreasuryStockCommonMember2023-01-012023-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-31 0001374328us-gaap:RetainedEarningsMember2023-01-012023-12-31 0001374328us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-01-012023-12-31 0001374328ftlf:CommonStockOutstandingMember2023-12-31 0001374328us-gaap:CommonStockMember2023-12-31 0001374328us-gaap:TreasuryStockCommonMember2023-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001374328us-gaap:RetainedEarningsMember2023-12-31 0001374328us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-12-31 0001374328ftlf:CommonStockOutstandingMember2021-12-31 0001374328us-gaap:CommonStockMember2021-12-31 0001374328us-gaap:TreasuryStockCommonMember2021-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001374328us-gaap:RetainedEarningsMember2021-12-31 0001374328us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2021-12-31 00013743282021-12-31 0001374328ftlf:CommonStockOutstandingMember2022-01-012022-12-31 0001374328us-gaap:CommonStockMember2022-01-012022-12-31 0001374328us-gaap:TreasuryStockCommonMember2022-01-012022-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0001374328us-gaap:RetainedEarningsMember2022-01-012022-12-31 0001374328us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2022-01-012022-12-31 0001374328ftlf:MimisRockCorpMember2023-01-012023-12-31 0001374328ftlf:MimisRockCorpMember2022-01-012022-12-31 0001374328ftlf:AssetsOfMusclepharmCorporationMember2023-01-012023-12-31 0001374328ftlf:AssetsOfMusclepharmCorporationMember2022-01-012022-12-31 xbrli:pure 0001374328ftlf:IsatoriProductsMembersrt:MinimumMember2023-12-31 0001374328us-gaap:SeriesAPreferredStockMember2023-12-31 0001374328ftlf:MimisRockCorpMember2022-12-042022-12-04 0001374328ftlf:MimisRockCorpMemberftlf:TermLoanAMember2022-12-042022-12-04 0001374328ftlf:MimisRockCorpMemberus-gaap:CashMember2022-12-042022-12-04 0001374328ftlf:AssetsOfMusclepharmCorporationMember2023-10-102023-10-10 0001374328ftlf:AssetsOfMusclepharmCorporationMemberftlf:TermLoanBMember2023-10-102023-10-10 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:OnlineSalesMember2023-01-012023-12-31 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:OnlineSalesMember2022-01-012022-12-31 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-01-012023-12-31 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberftlf:GNCMember2023-01-012023-12-31 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberftlf:GNCMember2022-01-012022-12-31 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:GNCMember2023-01-012023-12-31 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:GNCMember2022-01-012022-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:OneVendorMember2023-01-012023-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:OneVendorMember2022-01-012022-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:ThreeVendorsMember2023-01-012023-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2023-01-012023-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2023-01-012023-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorThreeMember2023-01-012023-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:TwoVendorsMember2022-01-012022-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2022-01-012022-12-31 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2022-01-012022-12-31 0001374328srt:MaximumMember2023-12-31 utr:Y 0001374328us-gaap:FurnitureAndFixturesMember2023-12-31 0001374328us-gaap:OfficeEquipmentMember2023-12-31 0001374328us-gaap:LeaseholdImprovementsMember2023-12-31 0001374328us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0001374328us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0001374328ftlf:BrandsMember2023-12-31 0001374328us-gaap:CustomerRelationshipsMember2023-12-31 0001374328ftlf:FormulationsMember2023-12-31 0001374328us-gaap:TrademarksMember2023-12-31 0001374328ftlf:WebsiteMember2023-12-31 0001374328us-gaap:CustomerRelationshipsMember2022-12-31 0001374328ftlf:FormulationsMember2022-12-31 0001374328us-gaap:TrademarksMember2022-12-31 0001374328ftlf:WebsiteMember2022-12-31 0001374328ftlf:ApproximationMember2022-12-31 0001374328ftlf:TermLoanAMember2023-12-31 0001374328ftlf:TermLoanAMember2022-12-31 0001374328ftlf:TermLoanBMember2023-12-31 0001374328ftlf:TermLoanBMember2022-12-31 0001374328ftlf:TermLoanAMember2023-02-23 0001374328us-gaap:RevolvingCreditFacilityMember2023-02-23 0001374328ftlf:TermLoanBMember2023-10-10 0001374328us-gaap:RevolvingCreditFacilityMember2023-10-10 0001374328ftlf:TermLoansMemberftlf:ApplicableRateMember2023-10-102023-10-10 0001374328ftlf:TermLoansMember2023-10-10 0001374328us-gaap:RevolvingCreditFacilityMember2023-12-31 0001374328us-gaap:RevolvingCreditFacilityMember2022-12-31 00013743282021-02-012021-02-28 0001374328us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2023-01-012023-12-31 0001374328us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2022-01-012022-12-31 0001374328us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2023-12-31 0001374328us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2022-12-31 0001374328ftlf:ShareRepurchaseProgramMember2019-11-06 0001374328ftlf:ShareRepurchaseProgramMember2019-11-062019-11-06 0001374328ftlf:ShareRepurchaseProgramMember2019-09-23 0001374328ftlf:ShareRepurchaseProgramMember2019-09-232019-09-23 0001374328ftlf:ShareRepurchaseProgramMember2019-10-06 0001374328ftlf:ShareRepurchaseProgramMember2019-10-062019-10-06 0001374328ftlf:ShareRepurchaseProgramMember2023-03-17 utr:M 0001374328ftlf:ShareRepurchaseProgramMember2023-03-172023-03-17 0001374328ftlf:ShareRepurchaseProgramMember2023-12-31 0001374328ftlf:ShareRepurchaseProgramMember2023-01-012023-12-31 00013743282021-01-012021-12-31 0001374328ftlf:RangeOneMember2023-01-012023-12-31 0001374328ftlf:RangeOneMember2023-12-31 0001374328ftlf:RangeTwoMember2023-01-012023-12-31 0001374328ftlf:RangeTwoMember2023-12-31 0001374328us-gaap:EmployeeStockOptionMember2023-12-31 0001374328us-gaap:EmployeeStockOptionMember2023-08-012023-08-31 0001374328us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-08-012023-08-31 0001374328us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0001374328us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0001374328us-gaap:EmployeeStockOptionMember2022-12-31 0001374328ftlf:MimisRockCorpMember2023-02-28 0001374328ftlf:MimisRockCorpMember2023-02-282023-12-31 0001374328ftlf:MimisRockCorpMember2023-04-282023-12-31 0001374328ftlf:AssetsOfMusclepharmCorporationMemberftlf:BrandsMember2023-10-102023-10-10 0001374328ftlf:AssetsOfMusclepharmCorporationMember2023-10-10 0001374328us-gaap:DomesticCountryMember2023-01-012023-12-31 0001374328us-gaap:DomesticCountryMember2022-01-012022-12-31 0001374328us-gaap:ForeignCountryMember2023-01-012023-12-31 0001374328us-gaap:ForeignCountryMember2022-01-012022-12-31 0001374328ftlf:ApproximationMember2023-01-012023-12-31 0001374328ftlf:ApproximationMember2022-01-012022-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2034Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2034Member2023-12-31 0001374328ftlf:TaxYear2034Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2035Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2035Member2023-12-31 0001374328ftlf:TaxYear2035Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2036Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2036Member2023-12-31 0001374328ftlf:TaxYear2036Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2037Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2037Member2023-12-31 0001374328ftlf:TaxYear2037Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2038Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2038Member2023-12-31 0001374328ftlf:TaxYear2038Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2039Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2039Member2023-12-31 0001374328ftlf:TaxYear2039Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2040Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2040Member2023-12-31 0001374328ftlf:TaxYear2040Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2041Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2041Member2023-12-31 0001374328ftlf:TaxYear2041Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2042Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2042Member2023-12-31 0001374328ftlf:TaxYear2042Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:TaxYear2043Member2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:TaxYear2043Member2023-12-31 0001374328ftlf:TaxYear2043Member2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberftlf:IndefiniteMember2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMemberftlf:IndefiniteMember2023-12-31 0001374328ftlf:IndefiniteMember2023-12-31 0001374328us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2023-12-31 0001374328us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMember2023-12-31 0001374328ftlf:TermLoanMemberus-gaap:SubsequentEventMember2024-01-012024-03-22 0001374328ftlf:TermLoanAMemberus-gaap:SubsequentEventMember2024-01-012024-03-22
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended December 31, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number:  000-52369

 

FITLIFE BRANDS, INC.

(Exact name of Registrant as specified in its charter)

 

Nevada

20-3464383

(State of Incorporation)

(IRS Employer Identification No.)

 

5214 S. 136th Street, Omaha, NE 68137

(Address of principal executive offices)

 

(402) 991-5618

(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share

FTLF

The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Exchange Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☐  No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ☐  No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such a shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer

☐

Accelerated filer

☐

Non–Accelerated filer 

☒

Small reporting company

☒

  

Emerging growth company 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

☐ Yes ☒ No  

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No  

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter, was $32,319,000.

 

As of March 28, 2024, there were 4,598,241 shares of common stock, $0.01 par value per share, issued and outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 
 

 

 

FITLIFE BRANDS, INC.

FORM 10-K ANNUAL REPORT

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 AND 2022

TABLE OF CONTENTS

 

 

PAGE

PART I

 1
   

ITEM 1.

Business

 1

ITEM 1A.

Risk Factors

 7

ITEM 1B.

Unresolved Staff Comments

 13

ITEM 1C.

Cybersecurity

 13

ITEM 2.

Properties

 13

ITEM 3.

Legal Proceedings

 13

ITEM 4.

Mine Safety Disclosures

 13
     

PART II

  
   

ITEM 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 14

ITEM 6.

Selected Financial Data

 15

ITEM 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 16

ITEM 7A.

Quantitative and Qualitative Disclosures About Market Risk

 24

ITEM 8.

Consolidated Financial Statements and Supplementary Data

 24

ITEM 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 24

ITEM 9A.

Controls and Procedures

 24

ITEM 9B.

Other Information

 25
     

PART III

  
   

ITEM 10.

Directors, Executive Officers, and Corporate Governance

 26

ITEM 11.

Executive Compensation

 26

ITEM 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 26

ITEM 13.

Certain Relationships and Related Transactions, and Director Independence

 26

ITEM 14.

Principal Accountant Fees and Services

 26
     

PART IV

  
   

ITEM 15.

Exhibits and Financial Statement Schedules

 26

ITEM 16.

Form 10-K Summary

 28
     

SIGNATURES

 29
   

CERTIFICATIONS

  

Exhibit 31 – Certification pursuant to Rule 13a-14(a) and 15d-14(a)

  

Exhibit 32 – Certification pursuant to 18 U.S.C 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

  

 

 
 

 

 

Forward Looking Statements — Cautionary Language

 

This Annual Report on Form 10-K (the “Annual Report”) contains various “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding future events or the future financial performance of the Company that involve risks and uncertainties. Certain statements included herein, including, without limitation, statements related to anticipated cash flow sources and uses, and words including but not limited to “anticipates”, “believes”, “plans”, “expects”, “future” and similar statements or expressions, identify forward looking statements. Any forward-looking statements herein are subject to certain risks and uncertainties in the Company’s business, including but not limited to, reliance on key customers and competition in its markets, market demand, product performance, technological developments, maintenance of relationships with key suppliers, difficulties of hiring or retaining key personnel and any changes in current accounting rules, all of which may be beyond the control of the Company. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth herein.

 

This Annual Report, quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC include additional factors, which could impact FitLife Brands, Inc.’s business and financial performance. Moreover, FitLife Brands, Inc. operates in a rapidly changing and competitive environment. New risks emerge from time to time and it is not possible for management to predict all such risks. Further, it is not possible to assess the impact of all risks on FitLife Brands, Inc.’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, FitLife Brands, Inc. disclaims any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of the report.

 

Use of Market and Industry Data 

 

This Annual Report includes market and industry data that we have obtained from third-party sources, including industry publications, as well as industry data prepared by our management on the basis of its knowledge of and experience in the industries in which we operate (including our management’s estimates and assumptions relating to such industries based on that knowledge). Management has developed its knowledge of such industries through its experience and participation in these industries. While our management believes the third-party sources referred to in this Annual Report are reliable, neither we nor our management have independently verified any of the data from such sources referred to in this Annual Report or ascertained the underlying economic assumptions relied upon by such sources. Furthermore, references in this Annual Report to any publications, reports, surveys or articles prepared by third parties should not be construed as depicting the complete findings of the entire publication, report, survey or article. The information in any such publication, report, survey or article is not incorporated by reference in this Annual Report. 

 

Forecasts and other forward-looking information obtained from these sources involve risks and uncertainties and are subject to change based on various factors, including those discussed in sections entitled “Forward-Looking Statements,” “Item 1A. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report.

 

 
 
 

PART I

 

ITEM 1.  BUSINESS

 

FitLife Brands, Inc. (the “Company”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products"); and (iv) MusclePharm.

 

Overview

 

FitLife Brands, Inc. (the “Company”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products"); and (iv) MusclePharm.

 

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.  The Company distributes the MRC Products primarily online.  MusclePharm’s products are sold to wholesale customers as well as online directly to the end consumer.

 

FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the Nasdaq Capital Market.

 

Recent Developments

 

Acquisition of Mimi’s Rock Corp

 

On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire MRC. On February 28, 2023, the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was $17,099, of which $12,500 was funded using proceeds from a new term loan, and $4,599 from the Company’s available cash. See Note 8 to the financial statements for additional disclosure regarding the acquisition of MRC.

 

Acquisition of MusclePharm Assets

 

On October 10, 2023, the Company acquired substantially all of the assets of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed none of the liabilities of MusclePharm other than de minimus cure costs relating to certain assumed contracts.  Total consideration for the acquisition was approximately $18,500 cash.  Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note 9 for additional disclosure regarding the acquisition of MusclePharm.

 

Industry Overview

 

We compete principally in the nutrition industry. The nutrition industry is generally categorized into the following segments:

 

 

●

Natural & Organic Foods (products such as cereals, milk, non-dairy beverages and frozen meals);
   

 
 

●

Functional Foods (products with added ingredients or fortification specifically for health or performance purposes);
   

 
 

●

Natural & Organic Personal Care and Household Products; and
   

 
 

●

Supplements.

 

-1-
 

 

Management believes that the following factors drive growth in the nutrition industry:

 

 

●

The general public’s awareness and understanding of the connection between diet and health;
   

 
 

●

The aging population in the Company’s markets who tend to use more nutritional supplements as they age;
   

 
 

●

Increasing healthcare costs and the consequential trend toward preventative medicine and non-traditional medicines; and
   

 
 

●

Product introductions in response to new scientific studies.

 

Our Products

 

The Company currently focuses its sales and marketing efforts on its full line of sports, weight loss and general nutrition products that are currently marketed and sold both domestically and internationally. The Company currently markets more than 100 different NDS Products to more than 700 GNC franchise locations located in the United States, as well as to additional franchise locations in other countries, all of which are distributed through GNC’s distribution system. In addition, following the launch of Metis Nutrition, we distribute products through more than 1,500 corporate GNC stores in the United States. We sell iSatori Products through more than 17,000 specialty, mass, and online retail locations. We sell the MRC Products primarily on Amazon.com (“Amazon”).  We sell MusclePharm products online directly to the end consumer as well as to wholesale partners.

 

A complete product list is available on our website at fitlifebrands.com.

 

NDS Products

 

The Company’s NDS Products consist of the following brands:

 

 

●

NDS – Premium weight loss, sports nutrition, and general health products;
   

 
 

●

PMD – Premium sports nutrition products;
   

 
 

●

SirenLabs – Premium weight loss and sports nutrition products;
   

 
 

●

Nutrology – Sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients;
   

 
 

●

Metis Nutrition – Premium male health and weight loss products; and
     
  ● Core Active Nutrition – Value-oriented sports nutrition and weight loss products.

 

-2-
 

 

iSatori Products

 

The Company’s iSatori Products consist of the following brands:

 

 

●

Energize – Energy products designed to boost energy through a combination of time-released caffeine, vitamins, and herbal formulations;
     
 

●

iSatori – High-quality weight loss and sports nutrition products; and
     
 

●

BioGenetic Laboratories – Value-oriented weight loss and general health products.

 

MRC Products

 

The Company acquired MRC on February 28, 2023. MRC is a dietary supplement and wellness company which markets and sells its products primarily on Amazon.  The MRC products include the following brands:

 

 

●

Dr. Tobias – General health supplements;
     
 

●

All Natural Advice – Natural skincare and beauty products; and
     
 

●

Maritime Naturals – Natural skincare and beauty products.

 

Products sold under the All Natural Advice and Maritime Naturals brand names are registered with Health Canada and under the EU Cosmetics Act.

 

MusclePharm Products

 

The MusclePharm assets were acquired by the Company on October 10, 2023. MusclePharm is a scientifically driven, performance lifestyle brand that develops, markets and distributes 33 branded sports nutrition and general health products. MusclePharm products are sold to wholesale customers as well as online directly to the end consumer. We believe MusclePharm’s brand recognition attracts a large and engaged customer base consisting of athletes and other active individuals.

 

Manufacturing, Sourcing and Availability of Raw Materials

 

All of the Company’s products are manufactured by FDA-regulated contract manufacturers within the United States. Each contract manufacturer is required by the Company to abide by current Good Manufacturing Practices (“cGMPs”) to ensure quality and consistency, and to manufacture its products according to the Company’s strict specifications. Nearly all our contract manufacturers are certified through a governing body such as the Natural Products Association or NSF International. In most cases, contract manufacturers purchase the raw materials based on the Company’s specifications; however, from time to time, the Company will license particular raw material ingredients and supply its own source to the manufacturer. Once produced, in addition to in-house testing performed by the contract manufacturer, the Company may also perform independent analysis and testing. The contract manufacturer either ships the finished product to one of our fulfillment centers or directly to our customers. The Company has implemented vendor qualification programs for all of its suppliers and manufacturers, including analytical testing of purchased products. As part of the vendor program, the Company also periodically inspects vendors’ facilities to monitor quality control and assurance procedures.

 

Product Reformulations and New Product Identification

 

From time to time, we reformulate existing products to address market developments and trends, and to respond to customer requests. We also continually expand our product line through the development of new products. New product ideas are derived from a number of sources including trade publications, scientific and health journals, consultants, distributors, and other third parties. Prior to reformulating existing products or introducing new products, we investigate product formulations as they relate to regulatory compliance and other issues. We introduced a total of 18 new products during the year ended December 31, 2023, which included 6 completely new products and 12 product reformulations and flavor extensions, and we introduced a total of 10 new products during the year ended December 31, 2022, which included 3 completely new products and 7 product reformulations and flavor extensions.

 

Management continually assesses and analyzes developing market trends to detect and proactively address what they believe are areas of unmet or growing demand that represent an opportunity for the Company and, where deemed appropriate, attempts to introduce new products and/or packaging solutions in direct response to meet that demand.

 

-3-
 

 

Sales, Marketing and Distribution

 

NDS Products

 

NDS Products are sold through more than 700 GNC franchise locations located throughout the United States. The Company also distributes NDS Products to additional franchise locations in other countries. In 2014, the Company transitioned distribution of NDS Products to GNC’s centralized distribution platform. For the years ended December 31, 2023 and 2022, the majority of NDS Product sales were through GNC’s centralized distribution platform.

 

Our sales and marketing efforts are designed to expand sales of NDS Products to additional GNC franchise locations both domestically and internationally. In addition, we relaunched our Core Active brand as an online-exclusive brand. The GNC domestic franchise market remains a strong business and a critical component of our operations. Management is committed to continue to work collaboratively with GNC and its franchisees to build on our established track record of innovation and operational performance.

 

iSatori Products

 

iSatori Products are distributed directly to consumers through the Company's own websites and through other e-commerce platforms such as Amazon, as well as through the specialty, drug and mass-market distribution channels. iSatori products are currently sold in over 17,000 retail locations.

 

In some cases, iSatori utilizes independent brokers, who work in conjunction with iSatori’s sales employees and management to oversee the drug and mass-market channels. iSatori sells its products to mass-market merchandisers either directly or through distributors of nutritional supplement products. In addition to the Company’s online distribution channels for direct-to-consumer sales, major iSatori customers include CVS, Rite Aid, Vitamin Shoppe and Walgreens.

 

iSatori’s core strategy is to build and strengthen brands among consumers seeking nutritional supplement products with a reputation for quality and innovation. iSatori utilizes social media campaigns, coupons, and online advertising, plus cooperative and other incentive programs, to build consumer awareness and generate trial and repeat purchases. Our marketing team regularly reviews the media mix for its effectiveness in creating consumer demand and the highest return on investment dollars.

 

MRC Products and MusclePharm

 

MRC Products are distributed primarily on Amazon. MusclePharm’s products are distributed via wholesale customers as well as directly to end consumers through the Company’s own websites and through other e-commerce platforms, including Amazon.

 

Product Returns

 

We currently have a 30-day product return policy for NDS Products, which allows for a 100% sales price refund for the return of unopened and undamaged products purchased from us online through one of our websites. Product sold to GNC may be returned from corporate store shelves or the distribution center in the event the product is damaged, short dated, expired or recalled. GNC maintains a customer satisfaction program that allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC may require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, MRC Products and MusclePharm whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.

 

Competition

 

The nutrition industry is highly competitive, and the Company has many competitors that sell products similar to the Company’s products. Many of the Company’s competitors have significantly greater financial and human resources than our own. The Company seeks to differentiate its products and marketing from its competitors based on product quality, benefits, and functional ingredients. Patent and trademark applications that protect brands, product names, and new technologies are pursued whenever possible. While we cannot assure that such measures will block competitive products, we believe our continued emphasis on innovation and new product development targeted at the needs of the consumer will enable the Company to effectively compete in the marketplace.

 

-4-
 

 

Regulatory Matters

 

Our business is subject to varying degrees of regulation by a number of government authorities in the U.S., including the Federal Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), the Consumer Product Safety Commission, the U.S. Department of Agriculture, and the Environmental Protection Agency. Various agencies of the states and localities in which we operate and in which our products are sold also regulate our business, such as the California Department of Health Services, Food and Drug Branch. The areas of our business that these and other authorities regulate include, among others:

 

 

●

product claims and advertising;
   

 
 

●

product labels;
   

 
 

●

product ingredients; and
   

 
 

●

how we manufacture, package, distribute, import, export, sell, and store our products.

 

The FDA, in particular, regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of vitamins and other nutritional supplements in the U.S., while the FTC regulates marketing and advertising claims. In August 2007, a new rule issued by the FDA went into effect requiring companies that manufacture, package, label, distribute or hold nutritional supplements to meet cGMPs to ensure such products are of the quality specified and are properly packaged and labeled. We are committed to meeting or exceeding the standards set by the FDA and believe we are currently operating within the FDA mandated cGMPs.

 

The FDA also regulates the labeling and marketing of dietary supplements and nutritional products, including the following:

 

 

●

the identification of dietary supplements or nutritional products and their nutrition and ingredient labeling;
   

 
 

●

requirements related to the wording used for claims about nutrients, health claims, and statements of nutritional support;
   

 
 

●

labeling requirements for dietary supplements or nutritional products for which “high potency” and “antioxidant” claims are made;
   

 
 

●

notification procedures for statements on dietary supplements or nutritional products; and
   

 
 

●

premarket notification procedures for new dietary ingredients in nutritional supplements.

 

The Dietary Supplement Health and Education Act of 1994 (“DSHEA”) revised the provisions of the Federal Food, Drug and Cosmetic Act (“FDCA”) concerning the composition and labeling of dietary supplements, and defined dietary supplements to include vitamins, minerals, herbs, amino acids and other dietary substances used to supplement diets. DSHEA generally provides a regulatory framework to help ensure safe, quality dietary supplements and the dissemination of accurate information about such products. The FDA is generally prohibited from regulating active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cure or prevent an illness, disease or malady, trigger drug status.

 

DSHEA also permits statements of nutritional support to be included in labeling for nutritional supplements without FDA premarket approval. These statements must be submitted to the FDA within 30 days of marketing and must bear a label disclosure that includes the following: “This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.” These statements may describe a benefit related to a nutrient deficiency disease, the role of a nutrient or nutritional ingredient intended to affect the structure or function in humans, the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, or the general well-being from consumption of a nutrient or dietary ingredient, but may not expressly or implicitly represent that a nutritional supplement will diagnose, cure, mitigate, treat or prevent a disease. An entity that uses a statement of nutritional support in labeling must possess scientific evidence substantiating that the statement is truthful and not misleading. If the FDA determines that a particular statement of nutritional support is an unacceptable drug claim or an unauthorized version of a disease claim for a food product, or if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading, we will be prevented from using the claim. 

 

-5-
 

 

In addition, DSHEA provides that so-called “third-party literature”, for example a reprint of a peer-reviewed scientific publication linking a particular nutritional ingredient with health benefits, may be used in connection with the sale of a nutritional supplement to consumers without the literature being subject to regulation as labeling. Such literature must not be false or misleading; the literature may not promote a particular manufacturer or brand of nutritional supplement; the literature must present a balanced view of the available scientific information on the nutritional supplement; if displayed in an establishment, the literature must be physically separate from the nutritional supplement; and the literature may not have appended to it any information by sticker or any other method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating it with our products, and any dissemination could subject our products to regulatory action as an illegal drug. Moreover, any written or verbal representation by us that would associate a nutrient in a product that we sell with an effect on a disease will be deemed evidence of intent to sell the product as an unapproved new drug, a violation of the FDCA. 

 

In December 2006, the Dietary Supplement and Nonprescription Drug Consumer Protection Act (“DSNDCPA”) was passed, which further revised the provisions of the FDCA. Under the act, manufacturers, packers or distributors whose name appears on the product label of a dietary supplement or nonprescription drug are required to include contact information on the product label for consumers to use in reporting adverse events associated with the product’s use and are required to notify the FDA of any serious adverse event report within 15 business days of receiving such report. Events reported to the FDA would not be considered an admission from a company that its product caused or contributed to the reported event. We are committed to meeting or exceeding the requirements of the DSNDCPA.

 

We are also subject to a variety of other regulations in the U.S., including those relating to bioterrorism, taxes, labor and employment, import and export, the environment, and intellectual property. All of these regulations require significant financial and operational resources to ensure compliance, and we cannot assure that we will always be in compliance despite our best efforts to do so.

 

Our operations outside the U.S. are similarly regulated by various agencies and entities in the countries in which we operate and in which our products are sold. The regulations of these countries may conflict with those in the U.S. and may vary from country to country. The sale of our products in certain European countries is subject to the rules and regulations of the European Union, which may be interpreted differently among the countries within the European Union. In other markets outside the U.S., we may be required to obtain approvals, licenses or certifications from a country’s ministry of health or comparable agency before we begin operations or the marketing of products in that country. Approvals or licenses may be conditioned on the reformulation of our products for a particular market or may be unavailable for certain products or product ingredients. These regulations may limit our ability to enter certain markets outside the U.S. Similar to the costs of regulatory compliance in the U.S., foreign regulations require significant financial and operational resources to ensure compliance, and we cannot assure that we will always be in compliance despite our best efforts to do so. Our failure to maintain regulatory compliance within and outside the U.S. could impact our ability to sell our products, and thus, materially impact our financial position and results of operations.

 

Patents, Trademarks and Proprietary Rights

 

The Company regards intellectual property, including its trademarks, service marks, website URLs (domains) and other proprietary rights, as valuable assets and part of its brand equity. The Company believes that protecting such intellectual property is crucial to its business strategy. The Company pursues registration of the registrable trademarks, service marks and patents, associated with its key products in the United States, Canada, Europe and other places it distributes its products.

 

The Company formulates its products using proprietary ingredient formulations, flavorings and delivery systems. To further protect its product formulations and flavors, the Company may enter into agreements with manufacturers that provide exclusivity to certain products formulations and delivery technologies. When appropriate, the Company will seek to protect its research and development efforts by filing patent applications for proprietary product technologies or ingredient combinations. We have abandoned or not pursued efforts to register certain other patents and marks identifying other items in our product line for various reasons, including the inability of some names to qualify for registration or patent applications to qualify for patent protection, and due to our abandonment of certain such products. All trademark registrations are protected for a period of ten years and then are renewable thereafter if still in use.

 

Employees

 

We had 37 and 27 full-time employees as of December 31, 2023 and 2022, respectively. In addition, the Company utilizes consultants and temporary or part-time employees for certain services on an as-needed basis. We consider our employee relations to be good.

 

-6-
 

 

Cost of Compliance with Environmental Laws

 

We have not incurred any costs associated with compliance with environmental regulations, nor do we anticipate any future costs associated with environmental compliance; however, no assurances can be given that we will not incur such costs in the future.

 

Available Information

 

As a public company, we are required to file our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A and other information (including any amendments) with the Securities and Exchange Commission (the “SEC”). The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. You can find our SEC filings at the SEC’s website at www.sec.gov.

 

Our Internet address is www.fitlifebrands.com. Information contained on our website is not part of this Annual Report. Our SEC filings (including any amendments) will be made available free of charge on www.fitlifebrands.com, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

 

ITEM 1A - Risk Factors

 

An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report, before investing in our securities. If any of the events anticipated by the risks described below occur, our results of operations and financial condition could be adversely affected, which could result in a decline in the market price of our securities, causing you to lose all or part of your investment.

 

Risk Factors Relating to our Business and Industry

 

The Company was profitable during the years ended December 31, 2023 and 2022. However, we may not be able to achieve sustained profitability. Our failure to sustain profitability or effectively manage growth could result in net losses, and therefore negatively affect our financial condition.

 

In the event of any decrease in sales, if we are not able to maintain growth, or if we are unable to effectively manage our growth, we may not be able to sustain profitability, and may incur net losses in the future, and those net losses could be material.  In the event we incur net losses, our financial condition could be negatively affected, and such effect could be material.

 

We are currently dependent on sales to GNC for a substantial portion of our total sales.

 

Sales to GNC’s centralized distribution platform, including indirect distribution of product to domestic and international franchisees, accounted for approximately 33% and 67% of our total sales for the years ended December 31, 2023 and 2022, respectively. GNC’s franchisees are not required to carry our products. In the event GNC ceases purchasing products from us, or otherwise reduces its purchases, our total revenue will be negatively impacted, and such impact could be material. Moreover, the transition to GNC’s centralized distribution system had the effect of concentrating a significant portion of our accounts receivable with a single payor. Prior to the transition, we collected receivables from numerous franchisees. We anticipate that GNC will continue to represent a substantial portion of all accounts receivable for the foreseeable future. In the event that our sales to GNC decrease, our results from operations will be negatively affected, and such effect may be material. 

 

Our ability to materially increase sales is largely dependent on the ability to increase sales of product to our wholesale partners as well as directly to the end consumer. We may invest significant amounts in these expansions with little success, and if we are unable to maintain good relationships with our existing customers and e-commerce platforms, our business could suffer.

 

We currently are focusing our marketing efforts on increasing the sale of products to GNC, both domestically and internationally, as well as increasing the number of retailers selling MusclePharm products. In addition, we are focused on increasing our direct-to-consumer revenue through e-commerce platforms such as Amazon. We may not be able to successfully increase sales through these channels.  Moreover, unilateral decisions could be taken by our distributors, customers, or third-party e-commerce platforms such as Amazon, to discontinue all or any of our products that they are carrying or selling at any time, which would cause our business to suffer. The inability to sell our products through e-commerce platforms, including Amazon, would materially impact our sales and operating results.

 

-7-
 

 

In addition, although we continued efforts to expand international distribution for our products in the years ended December 31, 2023 and 2022, we cannot assure that any further efforts to sell our products outside the United States will result in material increased revenue. We may need to overcome significant regulatory and legal barriers in order to continue to sell our products internationally, and we cannot give assurances as to whether we will be able to comply with such regulatory or legal requirements.

 

We are affected by extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints, which can make compliance costly and subject us to enforcement actions by governmental agencies.

 

The formulation, manufacturing, packaging, labeling, holding, storage, distribution, advertising and sale of our products are affected by extensive laws, governmental regulations and policies, administrative determinations, court decisions and similar constraints at the federal, state and local levels, both within the United States and in any country where we conduct business. There can be no assurance that we or our wholesale partners will be in compliance with all of these regulations. A failure by us or our wholesale partners to comply with these laws and regulations could lead to governmental investigations, civil and criminal prosecutions, administrative hearings and court proceedings, civil and criminal penalties, injunctions against product sales or advertising, civil and criminal liability for the Company and/or its principals, bad publicity, and tort claims arising out of governmental or judicial findings of fact or conclusions of law adverse to the Company or its principals. In addition, the adoption of new regulations and policies or changes in the interpretations of existing regulations and policies may result in significant new compliance costs or discontinuation of product sales, and may adversely affect the marketing of our products, resulting in decreases in revenue.

 

We are currently dependent on a limited number of independent suppliers and manufacturers of our products, which may affect our ability to deliver our products in a timely manner. If we are not able to ensure timely product deliveries, potential distributors and customers may not order our products, and our revenue may decrease.

 

We rely on a limited number of third parties to supply and manufacture our products. Our products are manufactured on a purchase order basis only, and manufacturers can terminate their relationships with us at will. These third-party manufacturers may be unable to satisfy our supply requirements, manufacture our products on a timely basis, fill and ship our orders promptly, provide services at competitive costs, or offer reliable products and services. The failure to meet any of these critical needs would delay or reduce product shipment and adversely affect our revenue, as well as jeopardize our relationships with our distributors and customers. In the event any of our third-party manufacturers were to become unable or unwilling to continue to provide us with products in required volumes and at suitable quality levels, we would be required to identify and obtain acceptable replacement manufacturing sources. There is no assurance that we would be able to obtain alternative manufacturing sources on a timely basis. Additionally, our third-party manufacturers source the majority of the raw materials for our products and, if we were to use alternative manufacturers, we may not be able to duplicate the exact taste and consistency profile of the product from the original manufacturer. An extended interruption in the supply of our products would likely result in decreased product sales and a corresponding decline in revenue. We believe that we can meet our current supply and manufacturing requirements with our current suppliers and manufacturers or with available substitute suppliers and manufacturers.

 

COVID-19 impacted global supply chains and such impacts have impacted us and our third-party suppliers. Future outbreaks of COVID-19 or other illnesses could have a material adverse impact on us in the future.

 

The coronavirus (COVID-19) pandemic had a material impact on global supply chains, including for certain raw materials imported from China, among other countries, and this impacted our third-party suppliers and our wholesale partners.  As a result, we had to increase purchases of certain raw materials and build additional finished goods inventory, especially in our best-selling products, to avoid, in addition to other consequences, stockouts.  Although COVID-19 has largely abated, as well as the concomitant supply change challenges resulting from the pandemic, in the event of future outbreaks of COVID-19 or other illnesses, our operations and those of our third-party suppliers or our wholesale partners could be adversely affected.

 

Uncertain or unfavorable economic conditions, including during periods of high inflation, recessions or other economic disruption, or as a result of the COVID-19 pandemic, could limit consumer and customer demand for our products, increase our costs or otherwise adversely affect us. 

 

-8-
 

 

The willingness of consumers to purchase our products depends in part on general or local economic conditions and consumers’ discretionary spending habits. For instance, in 2022, the U.S. experienced significantly heightened inflationary pressures which continued into 2023. In periods of adverse or uncertain economic conditions, including during periods of high inflation or recession concerns, or as a result of the COVID-19 pandemic, consumers may purchase less of our products, purchase more value or private label products or may forgo certain purchases altogether. In addition, our customers may seek to reduce their inventories in response to those economic conditions. In those circumstances, we could experience a reduction in sales. Further, during economic downturns, it may be more difficult to convince consumers to switch to, or continue to use, our brands or convince new users to choose our brands without expensive sampling programs and price promotions. Also, as a result of economic conditions, we may be unable to raise our prices sufficiently to protect profit margins. We experienced inflationary headwinds across our business during 2022 and 2023, and such inflationary pressures may not abate in 2024. This trend could have a materially adverse impact in the future if inflation rates were to significantly exceed our ability to achieve price increases or cost savings. Further, uncertain or unfavorable economic conditions have and could continue to negatively impact the financial stability of our customers or suppliers, which could lead to increased uncollectible receivables or non-performance. Current global geopolitical tensions, including related to Ukraine and Israel, may exacerbate any economic downturn and inflation. Any of these events could have an adverse effect on our business, financial condition, results of operations and cash flows.

 

We are dependent on our third-party manufacturers to supply our products in the compositions we require, and we do not independently analyze each production lot of our products. Any errors in our product manufacturing could result in product recalls, significant legal exposure, and reduced revenue.

 

Although we require that our manufacturers verify the accuracy of the contents of our products, we do not have the expertise or personnel to monitor the production of products by these third parties. We rely primarily, with limited independent verification, on certificates of analysis regarding product content provided by our third-party suppliers and limited safety testing by them. We cannot be assured that these outside manufacturers will continue to reliably supply products to us in the compositions we require. Errors in the manufacture of our products could result in product recalls, significant legal exposure, adverse publicity, and decreased revenue.

 

We face significant competition from existing suppliers of products similar to ours. If we are not able to compete with these companies effectively, we may not be able to maintain profitability.

 

We face intense competition from numerous resellers, manufacturers and wholesalers of nutritional supplements similar to ours, including retail, online and mail-order providers. Many of our competitors have longer operating histories, more-established brands in the marketplace, greater financial resources and better access to capital than we have. We anticipate that these competitors may use their resources to engage in various business activities that could result in reduced sales of our products. Companies with greater capital and research capabilities could re-formulate existing products or formulate new products that could gain wide marketplace acceptance, which could have a negative effect on our future sales. In addition, aggressive advertising and promotion by our competitors may require us to compete by lowering prices or by increasing our marketing expenditures, and the economic viability of our operations likely would be diminished.

 

Adverse publicity associated with our products, ingredients, or those of similar companies, could adversely affect our sales and revenue.

 

Our customers’ perception of the safety and quality of our products or similar products distributed by others can be significantly influenced by national media attention, publicized scientific research or findings, product liability claims, and other publicity concerning our products or similar products distributed by others. Adverse publicity, whether or not accurate, that associates consumption of our products or any similar products with illness or other adverse effects will likely diminish the public’s perception of our products. Claims that any products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could have a material adverse effect on the market demand for our products, including reducing our revenue.

 

The efficacy of nutritional supplement products is supported by limited conclusive clinical studies, which could result in reduced market acceptance of these products and lower revenue or lower revenue growth rates.

 

Our nutritional supplement products are made from various ingredients, including vitamins, minerals, amino acids, herbs, botanicals, fruits, berries, and other substances for which there is a long history of human consumption. However, there is little long-term experience with human consumption of certain product ingredients or combinations of ingredients in concentrated form. Although we believe that all of our products fall within the generally known safe limits for daily doses of each ingredient contained within them, nutrition science is imperfect. Moreover, some people have peculiar sensitivities or reactions to nutrients commonly found in certain foods and may have similar sensitivities or reactions to nutrients contained in our products. Furthermore, nutrition science is subject to change based on new research. New scientific evidence may disprove the efficacy of our products or prove our products to have effects not previously known. We could be adversely affected by studies that may assert that our products are ineffective or harmful to consumers, or if adverse effects are associated with a competitor’s similar products.

 

-9-
 

 

Our products may not meet health and safety standards or could become contaminated.

 

We do not have control over the third parties involved in the manufacturing of our products and their compliance with government health and safety standards. Even if our products meet these standards, they could otherwise become contaminated. A failure to meet these standards or contamination could occur in our operations or those of our distributors or suppliers. This could result in expensive production interruptions, recalls and liability claims. Moreover, negative publicity could be generated from false, unfounded or nominal liability claims or limited recalls. Any of these failures or occurrences could negatively affect our business and financial performance.

 

The sale of our products involves product liability and related risks that could expose us to significant insurance and loss expense.

 

We face an inherent risk of exposure to product liability claims if the use of our products results in, or is believed to have resulted in, illness or injury. Most of our products contain combinations of ingredients, and there is little long-term experience with the effect of these combinations. In addition, interactions of these products with other products, prescription medicines and over-the-counter drugs have not been fully explored or understood and may have unintended consequences. Although our third-party manufacturers perform tests in connection with the formulations of our products, these tests are not designed to evaluate the inherent safety of our products.

 

Although we maintain product liability insurance, it may not be sufficient to cover all product liability claims, and any claims that may arise could have a material adverse effect on our business. The successful assertion or settlement of an uninsured claim, a significant number of insured claims or a claim exceeding the limits of our insurance coverage would harm us by adding further costs to our business and by diverting the attention of our senior management from the operation of our business. Even if we successfully defend a liability claim, the uninsured litigation costs and adverse publicity may be harmful to our business.

 

Any product liability claim may increase our costs and adversely affect our revenue and operating income. Moreover, liability claims arising from a serious adverse event may increase our costs through higher insurance premiums and deductibles and may make it more difficult to secure adequate insurance coverage in the future. In addition, our product liability insurance may fail to cover future product liability claims, which, if adversely determined, could subject us to substantial monetary damages.

 

If the products we sell do not have the healthful effects intended, our business may suffer.

 

In general, our products sold consist of nutritional supplements that are classified in the United States as “dietary supplements”, which do not currently require approval from the FDA or other regulatory agencies prior to sale. Although many of the ingredients in such products are vitamins, minerals, herbs and other substances for which there is a long history of human consumption, our products often contain innovative ingredients or combinations of ingredients. Although we believe such products and the combinations of ingredients in them are safe when taken as directed by us, there is little long-term experience with human or other animal consumption of certain of these ingredients or combinations thereof in concentrated form. The products could have certain side effects if not taken as directed or if taken by a consumer that has certain medical conditions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects.  

 

A slower growth rate in the nutritional supplement industry could lead to reduced revenue or make it more difficult for us to sustain consistent revenue growth.

 

The nutritional supplement industry has been growing at a strong pace over the past ten years. However, any reported medical concerns with respect to ingredients commonly used in nutritional supplements could negatively impact the demand for our products. Additionally, low-carbohydrate products, liquid meal replacements and similar competing products addressing changing consumer tastes and preferences could affect the market for certain categories of supplements. All these factors could have a negative impact on our sales growth.

 

-10-
 

 

Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.

 

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and new regulations from the SEC, have created uncertainty for public companies such as ours. These laws, regulations, and standards are subject to varying interpretations in many cases and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations, and standards have resulted in, and are likely to continue to result in, increased expense and significant management time and attention.

 

Loss of key personnel could impair our ability to operate.

 

Our success depends on hiring, retaining and integrating senior management and skilled employees. We are currently dependent on certain current key employees who are vital to our ability to grow our business and maintain profitability. As with all employees, our officers can terminate their relationship with us at will. Our inability to retain these individuals may result in a reduced ability to operate our business.

 

Risk Factors Relating to our Common Stock

 

If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our Common Stock may be delisted and the price of our Common Stock and our ability to access the capital markets could be negatively impacted.

 

On September 18, 2023, our Common Stock began trading on the Nasdaq Stock Market, LLC (“Nasdaq”). Although we are currently in compliance with Nasdaq’s continued listing standards, no assurance can be given that we will continue to meet applicable Nasdaq continued listing standards. Failure to meet applicable Nasdaq continued listing standards could result in a delisting of our Common Stock, which could materially reduce the liquidity of our Common Stock and result in a corresponding material reduction in the price of our Common Stock.

 

The price of our securities could be subject to wide fluctuations and your investment could decline in value.

 

The market price of the securities of a company such as ours with little name recognition in the financial community and without significant revenue can be subject to wide price swings. For example, the closing price of our Common Stock has ranged from a high of $22.45 to a low of $15.28 during the year ending December 31, 2023. The market price of our securities may be subject to wide changes in response to quarterly variations in operating results, announcements of new products by us or our competitors, reports by securities analysts, volume trading, or other events or factors. In addition, the financial markets have experienced significant price and volume fluctuations for a number of reasons, including the failure of certain companies to meet market expectations. These broad market price swings, or any industry-specific market fluctuations, may adversely affect the market price of our securities.

 

Companies that have experienced volatility in the market price of their stock have been the subject of securities class action litigation. If we were to become the subject of securities class action litigation, it could result in substantial costs and a significant diversion of our management’s attention and resources.

 

-11-
 

 

We may issue Preferred Stock with rights senior to the Common Stock.

 

Our Articles of Incorporation authorize the issuance of up to 10 million shares of preferred stock, par value $0.01 per share ("Preferred Stock"), in the aggregate. Currently, we have the following classes of Preferred Stock authorized, which could be issued without shareholder approval: (i) 1,000 shares of Series A Preferred Stock, par value $0.01 per share, are authorized (the “Series A Preferred”); and (ii) 2,000 shares of Series B Junior Participating Preferred Stock, par value $0.01. However, the rights and preferences of any class or series of Preferred Stock, were we to designate or issue additional shares of Preferred Stock, would be established by our Board of Directors in its sole discretion and may have dividend, voting, liquidation and other rights and preferences that are senior to the rights of our Common Stock.

 

You should not rely on an investment in our Common Stock for the payment of cash dividends.

 

We have never paid cash dividends on our Common Stock and do not anticipate paying any cash dividends in the foreseeable future. You should not make an investment in our Common Stock if you require dividend income. Any return on investment in our Common Stock would only come from an increase in the market price of our stock, which is uncertain and unpredictable.

 

Our Chair of the Board of Directors, Chief Executive Officer and significant shareholder may have certain personal interests that may affect the Company.

 

Due to the securities held by Sudbury Capital Fund, LP ("Sudbury") and Dayton Judd, the Company’s Chair of the Board and Chief Executive Officer, Mr. Judd may be deemed to be the beneficial owner of a majority of the Company’s outstanding voting securities. Consequently, Mr. Judd individually, and together with Sudbury as stockholders acting together, can significantly influence all matters requiring approval by our stockholders, including the election of directors and significant corporate transactions, such as mergers or other business transactions requiring shareholder approval. This concentration of ownership may have effects such as delaying or preventing a change in control of the Company that may be favored by other shareholders or preventing transactions in which shareholders might otherwise recover a premium for their shares over current market prices. In addition, as a result of Mr. Judd’s position as Chair of the Board and Chief Executive Officer, he and/or Sudbury may have the ability to exert influence over both the actions of the Board of Directors, as well as the execution of management’s plans.

 

Risk Factors Related to Recent Acquisitions

 

We may experience difficulties in integrating the operations of MRC and/or MusclePharm into our business and in realizing the expected benefits of the acquisitions.

 

The success of the acquisition of MRC and/or MusclePharm (the “Acquisitions”) will depend in part on our ability to realize the anticipated business opportunities from integrating the operations of MRC and MusclePharm with our business in an efficient and effective manner. The integration process could take longer than anticipated and could result in the loss of key employees, the disruption of each company’s ongoing businesses, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to maintain relationships with customers, employees or other third parties, or our ability to achieve the anticipated benefits of the Acquisitions, and could harm our financial performance. If we are unable to successfully or timely integrate the operations of MRC and/or MusclePharm with our business, we may incur unanticipated liabilities and be unable to realize the revenue growth, synergies and other anticipated benefits resulting from the Acquisitions, and our business, results of operations and financial condition could be materially and adversely affected.

 

We have incurred, and will continue to incur, significant costs in connection with the Acquisitions. The substantial majority of these costs are non-recurring expenses related to the Acquisitions. We may incur additional costs in the integration of MRC’s and/or MusclePharm’s business and may not achieve cost synergies and other benefits sufficient to offset the incremental costs of the Acquisitions.

 

-12-
 

 

The Acquisitions will present challenges associated with integrating operations, personnel, and other aspects of the companies.

 

The Company’s ability to integrate MRC’s and MusclePharm’s business with the Company’s business in an efficient and effective manner will determine the success of the Acquisitions. The Company’s attempt to integrate MRC and MusclePharm may result in significant challenges, and the Company may be unable to accomplish the integrations smoothly or successfully. In particular, the necessity of coordinating geographically dispersed organizations and addressing possible differences in corporate cultures and management philosophies may increase the difficulties of integration. The integration may require the dedication of significant management resources, which may temporarily distract management’s attention from the day-to-day operations of the businesses of the combined company. The process of integrating operations and making such adjustments after the Acquisitions could cause an interruption of, or loss of momentum in, the activities of one or more of the combined companies’ businesses and the loss of key personnel. Employee uncertainty, lack of focus, or turnover during the integration process may also disrupt the businesses of the combined companies. Any inability of management to integrate the operations of the Company, MRC and/or MusclePharm successfully could have a material adverse effect on the business and financial condition of the combined company.

 

SHOULD ONE OR MORE OF THE FOREGOING RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD THE UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THOSE ANTICIPATED, BELIEVED, ESTIMATED, EXPECTED, INTENDED OR PLANNED.

 

ITEM 1B.  UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 1C.  CYBERSECURITY

 

Risk Management and Strategy

 

We recognize the critical importance of developing, implementing, and maintaining cybersecurity measures to maintain the security, confidentiality, integrity, and availability of our business systems and confidential information, including personal information and intellectual property. To this end, our processes are designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems (including such risks associated with the use of any third-party service providers) that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by third-party experts under supervision of management, and, where necessary or desired, include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data. We may also consult with outside advisors and experts to assist with assessing, identifying, and managing cybersecurity risks, including to anticipate future threats and trends, and their impact on our risk environment.

 

We consider cybersecurity, along with other significant risks that we face, within our overall enterprise risk management framework.  Our processes and resources are also designed to help enable us to actively identify, protect, detect, respond to, and recover from risks and threats. Nevertheless, we face certain ongoing cybersecurity risk threats that, if realized, are reasonably likely to materially affect us. As of the date of this report, we have not identified cybersecurity threats that have materially affected, or are reasonably likely to materially affect, our business, results of operations, or financial condition.

 

Governance

 

Third-party experts assist our senior management team in assessing and managing material risks from cybersecurity threats.  All employees and consultants are directed to report to our senior management any irregular or suspicious activity that could indicate a cybersecurity threat or incident. The Audit Committee of our Board of Directors evaluates our cybersecurity assessment and management policies, including quarterly discussions with our senior officers and independent registered accounting firm.

 

 

ITEM 2.    PROPERTIES

 

The Company, including its subsidiaries, leases its headquarters in Omaha, Nebraska, as well as office space in Oakville, Ontario, Canada.   Management believes that the Company's site is adequate to support the business and suitable for present purposes, and the property and equipment have been well maintained.

 

ITEM 3.    LEGAL PROCEEDINGS

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ directors or officers in their capacities as such, in which an adverse decision could have a material adverse effect.

 

ITEM 4.    MINE SAFETY DISCLOSURES

 

None.

 

-13-
 

 

PART II

 

ITEM 5.    MARKET FOR REGISTRANT’S COMMON STOCK, RELATED STOCKHOLDER MATTERS AND ISSUERS PURCHASES OF EQUITY SECURITIES

 

Our Common Stock was approved for listing and has traded since September 18, 2023 on the Nasdaq Capital Market under the symbol “FTLF”. Prior to September 18, 2023, our Common Stock traded in the over-the-counter market.

 

As of December 31, 2023, there were 4,598,241 shares of Common Stock outstanding and 22 shareholders of record of the Company’s Common Stock, in addition to an undetermined number of holders whose shares are held in “street name.”

 

The following table sets forth the high and low closing prices for our Common Stock for the periods indicated:

 

   

High

    

Low

  

Fiscal Year 2023

                

First Quarter (January - March 2023)

   $ 19.19     $ 15.50  

Second Quarter (April - June 2023)

   $ 17.25     $ 15.50  

Third Quarter (July - September 2023)

   $ 19.32     $ 15.28  

Fourth Quarter (October - December 2023)

   $ 22.45     $ 18.62  
                 
                 

Fiscal Year 2022

                

First Quarter (January - March 2022)

   $ 16.70     $ 11.80  

Second Quarter (April - June 2022)

   $ 11.10     $ 9.50  

Third Quarter (July - September 2022)

   $ 16.80     $ 10.25  

Fourth Quarter (October - December 2022)

   $ 17.00     $ 14.05  

 

On March 28, 2024, the closing price of our Common Stock was $23.81 per share.

 

Recent Sales of Unregistered Securities

 

No unregistered securities were issued during the fiscal year.

 

Share Repurchase Program

 

On August 16, 2019, the Company approved a share repurchase program, pursuant to which the Board authorized management to repurchase up to $500,000 of the Company's Common Stock over the subsequent 24 months (the "Share Repurchase Program"), as amended September 23, 2019 to increase the repurchase amount to $1,000,000, and include shares of the Company's Common Stock, its Series A Convertible Preferred Stock, par value $0.01 per share ("Series A Preferred"), and warrants to purchase shares of the Company's Common Stock ("Warrants") in the Share Repurchase Program, to be repurchased over the next 24 months, at a purchase price, in the case of Common Stock, equal to the fair market value of the Company's Common Stock on the date of purchase, and in the case of Series A Preferred and Warrants, at a purchase price determined by management, with the exact date and amount of such purchases to be determined by management; further amended on November 6, 2019 to increase the repurchase amount to $2,500,000 over the subsequent 24 months, and further amended on February 1, 2021 to increase the repurchase amount to up to $5,000,000 over the subsequent 24 months.

 

On March 17, 2023, the Board approved an extension of the Share Repurchase Program. Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $5,000,000 of the Company's Common Stock over the subsequent 24 months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management. All other terms of the Share Repurchase Program remain unchanged.

 

During the year ended December 31, 2023, the Company did not repurchase any shares of the Company’s Common Stock under the Share Repurchase Program. As of December 31, 2023, the Company may purchase up to $5,000,000 of additional shares of Common Stock under the Share Repurchase Program.

 

-14-
 

 

Common Stock repurchase activity under our publicly announced Share Repurchase Program during each quarter of 2023 and 2022 was as follows:

 

Trade date

  

Total

number of

shares

purchased

    

Average

price paid

per share

    

Total

number of

shares

purchased

as part of

publicly

announced

programs

    

Dollar

value of

shares that

may yet be

purchased

  
                                 

First quarter ended March 31, 2022

     -       -       -     $ 3,169,917  

Second quarter ended June 30, 2022

     -       -       -     $ 3,169,917  

Third quarter ended September 30, 2022

     -       -       -     $ 3,169,917  

Fourth quarter ended December 31, 2022

     48,596     $ 15.86       48,596     $ 2,398,979  

Subtotal

     48,596               48,596     $ 2,398,979  
                                 

First quarter ended March 31, 2023

     -       -       -     $ 5,000,000  

Second quarter ended June 30, 2023

     -       -       -     $ 5,000,000  

Third quarter ended September 30, 2023

     -       -       -     $ 5,000,000  

Fourth quarter ended December 31, 2023

     -       -       -     $ 5,000,000  

Subtotal

     -       -       -     $ 5,000,000  

 

Transfer Agent

 

Our transfer agent and registrar for the Common Stock is Colonial Stock Transfer located in Sandy, Utah.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

For a discussion of our equity compensation plans, please see Item 11 of this Annual Report.

 

ITEM 6.    SELECTED FINANCIAL DATA

 

Not a required disclosure for Smaller Reporting Companies.

 

-15-
 

 

ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OR PLAN OF OPERATION

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes”, “anticipates”, “may”, “will”, “should”, “expect”, “intend”, “estimate”, “continue”, and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this Annual Report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

 

The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes thereto and other financial information contained elsewhere in this Annual Report. Unless otherwise stated, all dollar amounts are in thousands, except per share data.

 

Recent Developments

 

Acquisition of Mimi’s Rock Corp

 

On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire MRC. On February 28, 2023, the Company completed the acquisition of MRC for $17,099. Of this amount, $12,500 was funded using proceeds from a term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances.  See Note 8 to the financial statements for additional disclosure regarding the acquisition.

 

Acquisition of MusclePharm Assets

 

On October 10, 2023, the Company acquired substantially all of the assets of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed none of the liabilities of MusclePharm other than de minimus cure costs relating to certain assumed contracts.  Total consideration for the acquisition was approximately $18,500.  Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note 9 to the financial statements for additional disclosure regarding the acquisition.

 

Critical Accounting Policies

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

 

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

 

Foreign Currency Translation

 

The functional currency of the Company is the U.S. dollar.  The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar.  The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

 

-16-
 

 

Accounts Receivable and Allowance for Doubtful Accounts

 

All of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts, estimating losses resulting from the inability of its customers to make required payments for products. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped into categories by the number of days the balance is past due, and the estimated loss is recorded based upon management’s assessment of collectability. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.

 

As of December 31, 2023 and 2022, the Company had provided a reserve for doubtful accounts of $17 and $50, respectively.

 

Income Taxes

 

The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC 740”). Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax liabilities of the Company relate primarily to intangible assets that are not deductible for tax purposes in the jurisdictions to which they relate.

 

The Company periodically evaluates its tax positions to determine whether it is more likely than not that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. The Company accrues interest and penalties, if incurred, on unrecognized tax benefits as components of the income tax provision in the accompanying consolidated statements of income and comprehensive income. As of December 31, 2023, and 2022, the Company has not established a liability for uncertain tax positions.

 

Product Returns, Sales Incentives and Other Forms of Variable Consideration

 

In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include, but are not limited to, product returns and sales incentives, such as markdowns and margin adjustments. For these types of arrangements, the adjustments to revenue are recorded at the later of when (i) the Company recognizes revenue for the transfer of the related products to the customers, or (ii) the Company pays, or promises to pay, the consideration.

 

We currently have a 30-day product return policy for direct-to-consumer sales, which allows for a 100% sales price refund for the return of unopened and undamaged products purchased from us online through one of our websites or e-commerce platforms. Product sold to certain wholesale customers may be returned from store shelves or the distribution center in the event product is damaged, short dated, expired or recalled.

 

GNC maintains a customer satisfaction program which allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC may require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.

 

-17-
 

 

For the sale of goods with a right of return, the Company estimates variable consideration using the most likely amount method and recognizes revenue for the consideration it expects to be entitled to when control of the related product is transferred to the customers and records a product returns liability for the amount it expects to credit back its customers. Under this method, certain forms of variable consideration are based on expected sell-through results, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. The product returns liability includes estimates that directly impact reported revenue. These estimates are calculated based on a history of actual returns, estimated future returns and information provided by customers regarding their inventory levels. Consideration of these factors results in an estimate for anticipated sales returns that reflects increases or decreases related to seasonal fluctuations. In addition, as necessary, product returns liability may be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include, but are not limited to, changes in the retail environment and the Company's decision to continue to support new and existing products.

 

Information for product returns is received on a regular basis and adjusted for accordingly. Adjustments for returns are based on factual information and historical trends for all Company Products and are specific to each distribution channel. We monitor, among other things, remaining shelf life and sell-through data on a weekly basis. If we determine there are any risks or issues with any specific products, we accrue sales return allowances based on management’s assessment of the overall risk and likelihood of returns in light of all information available.

 

Total allowance for product returns, sales returns and incentive programs as of December 31, 2023 and 2022 amounted to $571 and $590, respectively.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value, with costs determined on a first-in, first-out (FIFO) basis. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand and/or our ability to sell the product(s) concerned and production requirements. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market conditions or other factors, which may result in cancellations of advance orders or a reduction in the rate of reorders placed by customers. Additionally, our management’s estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. 

 

Total allowance for expiring, excess and slow-moving inventory items as of December 31, 2023 and 2022 amounted to $162 and $107, respectively.

 

Goodwill

 

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test.  The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach.  The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

 

As the Company uses the market approach to determine fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

 

There were no impairment charges incurred during the year ended December 31, 2023.

 

Revenue Recognition

 

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

 

The Company accounts for revenue in accordance with FASB ASC 606. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. 

 

-18-
 

 

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company’s products are also sold on e-commerce platforms including Amazon.  For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company: 1) owns the goods before they are transferred to the customer,   2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, 3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, 4) is subject to credit risk (i.e., credit card chargebacks), 5) establishes prices of its products, 6) can determine who fulfills the goods to the customer (Amazon or the Company) and 7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in selling, general and administrative expense in the consolidated statements of income and comprehensive income.

 

The Company disaggregates revenue into geographical regions and distribution channels.  The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. 

 

Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as third-party e-commerce platforms such as Amazon, for the year ended December 31, 2023 was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same twelve-month period in 2022.

 

Sales to customers in the U.S. were approximately 93% and 99% for the year ended December 31, 2023 and 2022, respectively, with the balance of sales to customers primarily in Canada.

 

Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

 

For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.

 

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

Stock Compensation.Expense

 

The Company periodically issues restricted share units (“RSUs”), stock options and warrants to employees and non-employees in non-capital raising transactions for services rendered. Such issuances vest and expire according to the terms established at the issuance date.

 

Stock-based payments to officers, directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock-based payments to officers, directors, and employees that are time vested are measured at the grant date fair value and compensation cost is recognized on a straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock-based payments is estimated using the Black-Scholes option-pricing model or other applicable valuation model such as the Monte Carlo valuation pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used could materially affect compensation expense recorded in future periods.

 

-19-
 

 

Recent Accounting Pronouncements

 

See Note 2 of the Notes to the Consolidated Financial Statements included in this Annual Report for a description of recent accounting pronouncements believed by management to have a material impact on our present or future financial statements.

 

Results of Operations

 

   

Year ended

December

31, 2023

    

Year ended

December

31, 2022

    

 $ Change

    

% Change

  

Revenue

   $ 52,700     $ 28,803     $ 23,897       83 %

Cost of goods sold

     31,268       16,769       14,499       86 %

Gross profit

     21,432       12,034       9,398       78 %

Gross margin percentage

     40.7 %     41.8 %                

Operating expense:

                                

Selling, general and administrative expense

     12,161       6,010       6,151       102 %

Merger and acquisition related expense

     1,627       257       1,370       533 %

Depreciation and amortization

     94       66       28       42 %

Total operating expense

     13,882       6,333       7,549       119 %

Income from operations

     7,550       5,701       1,849       32 %

Other expense (income)

     547       (121 )     668    

n/m

 %

Provision for income tax

     1,707       1,393       314       23 %

Net income

   $ 5,296     $ 4,429     $ 867       20 %

 

Fiscal Year Ended December 31, 2023 Compared to Fiscal Year Ended December 31, 2022

 

Revenue. Revenue for the year ended December 31, 2023 increased 83% to $52,700 as compared to $28,803 for the year ended December 31, 2022. The increased revenue for the year ended December 31, 2023 compared to the prior year is primarily due to revenue generated from MRC, which was acquired in the first quarter of 2023. Legacy FitLife revenue for the year ended December 31, 2023 was $28,100, a 3% decrease compared to the previous year, driven by a 9% decline in wholesale revenue, partially offset by a 14% increase in online revenue.

 

The acquisition of MusclePharm had minimal impact on revenue due to (1) the transaction closing during the fourth quarter, (2) the need to procure inventory since only $195 of inventory was acquired in the asset purchase, and (3) the need to negotiate new commercial agreements with MusclePharm’s existing customers.

 

Online revenue during the year ended December 31, 2023 was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same twelve-month period in 2022. Although no assurances can be given, management believes that online revenue will continue to increase in subsequent periods relative to prior comparable periods given management’s focus on higher margin online sales and the acquisition of both MRC and MusclePharm, which were consummated in the first and fourth quarters of fiscal 2023, respectively.

 

Sales to customers in the U.S. were approximately 93% and 99% for the year ended December 31, 2023 and 2022, respectively, with the balance of sales primarily to customers in Canada.

 

The Company continually reformulates and introduces new products, as well as seeks to increase both the number of stores and number of approved products that can be sold within the GNC franchise system that comprise its domestic and international distribution footprint. Management also believes that its focus on developing its e-commerce capabilities will drive additional incremental sales in the short-term, while yielding substantial benefits in the longer-term. 

 

Cost of Goods Sold. Cost of goods sold for the year ended December 31, 2023 increased 86% to $31,268 as compared to $16,769 for the year ended December 31, 2022. The increase of $14,499 is primarily due to an increase in revenue attributable to the acquisition of MRC as well as higher distribution costs resulting from increased sales through online channels.

 

-20-
 

 

Gross Profit. Gross profit for the year ended December 31, 2023 increased to $21,432 as compared to $12,034 for the year ended December 31, 2022. This 78% increase in gross profit is attributable to higher revenue driven primarily by the acquisition of MRC.

 

Gross Margin. Gross margin for the year ended December 31, 2023 decreased to 40.7% from 41.8% for the year ended December 31, 2022. The decrease in gross margin is primarily attributable to the amortization of the fair value step-up to MRC inventory acquired as well as higher product costs due to inflationary pressure. Excluding the $323 impact of the step-up amortization, gross margin would have been 41.3% during the year ended December 31, 2023.

 

Selling, General and Administrative Expense. Selling, general and administrative (“SG&A”) expense for the year ended December 31, 2023 increased by $6,151 to $12,161 as compared to $6,010 for the year ended December 31, 2022. The increase was primarily due to the inclusion of SG&A expense in the Company’s consolidated financial statements attributable to MRC.

 

Merger and Acquisition Related Expense. Merger and acquisition related expense increased to $1,627 for the year ended December 31, 2023 compared to $257 for the same period of 2022, driven primarily by acquisition costs related to MRC.

 

Net Income. We generated a net income of $5,296 for the year ended December 31, 2023, an increase of 20% compared to net income of $4,429 for the year ended December 31, 2022. The increase in net income for the year ended December 31, 2023 compared to the same period in 2022 was primarily attributable to the acquisition of MRC, partially offset by approximately $2.1 million of non-recurring items associated with the transaction.

 

Non-GAAP Measures

 

The financial presentation below contains certain financial measures not in accordance with GAAP, defined by the SEC as “non-GAAP financial measures”, including EBITDA and adjusted EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in this Annual Report in accordance with GAAP.

 

As presented below, EBITDA excludes interest, foreign exchange gains and losses, income taxes, and depreciation and amortization. Adjusted EBITDA excludes—in addition to interest, taxes, depreciation and amortization—stock-based  compensation, merger and acquisition related expense and other non-recurring costs. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company’s financial results with the Company’s historical financial results and is an important measure of the Company’s comparative financial performance.

 

   

Year ended December 31,

  
   

2023

    

2022

  
   

(Unaudited)

    

(Unaudited)

  

Net income

   $ 5,296     $ 4,429  

Interest expense

     1,025       -  

Interest income

     (289 )     (121 )

Foreign exchange (gain) loss

     (189 )     -  

Provision for income taxes

     1,707       1,393  

Depreciation and amortization

     94       66  

EBITDA

     7,644       5,767  

Non-cash and non-recurring adjustments

                

Stock compensation expense

     473       363  

Merger and acquisition related expense

     1,627       257  

Amortization of inventory step-up

     323       -  

Non-recurring loss on foreign currency forward contract

     112       -  

Restatement-related costs

     -       318  

Adjusted EBITDA

   $ 10,179     $ 6,705  

 

-21-
 

 

Liquidity and Capital Resources

 

As of December 31, 2023, the Company had positive working capital of $4,356, compared to $18,933 at December 31, 2022. Our principal sources of liquidity at December 31, 2023 consisted of $1,139 of cash and $2,046 of accounts receivable. The decrease in working capital is principally attributable to (i) the acquisition of MusclePharm for $18,788, of which $10,000 was funded from proceeds of the Amended Credit Agreement, defined below, and $8,788 from the Company’s available cash, and (ii) the acquisition of MRC for $17,099, of which $12,500 was funded from proceeds of the Credit Agreement, defined below, and $4,599 from the Company’s available cash, partially offset by cash flows from operating activities during fiscal 2023. 

 

The Amended Credit Agreement contains customary events of default (each an “Event of Default”), which upon the occurrence of an Event of Default, as defined in the Amended Credit Agreement, among other things, interest will accrue at the Applicable Rate plus 2% per annum, and the Bank may declare all Obligations, with interest thereon, immediately due and payable. The Amended Credit Agreement further contains customary representations and warranties of the Company; customary indemnification provisions whereby the Company will indemnify Bank for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of the Company, and certain other matters; and customary affirmative and negative covenants, including covenants to maintain a Fixed Charge Coverage Ratio (as defined in the Credit Agreement) of not less than 1.25 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending December 31, 2023, a Funded Debt to EBITDA Ratio (as defined in the Credit Agreement) of not more than 2.50 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending March 31, 2024, and to the extent the Term Loans still have a balance as of June 30, 2025 and a Cash Flow Leverage threshold (as defined in the Credit Agreement) of at least 1.15 is not met, the Company will be required to make a prepayment on the Term Loan equal to 50% of the Excess Cash Flow (as defined in the Credit Agreement). The Company was in compliance with all covenants as of December 31, 2023.

 

As of December 31, 2023 and 2022, no borrowings were outstanding on the Company’s $3,500 Line of Credit.

 

The Company has historically financed its operations primarily through cash flow from operations and equity and debt financings. The Company currently anticipates that cash derived from operations and existing cash resources, along with available borrowings under the Line of Credit, will be sufficient to provide for the Company’s liquidity for the next twelve months.

 

-22-
 

 

The Company is dependent on cash flow from operations and amounts available under the Line of Credit to satisfy its working capital requirements. No assurances can be given that cash flow from operations and/or the Line of Credit will be sufficient to provide for the Company’s liquidity for the next twelve months. Should the Company be unable to generate sufficient revenue in the future to achieve positive cash flow from operations, and/or should capital be unavailable under the terms of the Line of Credit, additional working capital will be required. Management currently has no intention to raise additional working capital through the sale of equity or debt securities and believes that the cash flow from operations and available borrowings under the Line of Credit will provide sufficient capital necessary to operate the business over the next twelve months. In the event the Company fails to achieve positive cash flow from operations, additional capital is unavailable under the terms of the Line of Credit, and management is otherwise unable to secure additional working capital through the issuance of equity or debt securities, the Company’s business would be materially and adversely harmed.

 

Cash Provided by Operating Activities

 

Net cash provided by operating activities was $4,220 during the year ended December 31, 2023, compared to net cash provided by operating activities of $4,130 for the year ended December 31, 2022. The increase in cash provided by operating activities was driven primarily by the acquisition of MRC, which was largely offset by transaction-related costs as well as payment of a number of payables and other expenses that were accrued at MRC at the time of the acquisition.

 

Cash Used in Investing Activities

 

Cash used in investing activities for the fiscal year ended December 31, 2023 was $35,993 and $0 during the years ended December 31, 2023 and 2022, respectively. The Company used $17,099 for the acquisition of MRC and $18,788 for the acquisition of MusclePharm assets during the year ended December 31, 2023.

 

Cash Provided by (Used in) Financing Activities

 

Cash provided by financing activities for the year ended December 31, 2023 was $20,296 as compared to cash used of $750 during the year ended December 31, 2022. The increase in cash provided by financing activities is primarily attributable to the funding of the Term Loans during the first and fourth quarters of fiscal 2023.

 

Off-Balance Sheet Arrangements

 

Other than contractual obligations incurred in the normal course of business, we do not have any off-balance sheet financing arrangements or liabilities, retained or contingent interests in transferred assets or any obligation arising out of a material variable interest in an unconsolidated entity.

 

-23-
 

 

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Our business is conducted principally in the United States.  However, due to the MRC acquisition in 2023, the Company now has more exposure to fluctuations in foreign currencies.  As a result, our financial results may be materially affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets.

 

Foreign Currency

 

In January 2023, the Company entered into a foreign currency hedging transaction to mitigate the risk of adverse changes in the USD/CAD exchange rate with respect to the pending acquisition of MRC. The Company entered into a forward contract to purchase CAD $25.0 million, as the Company anticipated providing additional working capital funding beyond the CAD $23.2 million purchase price for MRC. As the geographical scope of our business broadens, we may engage in additional foreign currency hedging transactions in the future.

 

Interest Rates

 

Our exposure to risk for changes in interest rates relates primarily to borrowings under the Amended Credit Agreement (which includes Term Loans A and B as well as our existing Line of Credit), and our investments in short-term financial instruments. As of December 31, 2023, the Company had $20,125 outstanding on the Term Loans and $0 under its existing Line of Credit.

 

Investments of our existing cash balances in both fixed-rate and floating-rate interest-earning instruments carry some interest rate risk. The fair value of fixed-rate securities may fall due to a rise in interest rates, while floating-rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income will vary due to changes in interest rates and we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.

 

ITEM 8.  FINANCIAL STATEMENTS

 

The information required hereunder in this Annual Report is set forth in the financial statements and the notes thereto beginning on Page F-1.

 

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

As described in the Company’s Current Reports on Form 8-K filed with the SEC on October 7, 2022 and October 18, 2022, on October 6, 2022, the Audit Committee of the Board of the Company recommended, and the Board approved Weinberg & Company P.A. (“Weinberg”) as its independent registered public accounting firm for the fiscal year ended December 31, 2022. On October 14, 2022, the Audit Committee of the Board of the Company recommended, and the Board approved, the dismissal of Weaver and Tidwell, LLP (“Weaver”) as the Company’s independent registered public accounting firm.

 

ITEM 9A.  CONTROLS AND PROCEDURES

 

(a)   Evaluation of Disclosure Controls and Procedures.

 

In connection with the filing of this Annual Report on Form 10-K for the period ended December 31, 2023, our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 

 

Management previously determined that our disclosure controls and procedures were ineffective due to certain material weaknesses, as disclosed in our Annual Reports on Form 10-K for the years ended December 31, 2021 and 2022, and in our quarterly reports through the quarter ended March 31, 2023. Management has implemented measures designed to improve our controls and procedures to remediate the identified material weaknesses (the “Remediation Plan”). As of the year ended December 31, 2023, the Remediation Plan had been implemented and the applicable controls had operated for a sufficient period of time, and therefore management concluded that the newly implemented and enhanced controls were operating effectively. We will continue to test such controls over time to ensure the adequacy of our controls and procedures.

 

-24-
 

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. 

 

Based on management’s evaluation of our disclosure controls and procedures, our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 31, 2023.

 

(b)   Management's Annual Report on Internal Control over Financial Reporting.

 

We are responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States.

 

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to an exemption for smaller reporting companies under Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

 

Our CEO and CFO evaluated the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control—Integrated Framework. Based on this evaluation, our CEO and CFO concluded that, as of December 31, 2023, our internal control over financial reporting was effective.

 

(c)   Changes in Internal Controls over Financial Reporting.

 

Our CEO and CFO have determined that, other than the Remediation Plan described above, there have been no changes in the Company’s internal control over financial reporting during the period covered by this Report identified in connection with the evaluation described in the above paragraph that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. 

 

 

ITEM 9B.  OTHER INFORMATION

 

None.

 

- 25-
 
 

PART III

 

 

ITEM 10.  DIRECTORS AND EXECUTIVE OFFICERS

 

In accordance with General Instruction G(3) to Form 10-K, certain information required by this Item is incorporated herein by reference to our definitive proxy statement for our 2024 annual meeting of stockholders to be filed with the SEC.

 

ITEM 11.  EXECUTIVE COMPENSATION

 

In accordance with General Instruction G(3) to Form 10-K, certain information required by this Item is incorporated herein by reference to our definitive proxy statement for our 2024 annual meeting of stockholders to be filed with the SEC.

 

ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

In accordance with General Instruction G(3) to Form 10-K, certain information required by this Item is incorporated herein by reference to our definitive proxy statement for our 2024 annual meeting of stockholders to be filed with the SEC.

 

ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

In accordance with General Instruction G(3) to Form 10-K, certain information required by this Item is incorporated herein by reference to our definitive proxy statement for our 2024 annual meeting of stockholders to be filed with the SEC.

 

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

In accordance with General Instruction G(3) to Form 10-K, certain information required by this Item is incorporated herein by reference to our definitive proxy statement for our 2024 annual meeting of stockholders to be filed with the SEC.

 

PART IV

 

ITEM 15.  EXHIBITS AND REPORTS

 

Exhibits

 

 

3.1

Articles of Incorporation (incorporated by reference to Exhibit 3.1 filed with Amendment No. 3 to the Company’s Registration Statement on Form SB2 (Commission File No. 333-137170)).

3.2

Amendments to Articles of Incorporation (incorporated by reference to Exhibit 3.2 filed with Amendment No. 3 to the Company’s Registration Statement on Form SB2 (Commission File No. 333-137170)).

3.3

Amended and Restated Bylaws of the Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 25, 2018).

3.4

Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on September 13, 2010).

3.5

Certificate of Amendment to Articles of Incorporation to change name to FitLife Brands, Inc.  (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 1, 2013).

3.6

Certificate of Amendment to Articles of Incorporation to effect 1-for-10 reverse split (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 1, 2013).

3.7

Certificate of Designations, Preferences and Rights of the Series A Convertible Preferred Stock, dated November 13, 2018 (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2018).

3.8

Certificates of Change, dated April 11, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 15, 2019).

3.9

Certificate of Designations, Preferences and Rights of the Series B Junior Preferred Stock, dated March 3, 2021 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 4, 2021).

3.10

Certificate of Change for FitLife Brands, Inc., effective as of December 2, 2021 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 7, 2021).

4.1

Form of Warrant, dated November 13, 2018 (incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2018).

 

-26-
 

 

4.2

Tax Benefit Preservation Plan, dated February 26, 2021 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March 4, 2021).

10.1

Assignment of Name (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on October 6, 2009).

10.2

Form of Subscription Agreement, dated November 13, 2018 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2018).

10.3

Employment Agreement, by and between FitLife Brands, Inc. and Patrick Ryan, dated June 13, 2019 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 18, 2019).

10.4

2019 Omnibus Incentive Plan (incorporated by reference to Appendix A to the Definitive Proxy Statement on Schedule 14A filed on July 12, 2019).

10.5

Revolving Line of Credit Agreement, dated as of September 24, 2019, between the Company and Mutual of Omaha Bank (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 26, 2019).

10.6

Note Payable Agreement by and between FitLife Brands, Inc. and CIT Bank, N.A. dated April 27, 2020 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 1, 2020).

10.7

Amended and Restated Credit Agreement, dated February 23, 2023, between FitLife Brands Inc., and First Citizens Bank (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 1, 2023).

10.8

Term Note, dated February 23, 2023, issued by FitLife Brands, Inc., to First Citizens Bank (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 1, 2023).

10.9

Security Agreement, dated February 23, 2023, among FitLife Brands, Inc., NDS Nutrition Products, Inc., iSatori, Inc., 1000374984 Ontario, Inc., and First Citizens Bank (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed March 1, 2023).

10.10

Guaranty Agreement, dated February 23, 2023, among NDS Nutrition Products, Inc., iSatori, Inc., 1000374984 Ontario, Inc., and First Citizens Bank (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed March 1, 2023).

10.11

Asset Purchase and Sale Agreement by and between MusclePharm Corporation and FitLife Brands, Inc., dated September 7, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 27, 2023).

10.12

Second Amended and Restated Credit Agreement, dated October 10, 2023, by and between FitLife Brands, Inc., and First Citizens Bank (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 13, 2023).

10.13

Term B Note, dated October 10, 2023, issued by FitLife Brands, Inc., to First Citizens Bank (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on October 13, 2023).

10.14

Reaffirmation of Guaranty, dated October 10, 2023, by NDS Nutrition Products, Inc., iSatori, Inc., 1000374984 Ontario Inc., and Mimi’s Rock Corp., to and in favor of First Citizens Bank & Trust Company (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on October 13, 2023).

10.15

Arrangement Agreement among FitLife Brands Inc., 1000374984 Ontario Inc., and Mimi’s Rock Corp, dated December 4, 2022 (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 8, 2022).

14.1

Code of Ethics (incorporated by reference to Exhibit 14.1 to the Company’s Annual Report on Form 10-K filed on March 27, 2009).

16.3

Letter from Weaver and Tidwell, LLP dated October 17, 2022 (incorporated by reference to Exhibit 16.1 to the Company’s Current Report on Form 8-K filed October 18, 2022).

21

List of Subsidiaries.

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.

31.2

Certification of Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.

32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.  

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (embedded within the Inline XBRL Document and included in Exhibit 101)

 

-27-
 

 

ITEM 16.  FORM 10-K SUMMARY    

 

None.

 

-28-
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

Registrant

FitLife Brands, Inc.

  
     

Date: March 29, 2024

By: /s/ Dayton Judd

  
 

Dayton Judd

  
 

Chief Executive Officer (Principal Executive Officer)

  
     

Date: March 29, 2024

By: /s/ Jakob York

  
 

Jakob York

  
 

Chief Financial Officer (Principal Financial Officer)

  

 

In accordance with the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

 

Date: March 29, 2024

By: /s/ Dayton Judd

  
 

Dayton Judd

  
 

Chief Executive Officer and Chair of the Board

  
     

Date: March 29, 2024

By: /s/ Grant Dawson

  
 

Grant Dawson

  
 

Director

  
     

Date: March 29, 2024

By: /s/ Lewis Jaffe

  
 

Lewis Jaffe

  
 

Director

  
     

Date: March 29, 2024

By: /s/ Todd Ordal

  
 

Todd Ordal

  
 

Director

  
     

Date: March 29, 2024

By: /s/ Seth Yakatan

  
 

Seth Yakatan

  
 

Director

  

 

-29-
 
 
 

FITLIFE BRANDS, INC.

TABLE OF CONTENTS

 

 

Page

  

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (Weinberg & Company, PA, PCAOB ID:572

F-1

CONSOLIDATED FINANCIAL STATEMENTS:

 

Consolidated Balance Sheets at December 31, 2023 and 2022

F-2

Consolidated Statements of Income and Comprehensive Income for the years ended December 31, 2023 and 2022

F-3

Consolidated Statement of Stockholders’ Equity for the years ended December 31, 2023 and 2022

F-4

Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

F-5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

F-6

 

 
 
 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Stockholders and the Board of Directors of FitLife Brands, Inc.
Omaha, NE
 
Opinion on the Financial Statements
 
We have audited the accompanying consolidated balance sheets of FitLife Brands, Inc. (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
 
Basis for Opinion
 
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
Critical Audit Matter
 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Acquisition of Mimi’s Rock - Fair Value of Intangible Assets
 
As described in Note 8 to the consolidated financial statements, the Company acquired Mimi’s Rock for net cash consideration of $17.1 million in 2023, which resulted in the recording of a $7.6 million an intangible asset. Management recorded the intangible asset acquired at fair value on the date of acquisition using an income approach. Management applied judgment in estimating the fair value of intangible asset acquired, which included the use of assumptions with respect to future earnings before interest, taxes, depreciation and amortization (EBITDA) margins, revenue growth rates and discount rates.
 

The principal considerations for our determination that performing procedures relating to the fair value of intangible asset recorded in the acquisition of Mimi’s Rock constituted a critical audit matter are: (i) there was a high degree of auditor judgment and subjectivity in performing procedures relating to the fair value measurement of intangible assets acquired due to the judgment applied by management when developing the estimate; (ii) that significant audit effort was required in evaluating the assumptions relating to the estimated fair value of intangible assets, including future EBITDA margins, revenue growth rates, and discount rates; and (iii) that the audit effort involved the use of professionals with specialized skill and knowledge.
 
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) reading the purchase agreement; (ii) testing management’s process for estimating the fair value of intangible assets; (iii) evaluating the appropriateness of the valuation method given the nature of the asset; (iv) testing the completeness, accuracy, relevance and reliability of the data used in estimating the fair value of intangible assets; and (v) evaluating the reasonableness of the significant assumptions used by management.
 
We have served as the Company’s auditor from 2018 through 2019, and since October 2022.

 

 

Weinberg & Company, P.A.
Los Angeles, California
March 29, 2024

 

F-1
 

 

 

FITLIFE BRANDS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

 

  

December 31,

2023

  

December 31,

2022

 

ASSETS:

        

CURRENT ASSETS

        

Cash and cash equivalents

 $1,139  $13,277 

Restricted cash

  759   - 

Accounts receivable, net of allowance of doubtful accounts of $17 and $50, respectively

  2,046   705 

Inventories, net of allowance for obsolescence of $162 and $107, respectively

  9,091   9,105 

Sales tax receivable

  1,019   - 

Prepaid expense and other current assets

  639   116 

Total current assets

  14,693   23,203 
         

Property and equipment, net

  137   46 

Right of use asset

  121   103 

Intangibles, net of amortization of $113 and $71, respectively

  26,309   150 

Goodwill

  13,294   358 

Deferred tax asset

  792   1,847 

TOTAL ASSETS

 $55,346  $25,707 
         

LIABILITIES AND STOCKHOLDERS' EQUITY:

        

CURRENT LIABILITIES:

        

Accounts payable

 $3,261  $2,995 

Accrued expense and other liabilities

  1,026   444 

Income taxes payable

  892   187 

Product returns

  571   590 

Term loan – current portion

  4,500   - 

Lease liability - current portion

  87   54 

Total current liabilities

  10,337   4,270 

Term loan, net of current portion and unamortized deferred finance costs

  15,509   - 

Long-term lease liability, net of current portion

  51   49 

Deferred tax liability

  2,413   - 

TOTAL LIABILITIES

  28,310   4,319 
         

STOCKHOLDERS’ EQUITY:

        

Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of December 31, 2023 and 2022

  -   - 

Common stock, $0.01 par value, 60,000 shares authorized; 4,598 and 4,507 issued and outstanding as of December 31, 2023 and 2022, respectively

  46   45 

Additional paid-in capital

  30,699   30,056 

Accumulated deficit

  (3,417)  (8,713)

Foreign currency translation adjustment

  (292)  - 

TOTAL STOCKHOLDERS' EQUITY

  27,036   21,388 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 $55,346  $25,707 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2
 

 

 

FITLIFE BRANDS, INC.

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(in thousands, except per share amounts)

 

  

Years ended

 
  

December 31,

 
  

2023

  

2022

 
         
         

Revenue

 $52,700  $28,803 

Cost of goods sold

  31,268   16,769 

Gross profit

  21,432   12,034 
         

OPERATING EXPENSE:

        

Selling, general and administrative

  12,161   6,010 

Merger and acquisition related

  1,627   257 

Depreciation and amortization

  94   66 

Total operating expense

  13,882   6,333 

OPERATING INCOME

  7,550   5,701 
         

OTHER EXPENSE (INCOME)

        

Interest income

  (289)  (121)

Interest expense

  1,025   - 

Foreign exchange gain

  (189)  - 

Total other expense (income)

  547   (121)
         

INCOME BEFORE INCOME TAXES

  7,003   5,822 
         

PROVISION FOR INCOME TAXES

  1,707   1,393 
         

NET INCOME

 $5,296  $4,429 
         

NET INCOME PER SHARE

        

Basic

 $1.18  $0.97 

Diluted

 $1.08  $0.89 

Basic weighted average common shares

  4,490   4,553 

Diluted weighted average common shares

  4,905   4,975 
         

COMPREHENSIVE INCOME:

        

NET INCOME

 $5,296  $4,429 

Foreign currency translation adjustment

  (292)  - 

Comprehensive income

 $5,004  $4,429 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3
 

 

 

FITLIFE BRANDS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

(in thousands)

 

              

Additional

      

Foreign currency

     
  

Common stock

  

Treasury

  

paid-in

  

Accumulated

  

translation

     
  

Shares

  

Amount

  

stock

  

capital

  

deficit

  

adjustment

  

Total

 
                             

YEAR ENDED DECEMBER 31, 2023

                            
                             

JANUARY 1, 2023

  4,507  $45  $-  $30,056  $(8,713) $-  $21,388 
                             

Shares surrendered by former employee

  (61)  -   -   -   -   -   - 

Exercise of stock options

  9   -   -   6   -   -   6 

Exercise of warrants

  143   1   -   164   -   -   165 

Stock-based compensation

  -   -   -   473   -   -   473 

Comprehensive (loss) income

  -   -   -   -   -   (292)  (292)

Net income

  -   -   -   -   5,296   -   5,296 
                             

DECEMBER 31, 2023

  4,598  $46  $-  $30,699  $(3,417) $(292) $27,036 
                             

YEAR ENDED DECEMBER 31, 2022

                            
                             

JANUARY 1, 2022

  4,552  $46  $(2,087) $32,529  $(13,142) $-  $17,346 
                             

Repurchase of common stock

  (48)  (1)  (771)  -   -   -   (772)

Retirement of treasury shares

  -   -   2,858   (2,865)  -   -   (7)

Exercise of stock options

  3   -   -   29   -   -   29 

Stock-based compensation

  -   -   -   363   -   -   363 

Net income

  -   -   -   -   4,429   -   4,429 
                             

DECEMBER 31, 2022

  4,507  $45  $-  $30,056  $(8,713) $-  $21,388 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4
 

 

 

FITLIFE BRANDS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

  

Years ended December 31,

 
  

2023

  

2022

 
         

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net income

 $5,296  $4,429 

Adjustments to reconcile net income to net cash provided by operating activities:

        

Depreciation and amortization

  94   66 

Allowance for doubtful accounts

  (33)  (6)

Allowance for inventory obsolescence

  55   51 

Stock compensation expense

  473   363 

Amortization of deferred finance costs

  15   - 

Amortization of inventory step-up

  323   - 
         

Changes in operating assets and liabilities:

        

Accounts receivable - trade

  (882)  247 

Inventories

  1,026   (2,636)

Deferred taxes

  957   1,199 

Prepaid expense and other assets

  (178)  204 

Right of use asset

  83   55 

Accounts payable

  (2,679)  115 

Income taxes payable

  (356)  184 

Lease liability

  (77)  (55)

Accrued liabilities and other liabilities

  122   (44)

Product returns

  (19)  (42)

Net cash provided by operating activities

  4,220   4,130 
         

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchase of property and equipment

  (106)  - 

Cash paid for acquisition of MRC

  (17,099)  - 
Cash paid for acquisition of MusclePharm assets  (18,788)  - 

Net cash used in investing activities

  (35,993)  - 
         

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Proceeds from exercise of stock options and warrants

  171   29 

Repurchases of common stock

  -   (779)

Borrowings on term loan

  22,500   - 

Payments on term loan

  (2,375)  - 

Net cash provided by (used in) financing activities

  20,296   (750)
         

Foreign currency impact on cash

  98   - 
         

CHANGE IN CASH AND RESTRICTED CASH

  (11,379)  3,380 

CASH, BEGINNING OF PERIOD

  13,277   9,897 

CASH AND RESTRICTED CASH, END OF PERIOD

 $1,898  $13,277 
         

Supplemental cash flow disclosure

        

Cash paid for income taxes

 $698  $3 

Cash paid for interest, net of amounts capitalized

 $777  $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 
F-5
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 

 

 

NOTE 1.  DESCRIPTION OF BUSINESS

 

Summary

 

FitLife Brands, Inc. (the “Company”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); and (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products"); and (iv) MusclePharm.

 

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.  The Company distributes the MRC Products primarily online.  MusclePharm’s products are sold to both wholesale customers as well as online directly to the end consumer.

 

FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the Nasdaq Capital Market.

 

Recent Developments

 

Acquisition of Mimi’s Rock Corp

 

On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire MRC. On February 28, 2023, the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was $17,099, of which $12,500 was funded using proceeds from a new term loan, and $4,599 from the Company’s available cash. See Note 8 to the financial statements for additional disclosure regarding the acquisition of MRC.

 

Acquisition of MusclePharm Assets

 

On October 10, 2023, the Company acquired substantially all of the assets of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed none of the liabilities of MusclePharm other than de minimus cure costs relating to certain assumed contracts.  Total consideration for the acquisition was approximately $18,500 cash.  Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note 9 for additional disclosure regarding the acquisition of MusclePharm.

 

 

NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Significant accounting policies are as follows:

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in the consolidated financial statements.

 

F- 6
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Foreign Currency Translation

 

The functional currency of the Company is the U.S. dollar.  The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar.  The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

 

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

 

Revenue Recognition

 

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

 

The Company accounts for revenue in accordance with FASB ASC 606. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. 

 

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company’s products are also sold on e-commerce platforms including Amazon.  For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company: 1) owns the goods before they are transferred to the customer,   2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, 3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, 4) is subject to credit risk (i.e., credit card chargebacks), 5) establishes prices of its products, 6) can determine who fulfills the goods to the customer (Amazon or the Company) and 7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in selling, general and administrative expense in the consolidated statements of income and comprehensive income.

 

F- 7
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

The Company disaggregates revenue into geographical regions and distribution channels.  The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. 

 

Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as third-party e-commerce platforms such as Amazon, for the year ended December 31, 2023 was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same twelve-month period in 2022.

 

Sales to customers in the U.S. were approximately 93% and 99% for the year ended December 31, 2023 and 2022, respectively, with the balance of sales to customers primarily in Canada.

 

Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

 

For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.

 

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

Customer and Vendor Concentration

 

Total net sales to GNC during 2023 and 2022 were 33% and 67 % of total revenue for the years ended December 31, 2023 and 2022, respectively. Accounts receivable attributable to GNC as of December 31, 2023 and 2022 represented 30% and 43% of the Company’s total accounts receivable balance, respectively.

 

As of December 31, 2023 and 2022, there was one vendor who accounted for 51% and 78% of the Company's consolidated accounts payable, respectively. For the year ended December 31, 2023, there were three vendors who accounted for 37%, 30%, and 10% of the Company's inventory-related purchases. For the year ended December 31, 2022, there were two vendors who accounted for 49% and 18% of the Company's inventory-related purchases, respectively.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

All of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts, estimating losses resulting from the inability of its customers to make required payments for products. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped into categories by the number of days the balance is past due, and the estimated loss is recorded based upon management’s assessment of collectability. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.

 

As of December 31, 2023 and 2022, the Company had provided a reserve for doubtful accounts of $17 and $50, respectively.

 

F- 8
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Product Returns, Sales Incentives and Other Forms of Variable Consideration 

 

In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include, but are not limited to, product returns and sales incentives, such as markdowns and margin adjustments. For these types of arrangements, the adjustments to revenue are recorded at the later of when (i) the Company recognizes revenue for the transfer of the related products to the customers, or (ii) the Company pays, or promises to pay, the consideration.

 

We currently have a 30-day product return policy for direct-to-consumer sales, which allows for a 100% sales price refund for the return of unopened and undamaged products purchased from us online through one of our websites or e-commerce platforms. Product sold to certain wholesale customers may be returned from store shelves or the distribution center in the event product is damaged, short dated, expired or recalled.

 

GNC maintains a customer satisfaction program which allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC may require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.

 

For the sale of goods with a right of return, the Company estimates variable consideration using the most likely amount method and recognizes revenue for the consideration it expects to be entitled to when control of the related product is transferred to the customers and records a product returns liability for the amount it expects to credit back its customers. Under this method, certain forms of variable consideration are based on expected sell-through results, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. The product returns liability includes estimates that directly impact reported revenue. These estimates are calculated based on a history of actual returns, estimated future returns and information provided by customers regarding their inventory levels. Consideration of these factors results in an estimate for anticipated sales returns that reflects increases or decreases related to seasonal fluctuations. In addition, as necessary, product returns liability may be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include, but are not limited to, changes in the retail environment and the Company's decision to continue to support new and existing products.

 

Information for product returns is received on a regular basis and adjusted for accordingly. Adjustments for returns are based on factual information and historical trends for Company products and are specific to each distribution channel. We monitor, among other things, remaining shelf life and sell-through data on a weekly basis. If we determine there are any risks or issues with any specific products, we accrue sales return allowances based on management’s assessment of the overall risk and likelihood of returns in light of all information available.

 

Total allowance for product returns, sales returns and incentive programs as of December 31, 2023 and 2022 amounted to $571 and $590, respectively.

 

Cost of Goods Sold

 

Cost of goods sold is comprised of the costs of products, in-bound freight charges, shipping and handling costs, purchase and receiving costs, and commissions paid to Amazon and other online selling platforms. Other expense not related to the production and distribution of our products is classified as operating expense.

 

Cash, Cash Equivalents, and Restricted Cash

 

The Company’s cash balances on deposit with banks are guaranteed by the Federal Deposit Insurance Corporation up to $250 at December 31, 2023. The Company may be exposed to risk for the amounts of funds held in bank accounts more than the insurance limit. In assessing the risk, the Company’s policy is to maintain cash balances with high-quality financial institutions. The Company had cash balances more than the guarantee during the years ended December 31, 2023 and 2022. Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.

 

Restricted cash consists of cash on deposit with a financial institution in an interest-bearing account pursuant to a credit card agreement.

 

F- 9
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Inventory

 

Inventory is stated at the lower of cost or net realizable value, with costs determined on a first-in, first-out (FIFO) basis. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand and/or our ability to sell the product(s) concerned and production requirements. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market conditions or other factors, which may result in cancellations of advance orders or a reduction in the rate of reorders placed by customers. Additionally, our management’s estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. 

 

As of December 31, 2023 and 2022, the aggregate allowance for expiring, slow moving and excess inventory amounted to $162 and $107, respectively.

 

Leases

 

The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

 

Property and Equipment

 

Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method. The Company amortizes leasehold improvements over the estimated life of these assets or the term of the lease, whichever is shorter. When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and proceeds realized. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized.

 

The range of estimated useful lives used to calculate depreciation for principal items of property and equipment are as follows:

 

Asset category

 

Depreciation / Amortization period (in years)

 

Furniture and fixtures

  3 

Office equipment

  3 

Leasehold improvements

  5 

 

Management regularly reviews property, equipment and other long-lived assets for possible impairment. This review occurs annually or more frequently if events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Based upon management’s annual assessment, there were no indicators of impairment of the Company’s property and equipment and other long-lived assets as of December 31, 2023 and 2022.

 

Intangible and Long-lived Assets

 

Intangible assets are recorded at cost and amortized using the straight-line method over their estimated useful lives. The Company regularly reviews the carrying value and estimated lives of its long-lived assets and intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.

 

F- 10
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

There were no impairment charges incurred during the years ended December 31, 2023 and 2022.

 

Goodwill

 

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test.  The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach.  The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

 

As the Company uses the market approach to determine fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

 

There were no impairment charges incurred during the years ended December 31, 2023 and 2022.

 

Acquisitions and Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.

 

Income Taxes

 

The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC 740”). Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax assets of the Company relate primarily to operating loss carryforwards for federal income tax purposes.  The deferred tax liabilities of the Company relate primarily to intangible assets that are not deductible for tax purposes in the jurisdictions to which they relate.

 

The Company periodically evaluates its tax positions to determine whether it is more likely than not that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. The Company accrues interest and penalties, if incurred, on unrecognized tax benefits as components of the income tax provision in the accompanying consolidated statements of income and comprehensive income. As of December 31, 2023, and 2022, the Company has not established a liability for uncertain tax positions.

 

F- 11
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

 

Basic and diluted weighted-average shares outstanding and antidilutive options that were excluded from diluted weighted average shares outstanding are as follows:

 

  

December 31,

 
  

2023

  

2022

 
         

Basic weighted average shares outstanding

  4,490   4,553 

Dilutive effect of potential common shares

  415   422 

Diluted weighted average shares outstanding

  4,905   4,975 
         

Antidilutive options

  117   29 

 

Fair Value Measurements

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:

 

 

●

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

  

 

 

●

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

  

 

 

●

Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company’s own data.

 

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of its notes payable approximate their fair value based on the market interest rates of these notes.

 

F- 12
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Stock Compensation Expense

 

The Company periodically issues restricted share units (“RSUs”), stock options and warrants to employees and non-employees in non-capital raising transactions for services rendered.

 

Such issuances vest and expire according to the terms established at the issuance date.

 

Stock-based payments to officers, directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock-based payments to officers, directors, and employees, which are generally time vested, are measured at the grant date fair value and compensation cost is recognized on a straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock-based payments is estimated using the Black-Scholes option-pricing model or other applicable valuation model such as the Monte Carlo valuation pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used could materially affect compensation expense recorded in future periods.

 

Segments

 

The Company operates in one segment for the distribution of our products.  In accordance with FASB ASC Topic 280, Segment Reporting, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.  Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue.  All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.  Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments included in ASU 2016-13 require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Although the new standard, known as the current expected credit loss (“CECL”) model, has a greater impact on financial institutions, most other organizations with financial instruments or other assets (trade receivables, contract assets, lease receivables, financial guarantees, loans and loan commitments, and held-to-maturity debt securities) are subject to the CECL model and will need to use forward-looking information to better evaluate their credit loss estimates. Many of the loss estimation techniques applied today will still be permitted, although the inputs to those techniques will change to reflect the full amount of expected credit losses. In addition, ASU 2016-13 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU 2016-13 was originally effective for public companies for fiscal years beginning after December 15, 2019. In November of 2019, the FASB issued ASU 2019-10, which delayed the implementation of ASU 2016-13 to fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company has adopted this guidance beginning January 1, 2023. This guidance did not have a significant impact on the Company’s financial statements.

 

In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. The ASU requires buyers to disclose information about their supplier finance programs. Interim and annual requirements include the disclosure of outstanding amounts under the obligations as of the end of the reporting period, and annual requirements include a roll-forward of those obligations for the annual reporting period, as well as a description of payment and other key terms of the programs. This update is effective for annual periods beginning after December 15, 2022, and interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted ASU 2022-04 on January 1, 2023, and there was no material impact on our financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, Segment Reporting, including the significant segment expense disclosures. This standard will be effective for the Company on January 1, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted. The updates required by this standard should be applied retrospectively to all periods presented in the financial statements. The Company does not expect this standard to have a material impact on its results of operations, financial position or cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

F- 13
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

 

 

NOTE 3. INTANGIBLE ASSETS

 

Intangible assets are amortized on a straight-line basis over their estimated useful lives.  The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of December 31, 2023 and 2022.

 

  As of December 31, 2023       
  

Gross

amount

  

Accumulated

amortization

  

Net book

value

  

Useful life

(years)

 

Brands

 $26,201  $-  $26,201  Indefinite 

Client relationships

  80   (55)  25   4 

Formulations

  70   (48)  22   4 

Trademarks

  60   -   60  

Indefinite

 

Website

  11   (10)  1   3 

Total identifiable assets

 $26,422  $(113) $26,309     

 

  As of December 31, 2022       
  

Gross

amount

  

Accumulated

amortization

  

Net book

value

  

Useful life

(years)

 

Client relationships

  80   (34)  46   4 

Formulations

  70   (30)  40   4 

Trademarks

  60   -   60  

Indefinite

 

Website

  11   (7)  4   3 

Total identifiable assets

 $221  $(71) $150     

 

Amortization expense was $42 for the years ended December 31, 2023 and 2022.

 

 

NOTE 4.  INVENTORIES

 

The Company’s inventories as of December 31, 2023 and 2022 were as follows:

 

  

December 31,

  

December 31,

 
  

2023

  

2022

 
         

Finished goods

 $8,292  $8,347 

Components

  961   865 

Allowance for obsolescence

  (162)  (107)

Total

 $9,091  $9,105 

 
 

NOTE 5.  PROPERTY AND EQUIPMENT

 

The Company's property and equipment balances as of December 31, 2023 and 2022 were as follows:

 

  

December 31,

  

December 31,

 
  

2023

  

2022

 

Equipment

 $951  $902 

Accumulated depreciation

  (814)  (856)

Total

 $137  $46 

 

Depreciation expense for property and equipment was $52 for the year ended December 31, 2023 compared to $24 for the year ended December 31, 2022.

 

F- 14
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 
 

NOTE 6.  NOTES PAYABLE

 

Notes payable consisted of the following:

 

  

December 31,

2023

  

December 31,

2022

 
         
Term loan A (8.21% as of December 31, 2023) $10,625  $- 
Term loan B (8.21% as of December 31, 2023)  9,500   - 
Unamortized debt issuance costs  (116)  - 

Total

  20,009  $- 
Current  (4,500)  - 
Long Term $15,509  $- 

 

Credit Agreements – First Citizens Bank

 

On February 23, 2023, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with First Citizens Bank (the “Bank”), amending and restating that certain Credit Agreement, dated September 24, 2019, between the Company and the Bank. Pursuant to the Previous Credit Agreement, the Bank provided the Company with a term loan for the principal amount of $12,500 (“Term Loan A”), and a revolving line of credit of $3,500 (the “Line of Credit”, and collectively with the Term Loans, the “Loan”). The Company used the proceeds from the Loan to fund the acquisition of MRC and for general working capital purposes, including those of MRC.

 

Second Amended and Restated Credit Agreement

 

On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with the Bank, amending and restating the Credit Agreement, between the Company and the Bank. Pursuant to the Amended Credit Agreement, the Bank provided the Company with an additional Term Loan (“Term Loan B”) for the principal amount of $10,000 and extended the Line of Credit of $3.5 million to December 15, 2024. The Company used the proceeds from the loan to fund the acquisition of assets of MusclePharm (discussed in further detail in Note 8) and for general working capital purposes.

 

Pursuant to the Amended Credit Agreement, the Term Loans accrue interest at a per annum rate equal to 2.75% above the one-month secured overnight financing rate published for such day by the Federal Reserve Bank of New York (“Term SOFR Rate”); and the Company shall make payments on March 10th, June 10th, September 10th, and December 10th of each calendar year, of principal plus accrued interest on the Term Loans in amounts sufficient to fully amortize Term Loan A through  February 28, 2028 and Term Loan B through October 10, 2028; and outstanding advances under the Line of Credit (“Advances”) will accrue interest at the Applicable Rate and the Company will pay the interest on the Advances monthly, with all principal and any accrued interest on outstanding Advances being due and payable in full on the Line of Credit maturity date. The Company may prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment.

 

The Agreement contains customary events of default (each an “Event of Default”), which upon the occurrence of an Event of Default, among other things, interest will accrue at the Applicable Rate plus 2% per annum, and the Bank may declare all obligations, with interest thereon, immediately due and payable. The Agreement further contains customary representations and warranties of the Company; customary indemnification provisions whereby the Company will indemnify Bank for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of the Company, and certain other matters; and customary affirmative and negative covenants, including covenants to maintain a Fixed Charge Coverage Ratio (as defined in the Agreement) of not less than 1.25 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending December 31, 2023, a Funded Debt to EBITDA Ratio (as defined in the Credit Agreement) of not more than 2.50 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending March 31, 2024, and to the extent the Term Loans still have a balance as of June 30, 2025 and a Cash Flow Leverage threshold (as defined in the Agreement) of at least 1.15 is not met, the Company will be required to make a prepayment on the Term Loan equal to 50% of the Excess Cash Flow (as defined in the Agreement). The Company was in compliance with all covenants as of December 31, 2023.

 

As of December 31, 2023, the borrowings outstanding on the Term Loans and Line of Credit were $20,125 and $0, respectively.

 

F- 15
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Maturities of the Company's Term Loans are as follows:

 

Year ending

    

2024

  4,500 

2025

  4,500 

2026

  4,500 

2027

  4,500 

2028

  2,125 

Total balance outstanding as of December 31, 2023

 $20,125 

 
 

NOTE 7.  EQUITY

 

The Company is authorized to issue 60,000 shares of Common Stock, $0.01 par value per share, of which 4,598 and 4,507 shares of Common Stock were issued and outstanding as of December 31, 2023 and 2022, respectively.

 

Common Stock Issued for Services

 

In February 2021, the Company granted an officer an aggregate of 160 restricted share units (“RSUs”) with a fair value of $468. The Company recorded $31 and $287 of stock compensation expense related to RSUs during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, there was $0 and $31 of unamortized compensation expense associated with the grant of the RSUs. 

 

Share Repurchase Program

 

On August 16, 2019, the Company approved a share repurchase program, pursuant to which the Board authorized management to repurchase up to $500 of the Company's Common Stock over the subsequent 24 months (the "Share Repurchase Program"), as amended September 23, 2019 to increase the repurchase amount to $1, and include shares of the Company's Common Stock, its Series A Convertible Preferred Stock, par value $0.01 per share ("Series A Preferred"), and warrants to purchase shares of the Company's Common Stock ("Warrants") in the Share Repurchase Program, to be repurchased over the next 24 months, at a purchase price, in the case of Common Stock, equal to the fair market value of the Company's Common Stock on the date of purchase, and in the case of Series A Preferred and Warrants, at a purchase price determined by management, with the exact date and amount of such purchases to be determined by management; further amended on November 6, 2019 to increase the repurchase amount to $2,500 over the subsequent 24 months, and further amended on February 1, 2021 to increase the repurchase amount to up to $5,000 over the subsequent 24 months.

 

On March 17, 2023, the Board approved an extension of the Share Repurchase Program. Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $5,000 of the Company's Common Stock over the subsequent 24 months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management. All other terms of the Share Repurchase Program remain unchanged.

 

During the year ended December 31, 2023, the Company did not repurchase any shares of the Company’s Common Stock under the Share Repurchase Program. As of December 31, 2023, the Company may purchase up to $5,000 of additional shares of Common Stock under the Share Repurchase Program.

 

F- 16
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

Treasury Shares

 

In January 2022, the Company retired all treasury shares. All shares repurchased by the Company subsequent to January 2022 were retired immediately upon acquisition.  As of December 31, 2023, there are no shares held in treasury.

 

Information regarding options outstanding as of December 31, 2023 is as follows:

 

  

Number of

  

Weighted

average

exercise

  

Weighted

average

remaining

life

 
  

options

  

price

  

(years)

 

Outstanding, December 31, 2021

  380  $3.44   6.2 

Issued

  10   15.65     

Exercised

  (4)  8.27     

Forfeited

  (7)  35.88     

Outstanding, December 31, 2022

  379  $3.09   5.3 

Issued

  117   19.10     

Exercised

  (9)  0.70     

Forfeited

  (3)  30.31     

Outstanding, December 31, 2023

  484  $6.82   4.5 

 

Outstanding

  

Exercisable

 

Exercise

price per

share

  

Total

number

of options

  

Weighted

average

remaining

life (years)

  

Weighted

average

exercise

price

  

Number of

vested

options

  

Weighted

average

exercise

price

 
                         
$0.70-5.24   349   4.5  $2.30   317  $2.01 
$11.55-19.20   135   4.6  $18.56   42  $17.63 
       484   4.5  $6.82   359  $3.85 

 

The closing price for the Company’s Common Stock on December 29, 2023 was $19.10, resulting in an intrinsic value of outstanding options of $5,155. 

 

During the year ended December 31, 2023, the Company granted stock options to employees to purchase 117 shares of Company Common Stock. The stock options are exercisable at an average price of $19.10 per share, expire in five years and primarily vest as follows: one-third vested immediately upon issuance, and the remainder vest equally in equal annual installments over a period of two years from grant date. The total fair value of these options at grant date was approximately $1,014, which was determined using the Black-Scholes option pricing model with the following average assumption: stock price of $19.10 per share, expected term of 5 years, volatility of 45%, dividend rate of 0% and risk-free interest rate of 4.1%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s Common Stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

During the year ended December 31, 2022, the Company granted stock options to employees to purchase 10 shares of Company Common Stock. The stock options are exercisable at an average price of $15.65 per share, expire in five years and vest as follows: one-fourth vested immediately upon issuance, and the remainder vest equally in equal annual installments over a period of three years from grant date. The total fair value of these options at grant date was approximately $90, which was determined using the Black-Scholes option pricing model with the following average assumption: stock price of $15.65 per share, expected term of 5 years, volatility of 67%, dividend rate of 0% and risk-free interest rate of 2.7%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s Common Stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

F- 17
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

The Company recognized $442 and $76 of stock compensation expense related to the vesting of these options during the years ended December 31, 2023 and 2022, respectively.  As of December 31, 2023, there was $740 of unvested stock compensation that will be recognized as an expense in future periods as the options vest.

 

Warrants

 

As of December 31, 2021, 143 warrants at an exercise price of $1.15 per share were outstanding. During the years ended December 31, 2023 and 2022, no warrants were granted and no warrants expired. During the year ended December 31, 2023, 143,480 shares of Common Stock were issued for the exercise of all outstanding warrants, resulting in net proceeds to the Company of $165.

 

Total outstanding warrants to purchase shares of Common Stock as of December 31, 2023 and 2022 amounted to 0 and 143,480, respectively.

 

 

NOTE 8. ACQUISITION OF MIMI’S ROCK CORP

 

On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire all of the equity interests of MRC. The acquisition closed on February 28, 2023. MRC is headquartered in Oakville, Ontario, Canada. The purchase price of $17,099 was paid with proceeds from the Term Loan as well as cash on hand. 

 

During the years ended December 31, 2023 and 2022, the Company incurred $1,570 and $225, respectively, of transaction-related costs for the acquisition of MRC.

 

The Company accounted for the acquisition as a business combination under Accounting Standards Codification (“ASC”) 805, Business Combinations. The following table summarizes the allocation of the purchase price based on the fair value of the assets acquired and liabilities assumed on the date of acquisition:

 

  

February 28,

2023

 

Assets acquired:

    

Accounts receivable

 $250 

Inventories

  1,166 

Prepaid expense and other assets

  220 

Sales tax receivable

  862 

Right of use asset

  98 

Property and equipment

  32 

Intangible assets

  7,630 

Goodwill

  12,764 

Accounts payable and accrued expense

  (2,694)

Income tax payable

  (651)

Product returns

  (23)

Lease liabilities

  (111)

Deferred tax liabilities

  (2,444)

Net assets acquired

 $17,099 

 

F- 18
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

The purchase was intended to augment and diversify the Company’s product offerings and lineup.  Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business.

 

Pro Forma Condensed Combined Financial Information (Unaudited) (In thousands)

 

The following presents the Company’s unaudited pro forma financial information for the years ended December 31, 2023 and 2022, respectively, giving effect to the acquisition of MRC as if it had occurred at January 1, 2022. Included in the pro forma information is: fair value adjustment to inventory acquired during the years ended December 31, 2023 and 2022, removal of transaction-related costs related to the acquisition of MRC, removal of the interest costs from MRC’s debt prior to the closing of the acquisition, and interest on borrowings made by the Company based on the projected balance of the Term Loan for the respective periods presented in this pro forma.

 

  

Year

ended

  

Year

ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

 
         

Revenue

 $57,755  $58,457 
         

Net income

 $7,076  $4,564 
         

Diluted net income per share

 $1.47  $0.92 

 

The pro forma adjustments do not reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does not purport to present what the Company’s results would actually have been had the transaction actually occurred on the dates presented or to project the combined company’s results of operations or financial position for any future period.

 

MRC revenue and net income for the period from February 28, 2023 to December 31, 2023 was $24,370 and $1,975, respectively.

 

 

NOTE 9. ACQUISITION OF MUSCLEPHARM

 

On October 10, 2023, the Company acquired substantially all of the assets and assumed none of the liabilities other than de minimus cure costs relating to certain assumed contracts of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. Total consideration for the acquisition, including legal costs, amounted to $18,788.

 

The Company accounted for the transaction as an asset acquisition under Accounting Standards Codification (“ASC”) 805. The assets acquired consist of indefinite life intellectual property – brands with an estimated value of $18,593 – and inventory of $195.

 

F- 19
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 
 

NOTE 10.  INCOME TAXES

 

Components of the total provision for income taxes are as follows:

 

  

Year ended

December 31,

2023

  

Year ended

December 31,

2022

 

Current tax expense (benefit)

        

Domestic

 $(77) $199 

Foreign

  755   - 
         

Deferred tax expense (benefit)

        

Domestic

  1,056   1,194 

Foreign

  (27)  - 
         

Provision for income taxes

 $1,707  $1,393 

 

The Company is subject to income tax in the U.S., Canada, Germany and Barbados through its wholly owned subsidiaries.  The combined statutory tax rate is 22% (24% in 2022)

 

The provision for income taxes differs from the amount determined by applying the federal statutory rate as follows:

 

  

Year ended

  

Year ended

 
  

December 31,

2023

  

December 31,

2022

 

Pre-tax net income

 $7,003  $5,822 

Federal income tax rate

  22.3%  24.0%

Provision for income taxes based on statutory rate

  1,562   1,397 
         

Increase (decrease) resulting from:

        

Non-deductible expenses

  28   - 

Difference in jurisdictional tax rates

  128   - 

True up of prior period

  (86)  - 

Other

  75   (4)
         

Provision for income taxes

 $1,707  $1,393 

 

F- 20
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

The tax effects of significant temporary differences and credit and operating loss carryforwards that give rise to the net deferred tax assets and tax liabilities are as follows:

 

  

December 31,

2023

  

December 31,

2022

 

Deferred tax assets (liabilities)

        

Loss carry forwards

  5,097   2,034 

Tangible assets

  (25)  - 

Intangible assets

  (2,540)  - 

Provisions and reserves

  490   157 

Other

  1   193 

Deferred tax assets (liabilities)

  3,023   2,384 

Valuation allowance

  (4,644)  (537)

Net deferred tax asset (liability)

 $(1,621) $1,847 

 

The Company has assessed the realizability of the net deferred tax assets by considering the relevant positive and negative evidence available to determine whether it is more likely than not that some portion or all of the deferred tax assets will be realized. In making such a determination, the Company considered all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and recent results of operations.

 

Deferred income taxes have not been recorded on the basis differences for investments in consolidated subsidiaries as these basis differences are indefinitely reinvested or will reverse in a non-taxable manner. Quantification of the deferred income tax liability, if any, associated with indefinitely reinvested basis differences is not practicable.

 

As of December 31, 2023, the Company has the following U.S. federal losses carried forward. U.S. federal losses incurred prior to 2018 have a carry forward of 20 years, subsequent losses can be carried forward indefinitely. The Canadian non-capital loss carry forwards expire between 2037 and 2043.

 

  

U.S. Federal

  

Canada (USD)

  

Total

 

2034

 $101  $-  $101 

2035

  950   -   950 

2036

  2,923   -   2,923 

2037

  -   20   20 

2038

  615   3,224   3,839 

2039

  -   2,875   2,875 

2040

  -   2,215   2,215 

2041

  -   1,838   1,838 

2042

  -   4,350   4,350 

2043

  -   1,079   1,079 

Indefinite

  -   -   - 
  $4,589  $15,601  $20,190 

 

Utilization of net operating loss carry forwards may be subject to limitations in the event of a change in ownership as defined under U.S. IRC Section 382, and similar state provisions. An "ownership change" is generally defined as a cumulative change in the ownership interest of significant stockholders of more than 50 percentage points over a three-year period. Such ownership change could result in a limitation of the Company's ability to reduce future income by net operating loss carry forwards. The Company acquired a subsidiary in 2015.

 

The Company operates in a number of tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who may challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. The Company recognizes the effects of uncertain tax positions in the consolidated financial statements after determining that it is more-likely-than-not the uncertain tax positions will be sustained.  As of December 31, 2023, the Company has not recorded any uncertain tax positions or any accrued interest and penalties on the consolidated balance sheet. During the year ended December 31, 2023, the Company did not record any interest and penalties in the consolidated statement of income and comprehensive income.

 

F- 21
FITLIFE BRANDS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
(in thousands, except per share amounts)
 
 

 

 

NOTE 11. COMMITMENTS AND CONTINGENCIES

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

 

NOTE 12.  SUBSEQUENT EVENTS

 

Subsequent to the end of 2023, the Company made a scheduled amortization payment of $1,100 on its term loans as well as a voluntary payment of $2,500 on its Term Loan A.

 

 

NOTE 13. RECLASSIFICATIONS

 

Certain prior year amounts have been reclassified to conform to current presentation.  These reclassifications had no effect on the reported operating income or net income on the Consolidated Statements of Income and Comprehensive Income.  Certain costs previously classified as selling, general and administrative expense have been reclassified to merger and acquisition related expense on the Consolidated Statements of Income and Comprehensive Income.

 

 
EX-21 2 ex_630109.htm EXHIBIT 21

Exhibit 21

 

SUBSIDIARIES OF REGISTRANT

 

Significant Subsidiaries

 

Company

  

Jurisdiction of

incorporation

  

Percentage of

voting

securities

owned

by registrant

    

Number

of US

subsidiaries

    

Number

of non-US

subsidiaries

  

NDS Nutrition Products, Inc.

  

Florida

     100 %   2     —  

iSatori, Inc.

  

Delaware

     100 %   —     —  

1000374984 Ontario Inc.

  

Canada

     100 %   —     4  

MP Acquisition Corp.

  

Nevada

     100 %   —     —  

 

 
 EX-31.1 3 ex_630111.htm EXHIBIT 31.1

Exhibit 31.1

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

 

I, Dayton Judd, Chief Executive Officer of the Company, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of FitLife Brands, Inc.;
 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 

 

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   

 
 

c.

Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
   

 
 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   

 
 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Registrant

 

Date: March 29, 2024

FitLife Brands, Inc.

By: /s/ Dayton Judd
 

Dayton Judd
 

Chief Executive Officer

(Principal Executive Officer)

 

 
 EX-31.2 4 ex_630112.htm EXHIBIT 31.2

Exhibit 31.2

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

 

I, Jakob York, Chief Financial Officer of the Company, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of FitLife Brands, Inc.;
 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 

 

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   

 
 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   

 
 

c.

Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
   

 
 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   

 
 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Registrant

 

Date: March 29, 2024

FitLife Brands, Inc.

 

By: /s/ Jakob York
 

Jakob York
 

Chief Financial Officer

(Principal Financial Officer)

 

 
 EX-32.1 5 ex_630113.htm EXHIBIT 32.1

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Annual Report of FitLife Brands, Inc. (the "Company") on Form 10-K for the year ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dayton Judd, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 

 

(2) 

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant

 

Date: March 29, 2024

FitLife Brands, Inc.

 

By: /s/ Dayton Judd
 

Dayton Judd
 

Chief Executive Officer

(Principal Executive Officer)

 

 

In connection with the Annual Report of FitLife Brands, Inc. (the "Company") on Form 10-K for the year ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jakob York, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 29, 2024

By: /s/ Jakob York
 

Jakob York
 

Chief Financial Officer

(Principal Financial Officer)

 

 
 EX-101.SCH 6 ftlf-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Income and Comprehensive Income link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statement of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 995452 - Disclosure - Note 1 - Description of Business link:calculationLink link:definitionLink link:presentationLink 995453 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 995454 - Disclosure - Note 3 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 995455 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 995456 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 995457 - Disclosure - Note 6 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 995458 - Disclosure - Note 7 - Equity link:calculationLink link:definitionLink link:presentationLink 995459 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Note 9 - Acquisition of MusclePharm link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 11 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 12 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 13 - Reclassifications link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 3 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 6 - Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 7 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 10 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 1 - Description of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 3 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 3 - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 4 - Inventories - Summary of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 6 - Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 6 - Notes Payable - Maturity (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 7 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 7 - Equity - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 7 - Equity - Exercise Price Range (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 9 - Acquisition of MusclePharm (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 10 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 10 - Income Taxes - Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 10 - Income Taxes - Operating Loss Carryforwards (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 12 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 ftlf-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ftlf-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ftlf-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share) Note To Financial Statement Details Textual Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Significant Accounting Policies Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 2 - Summary of Significant Accounting Policies Provision for income taxes based on statutory rate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Note 3 - Intangible Assets Note 4 - Inventories Note 5 - Property and Equipment Note 6 - Notes Payable Note 7 - Equity Note 8 - Acquisition of Mimi's Rock Corp Prepaid expense and other assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Note 10 - Income Taxes Accounts receivable us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Income Tax Disclosure [Text Block] Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details) Product returns Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details) Note 3 - Intangible Assets - Schedule of Intangible Assets (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Inventories us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Note 4 - Inventories - Summary of Inventory (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 5 - Property and Equipment - Property and Equipment (Details) Schedule of Maturities of Long-Term Debt [Table Text Block] Note 6 - Notes Payable - Debt Obligations (Details) Schedule of Debt [Table Text Block] Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals) Note 6 - Notes Payable - Maturity (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) Note 7 - Equity - Stock Option Activity (Details) Note 7 - Equity - Exercise Price Range (Details) Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Note 10 - Income Taxes - Provision for Income Taxes (Details) Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details) Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Note 10 - Income Taxes - Operating Loss Carryforwards (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Foreign currency translation adjustment us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Diluted net income per share (in dollars per share) us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted Term loan – current portion Current Comprehensive (loss) income Net income us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Business Acquisition, Pro Forma Information [Table Text Block] Revenue us-gaap_BusinessAcquisitionsProFormaRevenue Outstanding, weighted average remaining life (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Issued, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) us-gaap_AccruedIncomeTaxesCurrent Income taxes payable Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, number of options (in shares) Outstanding, number of options (in shares) Credit Facility [Axis] Credit Facility [Domain] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Trademarks [Member] us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) us-gaap_PaymentsToAcquireProductiveAssets Payments to Acquire Productive Assets Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustment Brands [Member] In reference to brands associated with the company. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Term Loans [Member] In reference to the Term Loans. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Term Loan A [Member] In relation Term Loan A Cash paid for income taxes Basic weighted average shares outstanding (in shares) us-gaap_WeightedAverageNumberOfSharesIssuedBasic CURRENT LIABILITIES: Vesting [Axis] ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable Income tax payable The amount of income tax payable which has been recognized as of the acquisition date. Vesting [Domain] Right of use asset ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset The amount of right of use asset recognized as of the acquisition date. Lease liability Share-Based Payment Arrangement, Tranche Two [Member] us-gaap_Assets TOTAL ASSETS ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductReturns Product returns The amount of product returns which has been recognized as of the acquisition date. Supplemental cash flow disclosure us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Customer Relationships [Member] Amortization of deferred finance costs In reference to the amortization of deferred finance costs. Deferred tax asset Finite-Lived Intangible Assets by Major Class [Axis] Amortization of inventory step-up in reference to the amortization of inventory step-up Finite-Lived Intangible Assets, Major Class Name [Domain] Award Type [Domain] Award Type [Axis] Net income NET INCOME Intangibles amortization Intangibles, amortization Intangibles, net of amortization of $113 and $71, respectively Restricted Stock Units (RSUs) [Member] Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Approximation [Member] Related to approximation. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] ftlf_EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, Federal, State, and Foreign Statutory Income Tax Rate Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to federal, state and local, and foreign income tax expense (benefit), net of federal tax expense (benefit). Commitments and Contingencies Disclosure [Text Block] Business Combination Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation Property and equipment, net Total Goodwill Goodwill Equipment Tax Year 2034 [Member] In relation to tax year 2034 Canada Revenue Agency [Member] Tax Year 2036 [Member] In relation to tax year 2036 Tax Year 2035 [Member] In relation to tax year 2035 Tax Year 2042 [Member] In relation to tax period 2042. Tax Year 2041 [Member] In relation to tax period 2041. Tax Year 2043 [Member] In relation to tax period 2043. Tax Year 2038 [Member] In relation to tax period 2038 Tax Year 2037 [Member] In relation to tax year 2037 Tax Year 2040 [Member] In relation to tax period 2040. Tax Year 2039 [Member] In relation to tax period 2039. Indefinite [Member] In relation to an indefinite time period. CASH FLOWS FROM INVESTING ACTIVITIES: NET INCOME PER SHARE Income taxes payable us-gaap_DeferredFinanceCostsGross Unamortized debt issuance costs PROVISION FOR INCOME TAXES Provision for income taxes us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_OperatingExpenses Total operating expense Restricted cash Cash and cash equivalents us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Amendment Flag COMPREHENSIVE INCOME: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Reclassifications [Text Block] Accrued liabilities and other liabilities Exercise of warrants (in shares) In reference to shares of warrants exercised. Exercise of warrants In reference to Warrants exercised in period. us-gaap_TreasuryStockSharesAcquired Repurchase of common stock (in shares) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Product returns us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Stated percentage Sales tax receivable ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsSalesTaxReceivable In reference to the sales tax receivable in relation to a business combination. Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Deferred taxes Document Period End Date us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expense and other assets Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company Merger and acquisition related Document Information [Line Items] Document Information [Table] us-gaap_NumberOfStores Number of Stores Entity Public Float Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers us-gaap_BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs Entity Well-known Seasoned Issuer Variable Rate [Domain] Variable Rate [Axis] us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable - trade Entity Tax Identification Number Entity Central Index Key Depreciation and amortization Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] Share Repurchase Program [Member] Information related to the Share Repurchase Program. us-gaap_TreasuryStockRetiredCostMethodAmount Retirement of treasury shares Legal Entity [Axis] ftlf_StockRepurchaseProgramExpirationPeriod Stock Repurchase Program Expiration Period (Year) Expiration period for the purchase of an entity's own shares under a stock repurchase plan. Entity Address, Address Line One Supplier Concentration Risk [Member] ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets us-gaap_TreasuryStockValueAcquiredCostMethod Repurchase of common stock Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] Geographic Concentration Risk [Member] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Axis] Material Terms of Trading Arrangement [Text Block] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss Entity Common Stock, Shares Outstanding Revenue, Segment Benchmark [Member] Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Nature of Operations [Text Block] Local Phone Number Exercise of stock options (in shares) Exercised, number of options (in shares) us-gaap_TableTextBlock Notes Tables GNC [Member] Information related to GNC. Online Sales [Member] Information related to online sales. us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Exercise of stock options Formulations [Member] Information related to formulations. Website [Member] Information related to website. Shares surrendered by former employee (in shares) Selling, general and administrative Allowance for doubtful accounts Stock-based compensation Issued, number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, number of options (in shares) us-gaap_CashFDICInsuredAmount Cash, FDIC Insured Amount us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY UNITED STATES Accumulated deficit Cash and Cash Equivalents [Axis] Debt Disclosure [Text Block] Cash and Cash Equivalents [Domain] Interest expense Cash [Member] Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Subsequent Event [Member] Long-term lease liability, net of current portion Schedule of Inventory, Current [Table Text Block] Subsequent Event Type [Axis] Lease liability - current portion ftlf_SharesForfeitedDuringPeriodValue Shares Forfeited During Period, Value Represents the value of shares forfeited during period. Subsequent Event Type [Domain] Mimi’s Rock Corp [Member] Relating to Mimi’s Rock Corp. Intangibles, gross Subsequent Events [Text Block] Right of use asset Deferred tax expense (benefit) Fair Value Measurement, Policy [Policy Text Block] ftlf_AccruedExpenseAndOtherLiabilitiesCurrent Accrued expense and other liabilities Amount of accrued expense and liabilities classified as other, due within one year or the normal operating cycle, if longer. Segment Reporting, Policy [Policy Text Block] Stock compensation expense ftlf_OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability Right of use asset Amount of right-of-use asset net of amortization and lease liability from operating lease. Foreign Currency Transactions and Translations Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Business Combinations Policy [Policy Text Block] Intangibles, useful life (Year) Earnings Per Share, Policy [Policy Text Block] OPERATING EXPENSE: Income Tax, Policy [Policy Text Block] Property, Plant and Equipment, Useful Life [Table Text Block] Tabular disclosure of useful life of physical assets used in the normal conduct of business and not intended for resale. us-gaap_Depreciation Depreciation us-gaap_DepreciationDepletionAndAmortization Depreciation and amortization Intangible Assets Disclosure [Text Block] us-gaap_AssetsCurrent Total current assets Equity [Text Block] us-gaap_TreasuryStockCommonShares Treasury Stock, Common, Shares (in shares) ftlf_ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period (in shares) The number of warrants or rights issued during period. ftlf_ClassOfWarrantOrRightExpiredDuringPeriod Class of Warrant or Right, Expired During Period (in shares) The number of warrants or rights expired during period. Compensation Related Costs, Policy [Policy Text Block] Common stock, $0.01 par value, 60,000 shares authorized; 4,598 and 4,507 issued and outstanding as of December 31, 2023 and 2022, respectively Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Issued (in shares) ftlf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value Fair value of options granted. Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Revenue from Contract with Customer [Policy Text Block] us-gaap_DeferredTaxAssetsValuationAllowance Valuation allowance Statistical Measurement [Domain] Maximum [Member] Provisions and reserves Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns, bad debt and inventory. ftlf_TreasuryStockValueAcquired Repurchase of common stock Represents the value of treasury stock acquired during the period. Minimum [Member] Product and Service [Axis] Product and Service [Domain] iSatori Products [Member] Represents iSatori products. us-gaap_DeferredTaxAssetsNet Net deferred tax asset Statistical Measurement [Axis] Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of December 31, 2023 and 2022 Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Cash paid for interest, net of amounts capitalized us-gaap_DeferredTaxAssetsOther Other Geographical [Axis] Property, Plant and Equipment Disclosure [Text Block] Geographical [Domain] Property, Plant and Equipment [Table Text Block] Deferred tax assets (liabilities) Preferred stock, shares authorized (in shares) Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Inventories, net of allowance for obsolescence of $162 and $107, respectively Inventory, Net Total Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Range One [Member] Information related to range one. Range Two [Member] Information related to range two. Revenue Allowance for obsolescence Inventory Valuation Reserves Allowance for obsolescence us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign exchange gain Finished goods ftlf_DebtInstrumentCovenantCashFlowLeverageThreshold Debt Instrument, Covenant, Cash Flow Leverage Threshold Rate of cash flow leverage threshold under covenant of the debt instrument. Customer [Axis] Assets of MusclePharm Corporation [Member] Represents the assets of MusclePharm Corporation. Customer [Domain] ftlf_DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow Debt Instrument, Covenant, Cash Flow Leverage Threshold, Percentage of Excess Cash Flow Percentage of excess cash flow for rate of cash floe leverage threshold under the covenant of the debt instrument. Term Loan B [Member] Represents term loan B. Components Property and equipment (Year) CASH FLOWS FROM OPERATING ACTIVITIES: Statement [Line Items] Allowance of doubtful accounts us-gaap_NumberOfOperatingSegments Number of Operating Segments Furniture and Fixtures [Member] Accounts receivable, net of allowance of doubtful accounts of $17 and $50, respectively Additional paid-in capital STOCKHOLDERS’ EQUITY: ftlf_DebtInstrumentAdditionalInterestRateDefault Debt Instrument, Additional Interest Rate, Default The percent additional interest rate of debt instrument in the event of default. ftlf_FixedChargeCoverageRatio Fixed Charge Coverage Ratio The fixed charge coverage ratio. ftlf_FundedDebtToEBITDARatio Funded Debt to EBITDA Ratio The Funded Debt to EBITDA Ratio. Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other expense (income) Term Loan [Member] Related to term loan. Long-Lived Tangible Asset [Domain] Loss carry forwards Chief Executive Officer [Member] OTHER EXPENSE (INCOME) CURRENT ASSETS Applicable Rate [Member] Related to applicable rate. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH, BEGINNING OF PERIOD CASH AND RESTRICTED CASH, END OF PERIOD Inventory, Policy [Policy Text Block] Foreign currency impact on cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect CHANGE IN CASH AND RESTRICTED CASH us-gaap_Liabilities TOTAL LIABILITIES us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities us-gaap_OperatingIncomeLoss OPERATING INCOME us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expense and other current assets us-gaap_DeferredTaxLiabilities Net deferred tax liability us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Intangible assets us-gaap_GrossProfit Gross profit Cost of goods sold Deferred tax liability Allowance for inventory obsolescence us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Tangible assets us-gaap_InterestAndOtherIncome Interest income Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member] us-gaap_PaymentsForRepurchaseOfCommonStock Repurchases of common stock Cost of Goods and Service [Policy Text Block] Scenario [Domain] us-gaap_ProceedsFromWarrantExercises Proceeds from Warrant Exercises Retained Earnings [Member] Proceeds from exercise of stock options and warrants Title of Individual [Domain] Title of Individual [Axis] Scenario [Axis] Treasury Stock, Common [Member] us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount Additional Paid-in Capital [Member] Share Repurchase Program [Domain] Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] Vendor One [Member] Related to vendor one. Three Vendors [Member] Related to three vendors. Vendor Three [Member] Related to vendor three. Term loan (8.21% as of December 31, 2023) Total balance outstanding as of December 31, 2023 Vendor Two [Member] Related to vendor two. Current tax expense (benefit) us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) Pre-tax net income INCOME BEFORE INCOME TAXES ICFR Auditor Attestation Flag us-gaap_LineOfCredit Long-Term Line of Credit Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Office Equipment [Member] us-gaap_RepaymentsOfLongTermDebt Payments on term loan Document Annual Report Cash and Cash Equivalents, Policy [Policy Text Block] Receivable [Policy Text Block] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current ftlf_NumberOfVendors Number of Vendors The number of vendors. Sales tax receivable The amount of sales taxes receivable. One Vendor [Member] Related to one vendor. Security Exchange Name Title of 12(b) Security Borrowings on term loan Inventory-related Purchases [Member] Related to inventory related purchases. Two Vendors [Member] Related to two vendors. Tax Period [Domain] Auditor Name Tax Period [Axis] Auditor Firm ID Auditor Location Segments [Axis] Revenue from Contract with Customer, Product Returns, Sales Incentives and Other Forms of Variable Consideration [Policy Text Block] Disclosure of accounting policy for product returns, sales incentives and other forms of variable consideration. Segments [Domain] Dilutive effect of potential common shares (in shares) us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment us-gaap_SharePrice Share Price (in dollars per share) Antidilutive options (in shares) Diluted weighted average common shares (in shares) Diluted weighted average shares outstanding (in shares) Operating loss carry forwards, 2034 Summary of Operating Loss Carryforwards [Table Text Block] Statement [Table] Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic weighted average common shares (in shares) Accounts Payable [Member] Business Acquisition [Axis] Basic (in dollars per share) Business Acquisition, Acquiree [Domain] Statement of Cash Flows [Abstract] us-gaap_ContractWithCustomerRefundLiability Contract with Customer, Refund Liability Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2026 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2027 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive 2028 Common Stock Outstanding [Member] Represents common stock outstanding. us-gaap_RepaymentsOfDebt Repayments of Debt us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2024 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2025 Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Asset Acquisition [Axis] us-gaap_AssetAcquisitionConsiderationTransferred Asset Acquisition, Consideration Transferred Other CASH FLOWS FROM FINANCING ACTIVITIES: Federal income tax rate Difference in jurisdictional tax rates Asset Acquisition [Domain] True up of prior period Asset Acquisition [Text Block] Series A Preferred Stock [Member] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Net assets acquired Balance us-gaap_StockholdersEquity TOTAL STOCKHOLDERS' EQUITY Balance Balance us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Lease liabilities Non-deductible expenses Class of Stock [Axis] Supplier [Axis] Class of Stock [Domain] Supplier [Domain] Term loan, net of current portion and unamortized deferred finance costs us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Deferred tax liabilities us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Cash paid for acquisition Outstanding, weighted average exercise price (in dollars per share) Weighted average remaining life (Year) Number of vested options (in shares) us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable Accounts payable and accrued expense Exercisable, weighted average exercise price (in dollars per share) Upper range limit (in dollars per share) Total number of options (in shares) Exercise Price Range [Axis] Exercise Price Range [Domain] Property and equipment us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Lower range limit (in dollars per share) EX-101.PRE 10 ftlf-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 28, 2024
Jun. 30, 2023
Document Information [Line Items]      
Entity Central Index Key 0001374328    
Entity Registrant Name FITLIFE BRANDS, INC.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 000-52369    
Entity Incorporation, State or Country Code NV    
Entity Tax Identification Number 20-3464383    
Entity Address, Address Line One 5214 S. 136th Street    
Entity Address, City or Town Omaha    
Entity Address, State or Province NE    
Entity Address, Postal Zip Code 68137    
City Area Code 402    
Local Phone Number 991-5618    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Trading Symbol FTLF    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 32,319,000
Entity Common Stock, Shares Outstanding   4,598,241  
Auditor Firm ID 572    
Auditor Name Weinberg & Company, P.A.    
Auditor Location Los Angeles, California    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 1,139 $ 13,277
Restricted cash 759 0
Accounts receivable, net of allowance of doubtful accounts of $17 and $50, respectively 2,046 705
Inventories, net of allowance for obsolescence of $162 and $107, respectively 9,091 9,105
Sales tax receivable 1,019 0
Prepaid expense and other current assets 639 116
Total current assets 14,693 23,203
Property and equipment, net 137 46
Right of use asset 121 103
Intangibles, net of amortization of $113 and $71, respectively 26,309 150
Goodwill 13,294 358
Deferred tax asset 792 1,847
TOTAL ASSETS 55,346 25,707
CURRENT LIABILITIES:    
Accounts payable 3,261 2,995
Accrued expense and other liabilities 1,026 444
Income taxes payable 892 187
Product returns 571 590
Lease liability - current portion 87 54
Total current liabilities 10,337 4,270
Term loan, net of current portion and unamortized deferred finance costs 15,509 0
Long-term lease liability, net of current portion 51 49
Deferred tax liability 2,413 0
TOTAL LIABILITIES 28,310 4,319
STOCKHOLDERS’ EQUITY:    
Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of December 31, 2023 and 2022 0 0
Common stock, $0.01 par value, 60,000 shares authorized; 4,598 and 4,507 issued and outstanding as of December 31, 2023 and 2022, respectively 46 45
Additional paid-in capital 30,699 30,056
Accumulated deficit (3,417) (8,713)
Foreign currency translation adjustment (292) 0
TOTAL STOCKHOLDERS' EQUITY 27,036 21,388
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 55,346 25,707
Term Loans [Member]    
CURRENT LIABILITIES:    
Term loan – current portion 4,500 0
Term loan, net of current portion and unamortized deferred finance costs $ 15,509 $ 0
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Allowance of doubtful accounts $ 17 $ 50
Allowance for obsolescence 162 107
Intangibles amortization $ 113 $ 71
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 10,000 10,000
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 60,000 60,000
Common stock, shares issued (in shares) 4,598 4,507
Common stock, shares outstanding (in shares) 4,598 4,507
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Income and Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue $ 52,700 $ 28,803
Cost of goods sold 31,268 16,769
Gross profit 21,432 12,034
OPERATING EXPENSE:    
Selling, general and administrative 12,161 6,010
Merger and acquisition related 1,627 257
Depreciation and amortization 94 66
Total operating expense 13,882 6,333
OPERATING INCOME 7,550 5,701
OTHER EXPENSE (INCOME)    
Interest income (289) (121)
Interest expense 1,025 0
Foreign exchange gain (189) 0
Total other expense (income) 547 (121)
INCOME BEFORE INCOME TAXES 7,003 5,822
PROVISION FOR INCOME TAXES 1,707 1,393
NET INCOME $ 5,296 $ 4,429
NET INCOME PER SHARE    
Basic (in dollars per share) $ 1.18 $ 0.97
Diluted (in dollars per share) $ 1.08 $ 0.89
Basic weighted average common shares (in shares) 4,490 4,553
Diluted weighted average common shares (in shares) 4,905 4,975
COMPREHENSIVE INCOME:    
Net income $ 5,296 $ 4,429
Foreign currency translation adjustment (292) 0
Comprehensive income $ 5,004 $ 4,429
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock Outstanding [Member]
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]
Total
Balance (in shares) at Dec. 31, 2021 4,552,000            
Balance at Dec. 31, 2021   $ 46 $ (2,087) $ 32,529 $ (13,142) $ 0 $ 17,346
Exercise of stock options (in shares) 3,000           4,000
Exercise of stock options   0 0 29 0 0 $ 29
Stock-based compensation   0 0 363 0 0 363
Net income   0 0 0 4,429 0 4,429
Repurchase of common stock (in shares) (48)            
Repurchase of common stock   (1)          
Repurchase of common stock     (771) 0 0 0 (772)
Retirement of treasury shares   0 2,858 (2,865) 0 0 (7)
Balance (in shares) at Dec. 31, 2022 4,507,000            
Balance at Dec. 31, 2022   45 0 30,056 (8,713) 0 $ 21,388
Shares surrendered by former employee (in shares) (61,000)            
Exercise of stock options (in shares) 9,000           9,000
Exercise of stock options   0 0 6 0 0 $ 6
Exercise of warrants (in shares) 143,000            
Exercise of warrants   1 0 164 0 0 165
Stock-based compensation       473     473
Comprehensive (loss) income   0 0 0 0 (292) (292)
Net income   0 0 0 5,296 0 5,296
Balance (in shares) at Dec. 31, 2023 4,598,000            
Balance at Dec. 31, 2023   $ 46 $ 0 $ 30,699 $ (3,417) $ (292) $ 27,036
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 5,296 $ 4,429
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 94 66
Allowance for doubtful accounts (33) (6)
Allowance for inventory obsolescence 55 51
Stock compensation expense 473 363
Amortization of deferred finance costs 15 0
Amortization of inventory step-up 323 0
Changes in operating assets and liabilities:    
Accounts receivable - trade (882) 247
Inventories 1,026 (2,636)
Deferred taxes 957 1,199
Prepaid expense and other assets (178) 204
Right of use asset 83 55
Accounts payable (2,679) 115
Income taxes payable (356) 184
Lease liability (77) (55)
Accrued liabilities and other liabilities 122 (44)
Product returns (19) (42)
Net cash provided by operating activities 4,220 4,130
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (106) 0
Net cash used in investing activities (35,993) 0
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of stock options and warrants 171 29
Repurchases of common stock 0 (779)
Borrowings on term loan 22,500 0
Payments on term loan (2,375) 0
Net cash provided by (used in) financing activities 20,296 (750)
Foreign currency impact on cash 98 0
CHANGE IN CASH AND RESTRICTED CASH (11,379) 3,380
CASH, BEGINNING OF PERIOD 13,277 9,897
CASH AND RESTRICTED CASH, END OF PERIOD 1,898 13,277
Supplemental cash flow disclosure    
Cash paid for income taxes 698 3
Cash paid for interest, net of amounts capitalized 777 0
Mimi’s Rock Corp [Member]    
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash paid for acquisition (17,099) 0
Assets of MusclePharm Corporation [Member]    
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash paid for acquisition $ (18,788) $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
 12 Months Ended
Dec. 31, 2023
Insider Trading Arr Line Items  
Material Terms of Trading Arrangement [Text Block]

ITEM 9B.  OTHER INFORMATION

 

None.

 
Rule 10b5-1 Arrangement Adopted [Flag] false
Non-Rule 10b5-1 Arrangement Adopted [Flag] false
Rule 10b5-1 Arrangement Terminated [Flag] false
Non-Rule 10b5-1 Arrangement Terminated [Flag] false
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Note 1 - Description of Business
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Nature of Operations [Text Block]

NOTE 1.  DESCRIPTION OF BUSINESS

 

Summary

 

FitLife Brands, Inc. (the “Company”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "iSatori Products"); and (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products"); and (iv) MusclePharm.

 

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.  The Company distributes the MRC Products primarily online.  MusclePharm’s products are sold to both wholesale customers as well as online directly to the end consumer.

 

FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the Nasdaq Capital Market.

 

Recent Developments

 

Acquisition of Mimi’s Rock Corp

 

On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire MRC. On February 28, 2023, the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was $17,099, of which $12,500 was funded using proceeds from a new term loan, and $4,599 from the Company’s available cash. See Note 8 to the financial statements for additional disclosure regarding the acquisition of MRC.

 

Acquisition of MusclePharm Assets

 

On October 10, 2023, the Company acquired substantially all of the assets of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed none of the liabilities of MusclePharm other than de minimus cure costs relating to certain assumed contracts.  Total consideration for the acquisition was approximately $18,500 cash.  Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note 9 for additional disclosure regarding the acquisition of MusclePharm.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Significant accounting policies are as follows:

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in the consolidated financial statements.

 

Foreign Currency Translation

 

The functional currency of the Company is the U.S. dollar.  The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar.  The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

 

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

 

Revenue Recognition

 

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

 

The Company accounts for revenue in accordance with FASB ASC 606. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. 

 

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company’s products are also sold on e-commerce platforms including Amazon.  For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company: 1) owns the goods before they are transferred to the customer,   2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, 3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, 4) is subject to credit risk (i.e., credit card chargebacks), 5) establishes prices of its products, 6) can determine who fulfills the goods to the customer (Amazon or the Company) and 7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in selling, general and administrative expense in the consolidated statements of income and comprehensive income.

 

The Company disaggregates revenue into geographical regions and distribution channels.  The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. 

 

Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as third-party e-commerce platforms such as Amazon, for the year ended December 31, 2023 was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same twelve-month period in 2022.

 

Sales to customers in the U.S. were approximately 93% and 99% for the year ended December 31, 2023 and 2022, respectively, with the balance of sales to customers primarily in Canada.

 

Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

 

For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.

 

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

Customer and Vendor Concentration

 

Total net sales to GNC during 2023 and 2022 were 33% and 67 % of total revenue for the years ended December 31, 2023 and 2022, respectively. Accounts receivable attributable to GNC as of December 31, 2023 and 2022 represented 30% and 43% of the Company’s total accounts receivable balance, respectively.

 

As of December 31, 2023 and 2022, there was one vendor who accounted for 51% and 78% of the Company's consolidated accounts payable, respectively. For the year ended December 31, 2023, there were three vendors who accounted for 37%, 30%, and 10% of the Company's inventory-related purchases. For the year ended December 31, 2022, there were two vendors who accounted for 49% and 18% of the Company's inventory-related purchases, respectively.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

All of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts, estimating losses resulting from the inability of its customers to make required payments for products. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped into categories by the number of days the balance is past due, and the estimated loss is recorded based upon management’s assessment of collectability. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.

 

As of December 31, 2023 and 2022, the Company had provided a reserve for doubtful accounts of $17 and $50, respectively.

 

Product Returns, Sales Incentives and Other Forms of Variable Consideration 

 

In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include, but are not limited to, product returns and sales incentives, such as markdowns and margin adjustments. For these types of arrangements, the adjustments to revenue are recorded at the later of when (i) the Company recognizes revenue for the transfer of the related products to the customers, or (ii) the Company pays, or promises to pay, the consideration.

 

We currently have a 30-day product return policy for direct-to-consumer sales, which allows for a 100% sales price refund for the return of unopened and undamaged products purchased from us online through one of our websites or e-commerce platforms. Product sold to certain wholesale customers may be returned from store shelves or the distribution center in the event product is damaged, short dated, expired or recalled.

 

GNC maintains a customer satisfaction program which allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC may require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.

 

For the sale of goods with a right of return, the Company estimates variable consideration using the most likely amount method and recognizes revenue for the consideration it expects to be entitled to when control of the related product is transferred to the customers and records a product returns liability for the amount it expects to credit back its customers. Under this method, certain forms of variable consideration are based on expected sell-through results, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. The product returns liability includes estimates that directly impact reported revenue. These estimates are calculated based on a history of actual returns, estimated future returns and information provided by customers regarding their inventory levels. Consideration of these factors results in an estimate for anticipated sales returns that reflects increases or decreases related to seasonal fluctuations. In addition, as necessary, product returns liability may be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include, but are not limited to, changes in the retail environment and the Company's decision to continue to support new and existing products.

 

Information for product returns is received on a regular basis and adjusted for accordingly. Adjustments for returns are based on factual information and historical trends for Company products and are specific to each distribution channel. We monitor, among other things, remaining shelf life and sell-through data on a weekly basis. If we determine there are any risks or issues with any specific products, we accrue sales return allowances based on management’s assessment of the overall risk and likelihood of returns in light of all information available.

 

Total allowance for product returns, sales returns and incentive programs as of December 31, 2023 and 2022 amounted to $571 and $590, respectively.

 

Cost of Goods Sold

 

Cost of goods sold is comprised of the costs of products, in-bound freight charges, shipping and handling costs, purchase and receiving costs, and commissions paid to Amazon and other online selling platforms. Other expense not related to the production and distribution of our products is classified as operating expense.

 

Cash, Cash Equivalents, and Restricted Cash

 

The Company’s cash balances on deposit with banks are guaranteed by the Federal Deposit Insurance Corporation up to $250 at December 31, 2023. The Company may be exposed to risk for the amounts of funds held in bank accounts more than the insurance limit. In assessing the risk, the Company’s policy is to maintain cash balances with high-quality financial institutions. The Company had cash balances more than the guarantee during the years ended December 31, 2023 and 2022. Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.

 

Restricted cash consists of cash on deposit with a financial institution in an interest-bearing account pursuant to a credit card agreement.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value, with costs determined on a first-in, first-out (FIFO) basis. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand and/or our ability to sell the product(s) concerned and production requirements. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market conditions or other factors, which may result in cancellations of advance orders or a reduction in the rate of reorders placed by customers. Additionally, our management’s estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. 

 

As of December 31, 2023 and 2022, the aggregate allowance for expiring, slow moving and excess inventory amounted to $162 and $107, respectively.

 

Leases

 

The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

 

Property and Equipment

 

Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method. The Company amortizes leasehold improvements over the estimated life of these assets or the term of the lease, whichever is shorter. When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and proceeds realized. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized.

 

The range of estimated useful lives used to calculate depreciation for principal items of property and equipment are as follows:

 

Asset category

 

Depreciation / Amortization period (in years)

 

Furniture and fixtures

  3 

Office equipment

  3 

Leasehold improvements

  5 

 

Management regularly reviews property, equipment and other long-lived assets for possible impairment. This review occurs annually or more frequently if events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Based upon management’s annual assessment, there were no indicators of impairment of the Company’s property and equipment and other long-lived assets as of December 31, 2023 and 2022.

 

Intangible and Long-lived Assets

 

Intangible assets are recorded at cost and amortized using the straight-line method over their estimated useful lives. The Company regularly reviews the carrying value and estimated lives of its long-lived assets and intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.

 

There were no impairment charges incurred during the years ended December 31, 2023 and 2022.

 

Goodwill

 

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test.  The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach.  The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

 

As the Company uses the market approach to determine fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

 

There were no impairment charges incurred during the years ended December 31, 2023 and 2022.

 

Acquisitions and Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.

 

Income Taxes

 

The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC 740”). Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax assets of the Company relate primarily to operating loss carryforwards for federal income tax purposes.  The deferred tax liabilities of the Company relate primarily to intangible assets that are not deductible for tax purposes in the jurisdictions to which they relate.

 

The Company periodically evaluates its tax positions to determine whether it is more likely than not that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. The Company accrues interest and penalties, if incurred, on unrecognized tax benefits as components of the income tax provision in the accompanying consolidated statements of income and comprehensive income. As of December 31, 2023, and 2022, the Company has not established a liability for uncertain tax positions.

 

Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

 

Basic and diluted weighted-average shares outstanding and antidilutive options that were excluded from diluted weighted average shares outstanding are as follows:

 

  

December 31,

 
  

2023

  

2022

 
         

Basic weighted average shares outstanding

  4,490   4,553 

Dilutive effect of potential common shares

  415   422 

Diluted weighted average shares outstanding

  4,905   4,975 
         

Antidilutive options

  117   29 

 

Fair Value Measurements

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:

 

 

●

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

  

 

 

●

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

  

 

 

●

Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company’s own data.

 

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of its notes payable approximate their fair value based on the market interest rates of these notes.

 

Stock Compensation Expense

 

The Company periodically issues restricted share units (“RSUs”), stock options and warrants to employees and non-employees in non-capital raising transactions for services rendered.

 

Such issuances vest and expire according to the terms established at the issuance date.

 

Stock-based payments to officers, directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock-based payments to officers, directors, and employees, which are generally time vested, are measured at the grant date fair value and compensation cost is recognized on a straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock-based payments is estimated using the Black-Scholes option-pricing model or other applicable valuation model such as the Monte Carlo valuation pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used could materially affect compensation expense recorded in future periods.

 

Segments

 

The Company operates in one segment for the distribution of our products.  In accordance with FASB ASC Topic 280, Segment Reporting, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.  Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue.  All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.  Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments included in ASU 2016-13 require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Although the new standard, known as the current expected credit loss (“CECL”) model, has a greater impact on financial institutions, most other organizations with financial instruments or other assets (trade receivables, contract assets, lease receivables, financial guarantees, loans and loan commitments, and held-to-maturity debt securities) are subject to the CECL model and will need to use forward-looking information to better evaluate their credit loss estimates. Many of the loss estimation techniques applied today will still be permitted, although the inputs to those techniques will change to reflect the full amount of expected credit losses. In addition, ASU 2016-13 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU 2016-13 was originally effective for public companies for fiscal years beginning after December 15, 2019. In November of 2019, the FASB issued ASU 2019-10, which delayed the implementation of ASU 2016-13 to fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company has adopted this guidance beginning January 1, 2023. This guidance did not have a significant impact on the Company’s financial statements.

 

In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. The ASU requires buyers to disclose information about their supplier finance programs. Interim and annual requirements include the disclosure of outstanding amounts under the obligations as of the end of the reporting period, and annual requirements include a roll-forward of those obligations for the annual reporting period, as well as a description of payment and other key terms of the programs. This update is effective for annual periods beginning after December 15, 2022, and interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted ASU 2022-04 on January 1, 2023, and there was no material impact on our financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, Segment Reporting, including the significant segment expense disclosures. This standard will be effective for the Company on January 1, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted. The updates required by this standard should be applied retrospectively to all periods presented in the financial statements. The Company does not expect this standard to have a material impact on its results of operations, financial position or cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Intangible Assets
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

NOTE 3. INTANGIBLE ASSETS

 

Intangible assets are amortized on a straight-line basis over their estimated useful lives.  The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of December 31, 2023 and 2022.

 

  As of December 31, 2023       
  

Gross

amount

  

Accumulated

amortization

  

Net book

value

  

Useful life

(years)

 

Brands

 $26,201  $-  $26,201  Indefinite 

Client relationships

  80   (55)  25   4 

Formulations

  70   (48)  22   4 

Trademarks

  60   -   60  

Indefinite

 

Website

  11   (10)  1   3 

Total identifiable assets

 $26,422  $(113) $26,309     

 

  As of December 31, 2022       
  

Gross

amount

  

Accumulated

amortization

  

Net book

value

  

Useful life

(years)

 

Client relationships

  80   (34)  46   4 

Formulations

  70   (30)  40   4 

Trademarks

  60   -   60  

Indefinite

 

Website

  11   (7)  4   3 

Total identifiable assets

 $221  $(71) $150     

 

Amortization expense was $42 for the years ended December 31, 2023 and 2022.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Inventories
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Inventory Disclosure [Text Block]

NOTE 4.  INVENTORIES

 

The Company’s inventories as of December 31, 2023 and 2022 were as follows:

 

  

December 31,

  

December 31,

 
  

2023

  

2022

 
         

Finished goods

 $8,292  $8,347 

Components

  961   865 

Allowance for obsolescence

  (162)  (107)

Total

 $9,091  $9,105 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Property and Equipment
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

NOTE 5.  PROPERTY AND EQUIPMENT

 

The Company's property and equipment balances as of December 31, 2023 and 2022 were as follows:

 

  

December 31,

  

December 31,

 
  

2023

  

2022

 

Equipment

 $951  $902 

Accumulated depreciation

  (814)  (856)

Total

 $137  $46 

 

Depreciation expense for property and equipment was $52 for the year ended December 31, 2023 compared to $24 for the year ended December 31, 2022.

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Notes Payable
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Debt Disclosure [Text Block]

NOTE 6.  NOTES PAYABLE

 

Notes payable consisted of the following:

 

  

December 31,

2023

  

December 31,

2022

 
         
Term loan A (8.21% as of December 31, 2023) $10,625  $- 
Term loan B (8.21% as of December 31, 2023)  9,500   - 
Unamortized debt issuance costs  (116)  - 

Total

  20,009  $- 
Current  (4,500)  - 
Long Term $15,509  $- 

 

Credit Agreements – First Citizens Bank

 

On February 23, 2023, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with First Citizens Bank (the “Bank”), amending and restating that certain Credit Agreement, dated September 24, 2019, between the Company and the Bank. Pursuant to the Previous Credit Agreement, the Bank provided the Company with a term loan for the principal amount of $12,500 (“Term Loan A”), and a revolving line of credit of $3,500 (the “Line of Credit”, and collectively with the Term Loans, the “Loan”). The Company used the proceeds from the Loan to fund the acquisition of MRC and for general working capital purposes, including those of MRC.

 

Second Amended and Restated Credit Agreement

 

On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with the Bank, amending and restating the Credit Agreement, between the Company and the Bank. Pursuant to the Amended Credit Agreement, the Bank provided the Company with an additional Term Loan (“Term Loan B”) for the principal amount of $10,000 and extended the Line of Credit of $3.5 million to December 15, 2024. The Company used the proceeds from the loan to fund the acquisition of assets of MusclePharm (discussed in further detail in Note 8) and for general working capital purposes.

 

Pursuant to the Amended Credit Agreement, the Term Loans accrue interest at a per annum rate equal to 2.75% above the one-month secured overnight financing rate published for such day by the Federal Reserve Bank of New York (“Term SOFR Rate”); and the Company shall make payments on March 10th, June 10th, September 10th, and December 10th of each calendar year, of principal plus accrued interest on the Term Loans in amounts sufficient to fully amortize Term Loan A through  February 28, 2028 and Term Loan B through October 10, 2028; and outstanding advances under the Line of Credit (“Advances”) will accrue interest at the Applicable Rate and the Company will pay the interest on the Advances monthly, with all principal and any accrued interest on outstanding Advances being due and payable in full on the Line of Credit maturity date. The Company may prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment.

 

The Agreement contains customary events of default (each an “Event of Default”), which upon the occurrence of an Event of Default, among other things, interest will accrue at the Applicable Rate plus 2% per annum, and the Bank may declare all obligations, with interest thereon, immediately due and payable. The Agreement further contains customary representations and warranties of the Company; customary indemnification provisions whereby the Company will indemnify Bank for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of the Company, and certain other matters; and customary affirmative and negative covenants, including covenants to maintain a Fixed Charge Coverage Ratio (as defined in the Agreement) of not less than 1.25 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending December 31, 2023, a Funded Debt to EBITDA Ratio (as defined in the Credit Agreement) of not more than 2.50 to 1.00 as tested quarterly on a trailing twelve-month basis, starting with the fiscal quarter ending March 31, 2024, and to the extent the Term Loans still have a balance as of June 30, 2025 and a Cash Flow Leverage threshold (as defined in the Agreement) of at least 1.15 is not met, the Company will be required to make a prepayment on the Term Loan equal to 50% of the Excess Cash Flow (as defined in the Agreement). The Company was in compliance with all covenants as of December 31, 2023.

 

As of December 31, 2023, the borrowings outstanding on the Term Loans and Line of Credit were $20,125 and $0, respectively.

 

Maturities of the Company's Term Loans are as follows:

 

Year ending

    

2024

  4,500 

2025

  4,500 

2026

  4,500 

2027

  4,500 

2028

  2,125 

Total balance outstanding as of December 31, 2023

 $20,125 

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Equity
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Equity [Text Block]

NOTE 7.  EQUITY

 

The Company is authorized to issue 60,000 shares of Common Stock, $0.01 par value per share, of which 4,598 and 4,507 shares of Common Stock were issued and outstanding as of December 31, 2023 and 2022, respectively.

 

Common Stock Issued for Services

 

In February 2021, the Company granted an officer an aggregate of 160 restricted share units (“RSUs”) with a fair value of $468. The Company recorded $31 and $287 of stock compensation expense related to RSUs during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, there was $0 and $31 of unamortized compensation expense associated with the grant of the RSUs. 

 

Share Repurchase Program

 

On August 16, 2019, the Company approved a share repurchase program, pursuant to which the Board authorized management to repurchase up to $500 of the Company's Common Stock over the subsequent 24 months (the "Share Repurchase Program"), as amended September 23, 2019 to increase the repurchase amount to $1, and include shares of the Company's Common Stock, its Series A Convertible Preferred Stock, par value $0.01 per share ("Series A Preferred"), and warrants to purchase shares of the Company's Common Stock ("Warrants") in the Share Repurchase Program, to be repurchased over the next 24 months, at a purchase price, in the case of Common Stock, equal to the fair market value of the Company's Common Stock on the date of purchase, and in the case of Series A Preferred and Warrants, at a purchase price determined by management, with the exact date and amount of such purchases to be determined by management; further amended on November 6, 2019 to increase the repurchase amount to $2,500 over the subsequent 24 months, and further amended on February 1, 2021 to increase the repurchase amount to up to $5,000 over the subsequent 24 months.

 

On March 17, 2023, the Board approved an extension of the Share Repurchase Program. Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $5,000 of the Company's Common Stock over the subsequent 24 months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management. All other terms of the Share Repurchase Program remain unchanged.

 

During the year ended December 31, 2023, the Company did not repurchase any shares of the Company’s Common Stock under the Share Repurchase Program. As of December 31, 2023, the Company may purchase up to $5,000 of additional shares of Common Stock under the Share Repurchase Program.

 

Treasury Shares

 

In January 2022, the Company retired all treasury shares. All shares repurchased by the Company subsequent to January 2022 were retired immediately upon acquisition.  As of December 31, 2023, there are no shares held in treasury.

 

Information regarding options outstanding as of December 31, 2023 is as follows:

 

  

Number of

  

Weighted

average

exercise

  

Weighted

average

remaining

life

 
  

options

  

price

  

(years)

 

Outstanding, December 31, 2021

  380  $3.44   6.2 

Issued

  10   15.65     

Exercised

  (4)  8.27     

Forfeited

  (7)  35.88     

Outstanding, December 31, 2022

  379  $3.09   5.3 

Issued

  117   19.10     

Exercised

  (9)  0.70     

Forfeited

  (3)  30.31     

Outstanding, December 31, 2023

  484  $6.82   4.5 

 

Outstanding

  

Exercisable

 

Exercise

price per

share

  

Total

number

of options

  

Weighted

average

remaining

life (years)

  

Weighted

average

exercise

price

  

Number of

vested

options

  

Weighted

average

exercise

price

 
                         
$0.70-5.24   349   4.5  $2.30   317  $2.01 
$11.55-19.20   135   4.6  $18.56   42  $17.63 
       484   4.5  $6.82   359  $3.85 

 

The closing price for the Company’s Common Stock on December 29, 2023 was $19.10, resulting in an intrinsic value of outstanding options of $5,155. 

 

During the year ended December 31, 2023, the Company granted stock options to employees to purchase 117 shares of Company Common Stock. The stock options are exercisable at an average price of $19.10 per share, expire in five years and primarily vest as follows: one-third vested immediately upon issuance, and the remainder vest equally in equal annual installments over a period of two years from grant date. The total fair value of these options at grant date was approximately $1,014, which was determined using the Black-Scholes option pricing model with the following average assumption: stock price of $19.10 per share, expected term of 5 years, volatility of 45%, dividend rate of 0% and risk-free interest rate of 4.1%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s Common Stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

During the year ended December 31, 2022, the Company granted stock options to employees to purchase 10 shares of Company Common Stock. The stock options are exercisable at an average price of $15.65 per share, expire in five years and vest as follows: one-fourth vested immediately upon issuance, and the remainder vest equally in equal annual installments over a period of three years from grant date. The total fair value of these options at grant date was approximately $90, which was determined using the Black-Scholes option pricing model with the following average assumption: stock price of $15.65 per share, expected term of 5 years, volatility of 67%, dividend rate of 0% and risk-free interest rate of 2.7%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s Common Stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

The Company recognized $442 and $76 of stock compensation expense related to the vesting of these options during the years ended December 31, 2023 and 2022, respectively.  As of December 31, 2023, there was $740 of unvested stock compensation that will be recognized as an expense in future periods as the options vest.

 

Warrants

 

As of December 31, 2021, 143 warrants at an exercise price of $1.15 per share were outstanding. During the years ended December 31, 2023 and 2022, no warrants were granted and no warrants expired. During the year ended December 31, 2023, 143,480 shares of Common Stock were issued for the exercise of all outstanding warrants, resulting in net proceeds to the Company of $165.

 

Total outstanding warrants to purchase shares of Common Stock as of December 31, 2023 and 2022 amounted to 0 and 143,480, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Acquisition of Mimi's Rock Corp
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

NOTE 8. ACQUISITION OF MIMI’S ROCK CORP

 

On December 4, 2022, the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“MRC”), pursuant to which the Company agreed to acquire all of the equity interests of MRC. The acquisition closed on February 28, 2023. MRC is headquartered in Oakville, Ontario, Canada. The purchase price of $17,099 was paid with proceeds from the Term Loan as well as cash on hand. 

 

During the years ended December 31, 2023 and 2022, the Company incurred $1,570 and $225, respectively, of transaction-related costs for the acquisition of MRC.

 

The Company accounted for the acquisition as a business combination under Accounting Standards Codification (“ASC”) 805, Business Combinations. The following table summarizes the allocation of the purchase price based on the fair value of the assets acquired and liabilities assumed on the date of acquisition:

 

  

February 28,

2023

 

Assets acquired:

    

Accounts receivable

 $250 

Inventories

  1,166 

Prepaid expense and other assets

  220 

Sales tax receivable

  862 

Right of use asset

  98 

Property and equipment

  32 

Intangible assets

  7,630 

Goodwill

  12,764 

Accounts payable and accrued expense

  (2,694)

Income tax payable

  (651)

Product returns

  (23)

Lease liabilities

  (111)

Deferred tax liabilities

  (2,444)

Net assets acquired

 $17,099 

 

The purchase was intended to augment and diversify the Company’s product offerings and lineup.  Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business.

 

Pro Forma Condensed Combined Financial Information (Unaudited) (In thousands)

 

The following presents the Company’s unaudited pro forma financial information for the years ended December 31, 2023 and 2022, respectively, giving effect to the acquisition of MRC as if it had occurred at January 1, 2022. Included in the pro forma information is: fair value adjustment to inventory acquired during the years ended December 31, 2023 and 2022, removal of transaction-related costs related to the acquisition of MRC, removal of the interest costs from MRC’s debt prior to the closing of the acquisition, and interest on borrowings made by the Company based on the projected balance of the Term Loan for the respective periods presented in this pro forma.

 

  

Year

ended

  

Year

ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

 
         

Revenue

 $57,755  $58,457 
         

Net income

 $7,076  $4,564 
         

Diluted net income per share

 $1.47  $0.92 

 

The pro forma adjustments do not reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does not purport to present what the Company’s results would actually have been had the transaction actually occurred on the dates presented or to project the combined company’s results of operations or financial position for any future period.

 

MRC revenue and net income for the period from February 28, 2023 to December 31, 2023 was $24,370 and $1,975, respectively.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Acquisition of MusclePharm
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Asset Acquisition [Text Block]

NOTE 9. ACQUISITION OF MUSCLEPHARM

 

On October 10, 2023, the Company acquired substantially all of the assets and assumed none of the liabilities other than de minimus cure costs relating to certain assumed contracts of MusclePharm Corporation (“MusclePharm”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. Total consideration for the acquisition, including legal costs, amounted to $18,788.

 

The Company accounted for the transaction as an asset acquisition under Accounting Standards Codification (“ASC”) 805. The assets acquired consist of indefinite life intellectual property – brands with an estimated value of $18,593 – and inventory of $195.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE 10.  INCOME TAXES

 

Components of the total provision for income taxes are as follows:

 

  

Year ended

December 31,

2023

  

Year ended

December 31,

2022

 

Current tax expense (benefit)

        

Domestic

 $(77) $199 

Foreign

  755   - 
         

Deferred tax expense (benefit)

        

Domestic

  1,056   1,194 

Foreign

  (27)  - 
         

Provision for income taxes

 $1,707  $1,393 

 

The Company is subject to income tax in the U.S., Canada, Germany and Barbados through its wholly owned subsidiaries.  The combined statutory tax rate is 22% (24% in 2022)

 

The provision for income taxes differs from the amount determined by applying the federal statutory rate as follows:

 

  

Year ended

  

Year ended

 
  

December 31,

2023

  

December 31,

2022

 

Pre-tax net income

 $7,003  $5,822 

Federal income tax rate

  22.3%  24.0%

Provision for income taxes based on statutory rate

  1,562   1,397 
         

Increase (decrease) resulting from:

        

Non-deductible expenses

  28   - 

Difference in jurisdictional tax rates

  128   - 

True up of prior period

  (86)  - 

Other

  75   (4)
         

Provision for income taxes

 $1,707  $1,393 

 

The tax effects of significant temporary differences and credit and operating loss carryforwards that give rise to the net deferred tax assets and tax liabilities are as follows:

 

  

December 31,

2023

  

December 31,

2022

 

Deferred tax assets (liabilities)

        

Loss carry forwards

  5,097   2,034 

Tangible assets

  (25)  - 

Intangible assets

  (2,540)  - 

Provisions and reserves

  490   157 

Other

  1   193 

Deferred tax assets (liabilities)

  3,023   2,384 

Valuation allowance

  (4,644)  (537)

Net deferred tax asset (liability)

 $(1,621) $1,847 

 

The Company has assessed the realizability of the net deferred tax assets by considering the relevant positive and negative evidence available to determine whether it is more likely than not that some portion or all of the deferred tax assets will be realized. In making such a determination, the Company considered all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and recent results of operations.

 

Deferred income taxes have not been recorded on the basis differences for investments in consolidated subsidiaries as these basis differences are indefinitely reinvested or will reverse in a non-taxable manner. Quantification of the deferred income tax liability, if any, associated with indefinitely reinvested basis differences is not practicable.

 

As of December 31, 2023, the Company has the following U.S. federal losses carried forward. U.S. federal losses incurred prior to 2018 have a carry forward of 20 years, subsequent losses can be carried forward indefinitely. The Canadian non-capital loss carry forwards expire between 2037 and 2043.

 

  

U.S. Federal

  

Canada (USD)

  

Total

 

2034

 $101  $-  $101 

2035

  950   -   950 

2036

  2,923   -   2,923 

2037

  -   20   20 

2038

  615   3,224   3,839 

2039

  -   2,875   2,875 

2040

  -   2,215   2,215 

2041

  -   1,838   1,838 

2042

  -   4,350   4,350 

2043

  -   1,079   1,079 

Indefinite

  -   -   - 
  $4,589  $15,601  $20,190 

 

Utilization of net operating loss carry forwards may be subject to limitations in the event of a change in ownership as defined under U.S. IRC Section 382, and similar state provisions. An "ownership change" is generally defined as a cumulative change in the ownership interest of significant stockholders of more than 50 percentage points over a three-year period. Such ownership change could result in a limitation of the Company's ability to reduce future income by net operating loss carry forwards. The Company acquired a subsidiary in 2015.

 

The Company operates in a number of tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who may challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. The Company recognizes the effects of uncertain tax positions in the consolidated financial statements after determining that it is more-likely-than-not the uncertain tax positions will be sustained.  As of December 31, 2023, the Company has not recorded any uncertain tax positions or any accrued interest and penalties on the consolidated balance sheet. During the year ended December 31, 2023, the Company did not record any interest and penalties in the consolidated statement of income and comprehensive income.

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

NOTE 11. COMMITMENTS AND CONTINGENCIES

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Subsequent Events
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Subsequent Events [Text Block]

NOTE 12.  SUBSEQUENT EVENTS

 

Subsequent to the end of 2023, the Company made a scheduled amortization payment of $1,100 on its term loans as well as a voluntary payment of $2,500 on its Term Loan A.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Reclassifications
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Reclassifications [Text Block]

NOTE 13. RECLASSIFICATIONS

 

Certain prior year amounts have been reclassified to conform to current presentation.  These reclassifications had no effect on the reported operating income or net income on the Consolidated Statements of Income and Comprehensive Income.  Certain costs previously classified as selling, general and administrative expense have been reclassified to merger and acquisition related expense on the Consolidated Statements of Income and Comprehensive Income.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in the consolidated financial statements.

 
Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

 

The functional currency of the Company is the U.S. dollar.  The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar.  The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

 
Use of Estimates, Policy [Policy Text Block]

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

 

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

 
Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

 

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

 

The Company accounts for revenue in accordance with FASB ASC 606. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. 

 

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company’s products are also sold on e-commerce platforms including Amazon.  For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company: 1) owns the goods before they are transferred to the customer,   2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, 3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, 4) is subject to credit risk (i.e., credit card chargebacks), 5) establishes prices of its products, 6) can determine who fulfills the goods to the customer (Amazon or the Company) and 7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in selling, general and administrative expense in the consolidated statements of income and comprehensive income.

 

The Company disaggregates revenue into geographical regions and distribution channels.  The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. 

 

Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as third-party e-commerce platforms such as Amazon, for the year ended December 31, 2023 was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same twelve-month period in 2022.

 

Sales to customers in the U.S. were approximately 93% and 99% for the year ended December 31, 2023 and 2022, respectively, with the balance of sales to customers primarily in Canada.

 

Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

 

For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.

 

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Customer and Vendor Concentration

 

Total net sales to GNC during 2023 and 2022 were 33% and 67 % of total revenue for the years ended December 31, 2023 and 2022, respectively. Accounts receivable attributable to GNC as of December 31, 2023 and 2022 represented 30% and 43% of the Company’s total accounts receivable balance, respectively.

 

As of December 31, 2023 and 2022, there was one vendor who accounted for 51% and 78% of the Company's consolidated accounts payable, respectively. For the year ended December 31, 2023, there were three vendors who accounted for 37%, 30%, and 10% of the Company's inventory-related purchases. For the year ended December 31, 2022, there were two vendors who accounted for 49% and 18% of the Company's inventory-related purchases, respectively.

 
Receivable [Policy Text Block]

Accounts Receivable and Allowance for Doubtful Accounts

 

All of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts, estimating losses resulting from the inability of its customers to make required payments for products. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped into categories by the number of days the balance is past due, and the estimated loss is recorded based upon management’s assessment of collectability. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.

 

As of December 31, 2023 and 2022, the Company had provided a reserve for doubtful accounts of $17 and $50, respectively.

 
Revenue from Contract with Customer, Product Returns, Sales Incentives and Other Forms of Variable Consideration [Policy Text Block]

Product Returns, Sales Incentives and Other Forms of Variable Consideration 

 

In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include, but are not limited to, product returns and sales incentives, such as markdowns and margin adjustments. For these types of arrangements, the adjustments to revenue are recorded at the later of when (i) the Company recognizes revenue for the transfer of the related products to the customers, or (ii) the Company pays, or promises to pay, the consideration.

 

We currently have a 30-day product return policy for direct-to-consumer sales, which allows for a 100% sales price refund for the return of unopened and undamaged products purchased from us online through one of our websites or e-commerce platforms. Product sold to certain wholesale customers may be returned from store shelves or the distribution center in the event product is damaged, short dated, expired or recalled.

 

GNC maintains a customer satisfaction program which allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC may require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.

 

For the sale of goods with a right of return, the Company estimates variable consideration using the most likely amount method and recognizes revenue for the consideration it expects to be entitled to when control of the related product is transferred to the customers and records a product returns liability for the amount it expects to credit back its customers. Under this method, certain forms of variable consideration are based on expected sell-through results, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. The product returns liability includes estimates that directly impact reported revenue. These estimates are calculated based on a history of actual returns, estimated future returns and information provided by customers regarding their inventory levels. Consideration of these factors results in an estimate for anticipated sales returns that reflects increases or decreases related to seasonal fluctuations. In addition, as necessary, product returns liability may be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include, but are not limited to, changes in the retail environment and the Company's decision to continue to support new and existing products.

 

Information for product returns is received on a regular basis and adjusted for accordingly. Adjustments for returns are based on factual information and historical trends for Company products and are specific to each distribution channel. We monitor, among other things, remaining shelf life and sell-through data on a weekly basis. If we determine there are any risks or issues with any specific products, we accrue sales return allowances based on management’s assessment of the overall risk and likelihood of returns in light of all information available.

 

Total allowance for product returns, sales returns and incentive programs as of December 31, 2023 and 2022 amounted to $571 and $590, respectively.

 
Cost of Goods and Service [Policy Text Block]

Cost of Goods Sold

 

Cost of goods sold is comprised of the costs of products, in-bound freight charges, shipping and handling costs, purchase and receiving costs, and commissions paid to Amazon and other online selling platforms. Other expense not related to the production and distribution of our products is classified as operating expense.

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash, Cash Equivalents, and Restricted Cash

 

The Company’s cash balances on deposit with banks are guaranteed by the Federal Deposit Insurance Corporation up to $250 at December 31, 2023. The Company may be exposed to risk for the amounts of funds held in bank accounts more than the insurance limit. In assessing the risk, the Company’s policy is to maintain cash balances with high-quality financial institutions. The Company had cash balances more than the guarantee during the years ended December 31, 2023 and 2022. Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.

 

Restricted cash consists of cash on deposit with a financial institution in an interest-bearing account pursuant to a credit card agreement.

 
Inventory, Policy [Policy Text Block]

Inventory

 

Inventory is stated at the lower of cost or net realizable value, with costs determined on a first-in, first-out (FIFO) basis. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand and/or our ability to sell the product(s) concerned and production requirements. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market conditions or other factors, which may result in cancellations of advance orders or a reduction in the rate of reorders placed by customers. Additionally, our management’s estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. 

 

As of December 31, 2023 and 2022, the aggregate allowance for expiring, slow moving and excess inventory amounted to $162 and $107, respectively.

 
Lessee, Leases [Policy Text Block]

Leases

 

The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method. The Company amortizes leasehold improvements over the estimated life of these assets or the term of the lease, whichever is shorter. When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and proceeds realized. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized.

 

The range of estimated useful lives used to calculate depreciation for principal items of property and equipment are as follows:

 

Asset category

 

Depreciation / Amortization period (in years)

 

Furniture and fixtures

  3 

Office equipment

  3 

Leasehold improvements

  5 

 

Management regularly reviews property, equipment and other long-lived assets for possible impairment. This review occurs annually or more frequently if events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Based upon management’s annual assessment, there were no indicators of impairment of the Company’s property and equipment and other long-lived assets as of December 31, 2023 and 2022.

 
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible and Long-lived Assets

 

Intangible assets are recorded at cost and amortized using the straight-line method over their estimated useful lives. The Company regularly reviews the carrying value and estimated lives of its long-lived assets and intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.

 

There were no impairment charges incurred during the years ended December 31, 2023 and 2022.

 
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

 

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test.  The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach.  The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

 

As the Company uses the market approach to determine fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

 

There were no impairment charges incurred during the years ended December 31, 2023 and 2022.

 
Business Combinations Policy [Policy Text Block]

Acquisitions and Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC 740”). Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax assets of the Company relate primarily to operating loss carryforwards for federal income tax purposes.  The deferred tax liabilities of the Company relate primarily to intangible assets that are not deductible for tax purposes in the jurisdictions to which they relate.

 

The Company periodically evaluates its tax positions to determine whether it is more likely than not that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. The Company accrues interest and penalties, if incurred, on unrecognized tax benefits as components of the income tax provision in the accompanying consolidated statements of income and comprehensive income. As of December 31, 2023, and 2022, the Company has not established a liability for uncertain tax positions.

 
Earnings Per Share, Policy [Policy Text Block]

Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

 

Basic and diluted weighted-average shares outstanding and antidilutive options that were excluded from diluted weighted average shares outstanding are as follows:

 

  

December 31,

 
  

2023

  

2022

 
         

Basic weighted average shares outstanding

  4,490   4,553 

Dilutive effect of potential common shares

  415   422 

Diluted weighted average shares outstanding

  4,905   4,975 
         

Antidilutive options

  117   29 

 
Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:

 

 

●

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

  

 

 

●

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

  

 

 

●

Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company’s own data.

 

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of its notes payable approximate their fair value based on the market interest rates of these notes.

 
Compensation Related Costs, Policy [Policy Text Block]

Stock Compensation Expense

 

The Company periodically issues restricted share units (“RSUs”), stock options and warrants to employees and non-employees in non-capital raising transactions for services rendered.

 

Such issuances vest and expire according to the terms established at the issuance date.

 

Stock-based payments to officers, directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock-based payments to officers, directors, and employees, which are generally time vested, are measured at the grant date fair value and compensation cost is recognized on a straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock-based payments is estimated using the Black-Scholes option-pricing model or other applicable valuation model such as the Monte Carlo valuation pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used could materially affect compensation expense recorded in future periods.

 
Segment Reporting, Policy [Policy Text Block]

Segments

 

The Company operates in one segment for the distribution of our products.  In accordance with FASB ASC Topic 280, Segment Reporting, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.  Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue.  All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.  Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.

 
New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments included in ASU 2016-13 require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Although the new standard, known as the current expected credit loss (“CECL”) model, has a greater impact on financial institutions, most other organizations with financial instruments or other assets (trade receivables, contract assets, lease receivables, financial guarantees, loans and loan commitments, and held-to-maturity debt securities) are subject to the CECL model and will need to use forward-looking information to better evaluate their credit loss estimates. Many of the loss estimation techniques applied today will still be permitted, although the inputs to those techniques will change to reflect the full amount of expected credit losses. In addition, ASU 2016-13 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU 2016-13 was originally effective for public companies for fiscal years beginning after December 15, 2019. In November of 2019, the FASB issued ASU 2019-10, which delayed the implementation of ASU 2016-13 to fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company has adopted this guidance beginning January 1, 2023. This guidance did not have a significant impact on the Company’s financial statements.

 

In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations. The ASU requires buyers to disclose information about their supplier finance programs. Interim and annual requirements include the disclosure of outstanding amounts under the obligations as of the end of the reporting period, and annual requirements include a roll-forward of those obligations for the annual reporting period, as well as a description of payment and other key terms of the programs. This update is effective for annual periods beginning after December 15, 2022, and interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted ASU 2022-04 on January 1, 2023, and there was no material impact on our financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, Segment Reporting, including the significant segment expense disclosures. This standard will be effective for the Company on January 1, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted. The updates required by this standard should be applied retrospectively to all periods presented in the financial statements. The Company does not expect this standard to have a material impact on its results of operations, financial position or cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Property, Plant and Equipment, Useful Life [Table Text Block]

Asset category

 

Depreciation / Amortization period (in years)

 

Furniture and fixtures

  3 

Office equipment

  3 

Leasehold improvements

  5 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
  

December 31,

 
  

2023

  

2022

 
         

Basic weighted average shares outstanding

  4,490   4,553 

Dilutive effect of potential common shares

  415   422 

Diluted weighted average shares outstanding

  4,905   4,975 
         

Antidilutive options

  117   29 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Intangible Assets and Goodwill [Table Text Block]
  As of December 31, 2023       
  

Gross

amount

  

Accumulated

amortization

  

Net book

value

  

Useful life

(years)

 

Brands

 $26,201  $-  $26,201  Indefinite 

Client relationships

  80   (55)  25   4 

Formulations

  70   (48)  22   4 

Trademarks

  60   -   60  

Indefinite

 

Website

  11   (10)  1   3 

Total identifiable assets

 $26,422  $(113) $26,309     
  As of December 31, 2022       
  

Gross

amount

  

Accumulated

amortization

  

Net book

value

  

Useful life

(years)

 

Client relationships

  80   (34)  46   4 

Formulations

  70   (30)  40   4 

Trademarks

  60   -   60  

Indefinite

 

Website

  11   (7)  4   3 

Total identifiable assets

 $221  $(71) $150     
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Inventories (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
  

December 31,

  

December 31,

 
  

2023

  

2022

 
         

Finished goods

 $8,292  $8,347 

Components

  961   865 

Allowance for obsolescence

  (162)  (107)

Total

 $9,091  $9,105 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

December 31,

  

December 31,

 
  

2023

  

2022

 

Equipment

 $951  $902 

Accumulated depreciation

  (814)  (856)

Total

 $137  $46 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Notes Payable (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Debt [Table Text Block]
  

December 31,

2023

  

December 31,

2022

 
         
Term loan A (8.21% as of December 31, 2023) $10,625  $- 
Term loan B (8.21% as of December 31, 2023)  9,500   - 
Unamortized debt issuance costs  (116)  - 

Total

  20,009  $- 
Current  (4,500)  - 
Long Term $15,509  $- 
Schedule of Maturities of Long-Term Debt [Table Text Block]

Year ending

    

2024

  4,500 

2025

  4,500 

2026

  4,500 

2027

  4,500 

2028

  2,125 

Total balance outstanding as of December 31, 2023

 $20,125 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of

  

Weighted

average

exercise

  

Weighted

average

remaining

life

 
  

options

  

price

  

(years)

 

Outstanding, December 31, 2021

  380  $3.44   6.2 

Issued

  10   15.65     

Exercised

  (4)  8.27     

Forfeited

  (7)  35.88     

Outstanding, December 31, 2022

  379  $3.09   5.3 

Issued

  117   19.10     

Exercised

  (9)  0.70     

Forfeited

  (3)  30.31     

Outstanding, December 31, 2023

  484  $6.82   4.5 
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Outstanding

  

Exercisable

 

Exercise

price per

share

  

Total

number

of options

  

Weighted

average

remaining

life (years)

  

Weighted

average

exercise

price

  

Number of

vested

options

  

Weighted

average

exercise

price

 
                         
$0.70-5.24   349   4.5  $2.30   317  $2.01 
$11.55-19.20   135   4.6  $18.56   42  $17.63 
       484   4.5  $6.82   359  $3.85 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Acquisition of Mimi's Rock Corp (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
  

February 28,

2023

 

Assets acquired:

    

Accounts receivable

 $250 

Inventories

  1,166 

Prepaid expense and other assets

  220 

Sales tax receivable

  862 

Right of use asset

  98 

Property and equipment

  32 

Intangible assets

  7,630 

Goodwill

  12,764 

Accounts payable and accrued expense

  (2,694)

Income tax payable

  (651)

Product returns

  (23)

Lease liabilities

  (111)

Deferred tax liabilities

  (2,444)

Net assets acquired

 $17,099 
Business Acquisition, Pro Forma Information [Table Text Block]
  

Year

ended

  

Year

ended

 
  

December 31,

  

December 31,

 
  

2023

  

2022

 
         

Revenue

 $57,755  $58,457 
         

Net income

 $7,076  $4,564 
         

Diluted net income per share

 $1.47  $0.92 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year ended

December 31,

2023

  

Year ended

December 31,

2022

 

Current tax expense (benefit)

        

Domestic

 $(77) $199 

Foreign

  755   - 
         

Deferred tax expense (benefit)

        

Domestic

  1,056   1,194 

Foreign

  (27)  - 
         

Provision for income taxes

 $1,707  $1,393 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year ended

  

Year ended

 
  

December 31,

2023

  

December 31,

2022

 

Pre-tax net income

 $7,003  $5,822 

Federal income tax rate

  22.3%  24.0%

Provision for income taxes based on statutory rate

  1,562   1,397 
         

Increase (decrease) resulting from:

        

Non-deductible expenses

  28   - 

Difference in jurisdictional tax rates

  128   - 

True up of prior period

  (86)  - 

Other

  75   (4)
         

Provision for income taxes

 $1,707  $1,393 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

December 31,

2023

  

December 31,

2022

 

Deferred tax assets (liabilities)

        

Loss carry forwards

  5,097   2,034 

Tangible assets

  (25)  - 

Intangible assets

  (2,540)  - 

Provisions and reserves

  490   157 

Other

  1   193 

Deferred tax assets (liabilities)

  3,023   2,384 

Valuation allowance

  (4,644)  (537)

Net deferred tax asset (liability)

 $(1,621) $1,847 
Summary of Operating Loss Carryforwards [Table Text Block]
  

U.S. Federal

  

Canada (USD)

  

Total

 

2034

 $101  $-  $101 

2035

  950   -   950 

2036

  2,923   -   2,923 

2037

  -   20   20 

2038

  615   3,224   3,839 

2039

  -   2,875   2,875 

2040

  -   2,215   2,215 

2041

  -   1,838   1,838 

2042

  -   4,350   4,350 

2043

  -   1,079   1,079 

Indefinite

  -   -   - 
  $4,589  $15,601  $20,190 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Note 1 - Description of Business (Details Textual)
$ / shares in Units, $ in Thousands
 12 Months Ended
Oct. 10, 2023
USD ($)
Dec. 04, 2022
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares     $ 0.01 $ 0.01
Assets of MusclePharm Corporation [Member]        
Payments to Acquire Productive Assets $ 18,500      
Term Loan B [Member] | Assets of MusclePharm Corporation [Member]        
Payments to Acquire Productive Assets $ 10,000      
Mimi’s Rock Corp [Member]        
Business Combination, Consideration Transferred   $ 17,099    
Payments to Acquire Businesses, Gross     $ 17,099 $ (0)
Mimi’s Rock Corp [Member] | Cash [Member]        
Payments to Acquire Businesses, Gross   4,599    
Mimi’s Rock Corp [Member] | Term Loan A [Member]        
Payments to Acquire Businesses, Gross   $ 12,500    
Series A Preferred Stock [Member]        
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares     $ 0.01  
Minimum [Member] | iSatori Products [Member]        
Number of Stores     17,000  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Accounts Receivable, Allowance for Credit Loss $ 17 $ 50
Contract with Customer, Refund Liability 571 590
Inventory Valuation Reserves $ 162 $ 107
Number of Operating Segments 1  
Maximum [Member]    
Cash, FDIC Insured Amount $ 250  
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Online Sales [Member]    
Concentration Risk, Percentage 63.00% 28.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | GNC [Member]    
Concentration Risk, Percentage 33.00% 67.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | GNC [Member]    
Concentration Risk, Percentage 30.00% 43.00%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES    
Concentration Risk, Percentage 93.00% 99.00%
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One Vendor [Member]    
Concentration Risk, Percentage 51.00% 78.00%
Number of Vendors 1 1
Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Three Vendors [Member]    
Number of Vendors 3  
Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Vendor One [Member]    
Concentration Risk, Percentage 37.00% 49.00%
Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Vendor Two [Member]    
Concentration Risk, Percentage 30.00% 18.00%
Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Vendor Three [Member]    
Concentration Risk, Percentage 10.00%  
Supplier Concentration Risk [Member] | Inventory-related Purchases [Member] | Two Vendors [Member]    
Number of Vendors   2
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details)
Dec. 31, 2023
Furniture and Fixtures [Member]  
Property and equipment (Year) 3 years
Office Equipment [Member]  
Property and equipment (Year) 3 years
Leasehold Improvements [Member]  
Property and equipment (Year) 5 years
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Basic weighted average shares outstanding (in shares) 4,490 4,553
Dilutive effect of potential common shares (in shares) 415 422
Diluted weighted average shares outstanding (in shares) 4,905 4,975
Share-Based Payment Arrangement, Option [Member]    
Antidilutive options (in shares) 117 29
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Intangible Assets (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Amortization of Intangible Assets $ 42 $ 42
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Intangibles, gross $ 26,422 $ 221
Intangibles, amortization (113) (71)
Intangibles, net of amortization of $113 and $71, respectively 26,309 150
Approximation [Member]    
Intangibles, amortization   (71)
Customer Relationships [Member]    
Intangibles, gross 80 80
Intangibles, amortization (55) (34)
Intangibles, net of amortization of $113 and $71, respectively $ 25 $ 46
Intangibles, useful life (Year) 4 years 4 years
Formulations [Member]    
Intangibles, gross $ 70 $ 70
Intangibles, amortization (48) (30)
Intangibles, net of amortization of $113 and $71, respectively $ 22 $ 40
Intangibles, useful life (Year) 4 years 4 years
Website [Member]    
Intangibles, gross $ 11 $ 11
Intangibles, amortization (10) (7)
Intangibles, net of amortization of $113 and $71, respectively $ 1 $ 4
Intangibles, useful life (Year) 3 years 3 years
Brands [Member]    
Intangibles, gross $ 26,201  
Intangibles, amortization 0  
Intangibles, net of amortization of $113 and $71, respectively 26,201  
Trademarks [Member]    
Intangibles, gross 60 $ 60
Intangibles, amortization 0 0
Intangibles, net of amortization of $113 and $71, respectively $ 60 $ 60
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Inventories - Summary of Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finished goods $ 8,292 $ 8,347
Components 961 865
Allowance for obsolescence (162) (107)
Total $ 9,091 $ 9,105
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Property and Equipment (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Depreciation $ 52 $ 24
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Equipment $ 951 $ 902
Accumulated depreciation (814) (856)
Total $ 137 $ 46
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Notes Payable (Details Textual) - USD ($)
$ in Thousands
Oct. 10, 2023
Dec. 31, 2023
Feb. 23, 2023
Dec. 31, 2022
Revolving Credit Facility [Member]        
Line of Credit Facility, Maximum Borrowing Capacity $ 3,500   $ 3,500  
Long-Term Line of Credit   $ 20,125   $ 0
Term Loan A [Member]        
Debt Instrument, Face Amount     $ 12,500  
Term Loan B [Member]        
Debt Instrument, Face Amount $ 10,000      
Term Loans [Member]        
Debt Instrument, Additional Interest Rate, Default 2.00%      
Fixed Charge Coverage Ratio 1.25      
Funded Debt to EBITDA Ratio 2.5      
Debt Instrument, Covenant, Cash Flow Leverage Threshold 1.15      
Debt Instrument, Covenant, Cash Flow Leverage Threshold, Percentage of Excess Cash Flow 50.00%      
Term Loans [Member] | Applicable Rate [Member]        
Debt Instrument, Basis Spread on Variable Rate 2.75%      
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Notes Payable - Debt Obligations (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Term loan (8.21% as of December 31, 2023) $ 20,125  
Term loan, net of current portion and unamortized deferred finance costs 15,509 $ 0
Term Loan A [Member]    
Term loan (8.21% as of December 31, 2023) 10,625 0
Term Loan B [Member]    
Term loan (8.21% as of December 31, 2023) 9,500 0
Term Loans [Member]    
Term loan (8.21% as of December 31, 2023) 20,009 0
Unamortized debt issuance costs (116) 0
Current (4,500) 0
Term loan, net of current portion and unamortized deferred finance costs $ 15,509 $ 0
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals)
Dec. 31, 2023
Term Loan A [Member]  
Stated percentage 8.21%
Term Loan B [Member]  
Stated percentage 8.21%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Notes Payable - Maturity (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
2024 $ 4,500
2025 4,500
2026 4,500
2027 4,500
2028 2,125
Total balance outstanding as of December 31, 2023 $ 20,125
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Equity (Details Textual) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Mar. 17, 2023
Nov. 06, 2019
Oct. 06, 2019
Sep. 23, 2019
Aug. 31, 2023
Feb. 28, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Common Stock, Shares Authorized (in shares)             60,000 60,000  
Common Stock, Par or Stated Value Per Share (in dollars per share)             $ 0.01 $ 0.01  
Common Stock, Shares, Issued (in shares)             4,598 4,507  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)           160      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value           $ 468      
Preferred Stock, Par or Stated Value Per Share (in dollars per share)             $ 0.01 $ 0.01  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value             $ 5,155    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)             117 10  
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)             $ 19.1 $ 15.65  
Class of Warrant or Right, Outstanding (in shares)             0 143,480 143
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)                 $ 1.15
Class of Warrant or Right, Issued During Period (in shares)             0    
Class of Warrant or Right, Expired During Period (in shares)               0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)             143,480    
Proceeds from Warrant Exercises             $ 165    
Share Repurchase Program [Member]                  
Stock Repurchase Program, Authorized Amount $ 5,000 $ 500 $ 2,500 $ 1          
Stock Repurchase Program Expiration Period (Year) 24 months 24 years 24 years 24 years          
Preferred Stock, Par or Stated Value Per Share (in dollars per share)       $ 0.01          
Treasury Stock, Common, Shares (in shares)             0    
Stock Repurchase Program, Remaining Authorized Repurchase Amount             $ 5,000    
Shares Forfeited During Period, Value             0    
Share-Based Payment Arrangement, Option [Member]                  
Share-Based Payment Arrangement, Expense             442 $ 76  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount             $ 740    
Share Price (in dollars per share)             $ 19.1    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)               10  
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)               $ 15.65  
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)         5 years     5 years  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value             $ 1,014 $ 90  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)             $ 19.1 $ 15.65  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)             5 years 5 years  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate             45.00% 67.00%  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate             0.00% 0.00%  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate             4.10% 2.70%  
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)         3 years        
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]                  
Share-Based Payment Arrangement, Expense             $ 31 $ 287  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount             $ 0 $ 31  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Equity - Stock Option Activity (Details) - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Outstanding, number of options (in shares) 379 380  
Outstanding, weighted average exercise price (in dollars per share) $ 3.09 $ 3.44  
Outstanding, weighted average remaining life (Year) 4 years 6 months 5 years 3 months 18 days 6 years 2 months 12 days
Issued, number of options (in shares) 117 10  
Issued, weighted average exercise price (in dollars per share) $ 19.1 $ 15.65  
Exercised, number of options (in shares) (9) (4)  
Exercised, weighted average exercise price (in dollars per share) $ 0.7 $ 8.27  
Forfeited, number of options (in shares) (3) (7)  
Forfeited, weighted average exercise price (in dollars per share) $ 30.31 $ 35.88  
Outstanding, number of options (in shares) 484 379 380
Outstanding, weighted average exercise price (in dollars per share) $ 6.82 $ 3.09 $ 3.44
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Equity - Exercise Price Range (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Total number of options (in shares) | shares 484
Weighted average remaining life (Year) 4 years 6 months
Outstanding, weighted average exercise price (in dollars per share) $ 6.82
Number of vested options (in shares) | shares 359
Exercisable, weighted average exercise price (in dollars per share) $ 3.85
Range One [Member]  
Lower range limit (in dollars per share) 0.7
Upper range limit (in dollars per share) $ 5.24
Total number of options (in shares) | shares 349
Weighted average remaining life (Year) 4 years 6 months
Outstanding, weighted average exercise price (in dollars per share) $ 2.3
Number of vested options (in shares) | shares 317
Exercisable, weighted average exercise price (in dollars per share) $ 2.01
Range Two [Member]  
Lower range limit (in dollars per share) 11.55
Upper range limit (in dollars per share) $ 19.2
Total number of options (in shares) | shares 135
Weighted average remaining life (Year) 4 years 7 months 6 days
Outstanding, weighted average exercise price (in dollars per share) $ 18.56
Number of vested options (in shares) | shares 42
Exercisable, weighted average exercise price (in dollars per share) $ 17.63
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Acquisition of Mimi's Rock Corp (Details Textual) - Mimi’s Rock Corp [Member] - USD ($)
$ in Thousands
 8 Months Ended 10 Months Ended 12 Months Ended
Dec. 04, 2022
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Business Combination, Consideration Transferred $ 17,099        
Business Combination, Acquisition Related Costs       $ 1,570 $ 225
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual     $ 24,370    
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual   $ 1,975      
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Feb. 28, 2023
Dec. 31, 2022
Goodwill $ 13,294   $ 358
Mimi’s Rock Corp [Member]      
Accounts receivable   $ 250  
Inventories   1,166  
Prepaid expense and other assets   220  
Sales tax receivable   862  
Right of use asset   98  
Property and equipment   32  
Intangible assets   7,630  
Goodwill   12,764  
Accounts payable and accrued expense   (2,694)  
Income tax payable   (651)  
Product returns   (23)  
Lease liabilities   (111)  
Deferred tax liabilities   (2,444)  
Net assets acquired   $ 17,099  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details) - Mimi’s Rock Corp [Member] - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue $ 57,755 $ 58,457
Net income $ 7,076 $ 4,564
Diluted net income per share (in dollars per share) $ 1,470 $ 920
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Acquisition of MusclePharm (Details Textual) - USD ($)
$ in Thousands
Oct. 10, 2023
Dec. 31, 2023
Dec. 31, 2022
Inventory, Net   $ 9,091 $ 9,105
Assets of MusclePharm Corporation [Member]      
Asset Acquisition, Consideration Transferred $ 18,788    
Inventory, Net 195    
Assets of MusclePharm Corporation [Member] | Brands [Member]      
Asset Acquisition, Consideration Transferred $ 18,593    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Federal, State, and Foreign Statutory Income Tax Rate 22.00% 24.00%
Unrecognized Tax Benefits, Ending Balance   $ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total   $ 0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes - Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Provision for income taxes $ 1,707 $ 1,393
Domestic Tax Authority [Member]    
Current tax expense (benefit) (77) 199
Deferred tax expense (benefit) 1,056 1,194
Foreign Tax Authority [Member]    
Current tax expense (benefit) 755 0
Deferred tax expense (benefit) $ (27) $ 0
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pre-tax net income $ 7,003 $ 5,822
Federal income tax rate 22.30% 24.00%
Provision for income taxes based on statutory rate $ 1,562 $ 1,397
Non-deductible expenses 28 0
Difference in jurisdictional tax rates 128 0
True up of prior period (86) 0
Other 75 (4)
Provision for income taxes 1,707 1,393
Approximation [Member]    
Pre-tax net income $ 7,003 $ 5,822
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Loss carry forwards $ 5,097 $ 2,034
Tangible assets (25) 0
Intangible assets (2,540) 0
Provisions and reserves 490 157
Other 1 193
Deferred tax assets (liabilities) 3,023 2,384
Valuation allowance (4,644) (537)
Net deferred tax liability $ (1,621)  
Net deferred tax asset   $ 1,847
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Income Taxes - Operating Loss Carryforwards (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Operating loss carry forwards, 2034 $ 20,190
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 4,589
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 15,601
Tax Year 2034 [Member]  
Operating loss carry forwards, 2034 101
Tax Year 2034 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 101
Tax Year 2034 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2035 [Member]  
Operating loss carry forwards, 2034 950
Tax Year 2035 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 950
Tax Year 2035 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2036 [Member]  
Operating loss carry forwards, 2034 2,923
Tax Year 2036 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 2,923
Tax Year 2036 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2037 [Member]  
Operating loss carry forwards, 2034 20
Tax Year 2037 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2037 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 20
Tax Year 2038 [Member]  
Operating loss carry forwards, 2034 3,839
Tax Year 2038 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 615
Tax Year 2038 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 3,224
Tax Year 2039 [Member]  
Operating loss carry forwards, 2034 2,875
Tax Year 2039 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2039 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 2,875
Tax Year 2040 [Member]  
Operating loss carry forwards, 2034 2,215
Tax Year 2040 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2040 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 2,215
Tax Year 2041 [Member]  
Operating loss carry forwards, 2034 1,838
Tax Year 2041 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2041 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 1,838
Tax Year 2042 [Member]  
Operating loss carry forwards, 2034 4,350
Tax Year 2042 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2042 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 4,350
Tax Year 2043 [Member]  
Operating loss carry forwards, 2034 1,079
Tax Year 2043 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Tax Year 2043 [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 1,079
Indefinite [Member]  
Operating loss carry forwards, 2034 0
Indefinite [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating loss carry forwards, 2034 0
Indefinite [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]  
Operating loss carry forwards, 2034 $ 0
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member]
$ in Millions
 3 Months Ended
Mar. 22, 2024
USD ($)
Term Loan [Member]  
Repayments of Debt $ 1.1
Term Loan A [Member]  
Repayments of Debt $ 2.5
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

58?8:WBSNX):.88KE$ \-0B:0+UXLY?,*E\=36D$SK O7@TANI5N#6 M"%L4Q@(R$9[TVU(V*%](CH*KA-I2LZ;:*T?2-'<"@MCCI[ @8-DF)-U+B"<+ MAK@X&X_'<&>P$C(#?*3Q:2 MU1OX27<\B. 7K;.-+ J(D^YD/'R*H!+;8(R1*-?&XY.K1TEW?#R$]X1*J<7@ M7RM_-![%](4\R7SJR&WGC;*D,J"WOR.-1RBD6,J""D6A'<4QBU]BCH92&*"> M?4^ZPR&;NJ$(Q?-\4VKC23)+8D:@$O6N\*N0!8XDHP%O MK,RW@3$-E[C2\>0#Q=PXK7/RAKAA@PYW@J]Z\!FWD-,=H8FG;BT MU788D:JD#=N5+_+-4*LVVQNDAF0%757:.*\D%8TP*)U5$<8+)5O:0% N:>"D MY7J[_1X@R ,@*U2L@9![QXUOM_2\XFQNI%M+%724)]\9E6::]55KE2$W= .& MOFD;J,?EA'#'D6W**Y$@:\8,'9Z&XY6JEX#00%^5\)FDY+R'HRLVJKTE>/L^ ME"O7!5WW'%\8)TRY0R7Q+0@7!P(ZY#M[.P;^SR#Y3:C0R?7;I/=#P;\( MK,':.SZ3/JP*"Z2&]]S^HTEW,AKQ8=H=CB:!R;)NG+?4A=%D3+_#[HBZ[U(6 M@4WJ282*#W8M# O'O>&$?J+><5)3?I<2D?U+FT"XEB#3H+0+?SQV3>,(5W8/ MMTT7X4M-0]3H\L"$>QG[->V\WDZ>Q.L= M[UH04XGI!>:D&O4FM!69>F^J'YRNPJZRU(XVGW!Z[ISFX>V,!N M>9W]!U!+ P04 " WBGU8-Z&(U(<" ![!0 &0 'AL+W=O<6,^J.](G] M\3OZ3=#NM&R(P:7BOUAARUDTB:# +:FY?5#[;]CJ.?-X5'$3OK!O8K-Q!+0V M5HDVV3$03#9_\MK>0R]ADGR0D+8):>#='!187A%+\JE6>] ^VJ'Y09 :LATY M)OVCK*UVN\SEV?Q.681S^ )S^EPSP\)5J2W0IJDV1&\K).=!;SL MB&P#5L$-DT121CBL+;'HRLV:0X(;N-%A..^<"U,1BK/(6<.@?L$H/_DT'">7 M1\B..K*C8^CYW!CGSOX#_7[$5PL+KNC3GT-LC^(=9GMW_W@-YP.XEW!/K=J@ MAF'2W/&^A?>M*5;HG=,&N"X=:G)X.M9!+JQ M>C.QJ@KVVBCKS!J&I>N.J'V V]\J5VOMQ!_0]=O\+U!+ P04 " WBGU8 MNO)J*0\& #4#0 &0 'AL+W=OB5KS,RU MJ81#URR&=F6D*/RFJAS&83@:5D+5O?-3/W9KSD]UXTI5RUM#MJDJ89XN9*G7 M9[VHMQGX42V6C@>&YZW1KTAELIA:ID;96NR]=='*1\GJ_ MX"#Q("]E6;(@F/%')[.W5&69[U)CPHY%TWI?M3K[V7G3\;R[E:1M_)*.'%^:O2:#*^&-'[QKOK= M,$[5G)0[9S"KL,^=WV@G*0KIF*[K7%>2[L6CM*=#!]F\8IAW$D$.;V.MR*2_>+XV(YL2N1R[,>JL%*\R![Y]]^$XW"_QXP M-MT:FQZ2?OZ<#+I2-B^U;8RD_]W+1T<7IW_WG4EDRW MK_L*E<$X'/MG,DWH'@'BD(GZB90%P+)2F$?[U$0)](KVMX \%6%4H8)>W :X7TF?)3 M@'+CM'GRN@QPS9;$\5OXD[YEY3ZVO.= $@LU1^"01:,K;ZVH=(-4%-+!4*]H M!F-7J_))U0N_8BX+:0"-9P.\\E>@&;! M!$L^=/IW(NT-B.-!0F\I3@2R9Q>$&;^YD$49*/8)WC,W(@3CS%4R/;M M"">2!?-S&#A:)W2CZV/XU>"8F95R@SKD8,* ](&5=2XY%;\W1ME"^7,)IF]L MMA3YQ?>FD=2LN/161L'>E<2CH/YDY)'Y"7$W0#KU4_3_3YSZBH Q>5O;%I!7 M,N31'H*?D7 M)B8!.Q<'R22EGT39B/;2PF$0#)M^&HQ2SG<_2YB@;O8&]5GH$S-C/PI&<=22 M9#!)QR^8:HDX\R;+^.<\ =BE^K/;OB'^UY(''LCAND+U;:C X*[UP$!:::OX MLN7C4LN%\!WY@,7LBG@0JA0<5 !D2RV@.NDC!J"!NBK0,9#Q18+] *N::NV> MP_@"YDL!Z3S-_^\\K+^"#;?1! U^B%\$M$V1O./NZ34&:>B'XBC;M&$:80B9@XBVQ5",H31(H+IMV16_*AQ/N_8:!#M7M0*+ M'?N_-UB;3:;L01:,O#MQB%,OI,].<-\U;KASTZZD6?CO"<2(3\GVTKT= MW7ZRO&MOZL_+V^^=C\(L% PLY1Q;P\$87PBF_89H.TZO_+U]IAV^ OSK$I]= MTO "S,\U;K1=AQ5L/^3._P)02P,$% @ -XI]6/:N>S\T @ Z 0 !D M !X;"]W;W)K&UL?51-;]LP#/TKA ?LM,6QG79# MEAAH^H'MT*YHNO4P[*#:3"Q4ECR);M)_/TIVO0Q(?4@L2GR/[TFB%CMCGUR% M2+"OE7;+J")JYG'LB@IKX2:F0P:BZ(,H%K%Z71Z&M="ZBA? MA+E;FR],2TIJO+7@VKH6]F6%RNR641*]3MS);45^(LX7C=CB&NE'6 M4M:HG30:+&Z6T5DR7\U\?DCX*7'G#L;@G3P:\^2#;^4RFGI!J+ @SR#X\XSG MJ)0G8AE_>LYH*.F!A^-7]JO@G;T\"H?G1CW(DJIE]#F"$C>B571G=E^Q]W/B M^0JC7/B'79=[,HN@:!V9N@>S@EKJ[BOV_3X< ++L#4#: ]*@NRL45%X($OG" MFAU8G\UL?A"L!C2+D]H?RIHLKTK&47YC""%)X".CW88>*?5B.!15(,@( -X$ 9 >&PO=V]R:W-H M965T*J7=+"J)ZK,X M=GF)E7 #4Z/FG;6QE2 V[29VM451A*!*Q!)70NHHG8:U6YM.34-*:KRU MX)JJ$O9UCLIL9]$H>ENXDYN2_$*<3FNQP0QI6=]:MN*>4L@*M9-&@\7U+#H? MG$"K,R1,$?Y[Q I7R();QU#&C/J4/ MW)V_T:]"[5S+2CB\,.JG+*B<1:<1%+@6C:([L_V*73W'GI<;Y<((V]9WS!GS MQI&INF"V*ZG;KWCISF$GX/AT3T#2!21!=YLHJ+P4)-*I-5NPWIMI?A)*#=$L M3FI_*1E9WI4<1^F-(811 I\@:U8.GQK4!(MG'MTT)D[@W>*\@\U;6+('QIQK MHZETL- %%O\"8E;6RTO>Y,V3@\1+S '0/F.4?OPP.AE^.2!VTHN='**G M_]T(_+K'%X*Y,OGC[_?4'N;=?+]?\%T/(%O.L\6/Y>+F'A8//&:[E\^'0R4" MZ@+,.IS[T7NUQ#MOKD*["9WE(#>-IO;Y]:M]\YZW;_:O>]OYU\)NI':@<,VA MP\'GXPALVTVM0:8.+WAEB/LA3$O^ :'U#KR_-GRMG>$3]+^T] ]02P,$% M @ -XI]6.C &_=1 @ (@4 !D !X;"]W;W)K&UL?51-;]LP#/TKA ?LM,6.G79%EQAH^H'MT"Y(NNTP[*#83"Q4ECR):=)_ M7TIVO Q+<[%)B7Q\I$B.M\8^N0J18%-6.,"Z7LSLZS%/4HI:]1.&@T65Y/H:G@Y'7G[8/!#XM8=R. S M61KSY)6OY21*/"%46)!'$/Q[QFM4R@,QC3\=9M2'](Z'\A[]+N3.N2R%PVNC M?LJ2JDET$4&)*[%1-#?;+]CE<^;Q"J-<^,*VM98*.&<7,E"^(*Y<4PNF>WC0]B7B#Q0"RX0=(DS0[@9?UZ68!+SN1K@,R<">UT(44"A8D"+G-Z&C" M+=SH.)R?F$O7B (G$8^$0_N,4?[^W? \^7R"[*@G.SJ%GO_W(O#K$7<$4V6* MI]_'V)[&>_CV>,MO/8!KM,3S"HV5QL(+"@NB-ALN 53B&6&)Z"=N'QU+7['" M:+\#@KBQE@L&(6=-@=P 'BO6#MSVI"M1@C;'ZA$?]&V-=AVFTW$DIM*V<'_: M+X"KMN__FK?;XU[8M>1@"E?LF@P^G45@VXEL%3)-F(*E(9ZI(%:\Q-!Z [Y? M&6Z-3O$!^K68OP)02P,$% @ -XI]6.U6K,'W%@ &ULK3Q;<]LVUG\%XW[MI#.R+,FWN$TRXSB7 M]4[:>N*D^[#S/4 D)&%-D5J M*S^^CTW@*1$T9?=AS@221PK,NW)U? M&%.JAV66^[<'B[)<_7)TY).%66H_+%8FASNSPBUU"5_=_,BOG-$I+5IF1Y/1 MZ.QHJ6U^\.X-7;MQ[]X459G9W-PXY:OE4KO->Y,5Z[<'XX-PX:N=+TJ\%1YD6 MQ1U^N4[?'HP0(Y.9I$00&OZ[-U_:BW/C@Y44OFR6,IBP&!I M<_Y?/P@AGK)@(@LFA#=O1%A^T*5^]\85:^7P:8"&'^BHM!J0LSERY;9T<-?" MNO+=K9WG=F83G9?J,DF**B]M/E MV..)^JW(RX57'_/4I&T 1X!HQ'82L'T_Z87XP21#=3P>J,EH_IC@ M'>^!UW7B?UY.?>E 6OZ_Z\0,[Z0;'JK0+WZE$_/V '3$&W=O#M[]],/X;/1K M#[8G$=N3/NCOKHK< Y:I1GD>,,8;]4_Y_YMY*-7[K$CN.A'O!=V-^(VS>6)7 M&1"EF*G6[NK;PJ@D7C&IFMEP/JM2HTIX6C.M"19^ORJ6 M*YUOE,Y39>&RKZ;>IE8[8,)07>>E<4EX)"S%9X$WN=>DTUXM]+U14V-R93(+ MZD&HV)PV>!2]H>IARFEDRFDO4\ V@.;GZJIRSN3(AR9^B#!=R#1?>![3>K?N M9EHW/EG-M5F5$W) BB0\L\42Z^GK]^'M4*5%EFDW?.+2GWYX/1F?_^K5E;P+7W1EB<63VUF2VMV9:6"'\FQVR!U\ZP>&0B!V71/(17E4=5 M-WEZ6,P.5\;9(E7F(5GH?&Z4@T4@$U?T#647O,ZJ< A)+Z/H[D>S$Z5RH4M5 M)$ N6*DT@/3@+_#QI-ZGC0+(<[E&D>X"* 3H8 41 /6CS3DBBN@AJ4: &CE8 M-@1$I_\"GX/:,52?GO8@,C7"IS.BVA8YWH)C@@=+[A9%EAH7D3?_KFRY"7J* MVDW,1=ZTE':J,U!:H\B] 6N^FGN35X:.:1X@,/&F;0XJCS<5& 6GA9P*5.-> M YL >%HY_ \W%>:+=#G#$M, -FPJLII#?"-,+T A*_ $=APYHIEFX5JEE5) M68G*IR8O&J9)-W0']G8(B@FQ1[V,3A:U#&QV&,H'0+$B,82 S M6W<6;=U9KZW[#J>%'3[ZTBY14I_K@WJA=YNS[2V)!Y<>@L@5GQ%-!SR^TGQH M4L1N5X2RA6$LBM[:E@OU^?+R!B@'P@C;05"5@\R01(/96.H[HTQK5]W8E=D_ MFT%LJ5[9GX4'3[46 U@CBU+K$Q"IRM$Q 4,,1A"'/7;F+B_6.2)H'JS'IX(( MH\:P%'6='F5F54TS"ZJ4#@@JH-"-.$+,(1_P.I.3!UUS)BD@7/P+'MU1):^( M:>"V4[3GA>\C7X@+ZB> ,4J83D<"50#SA:'[-&O$#H"!L?<:KL$A,D@IR#[@ M8IN#;2@+T(]B"A;$^ 3T!YY:N2(%98259>5R('UJ %&@#\+-K&P'3\$Q2HY& M4")62#?>(XF"M:H<:+E'@;.)*/X4?8KQ'JW>%+4<#X@4UMG&6P)NP;I9MQ2# M."^*=&VS; HZ85 M>AK(CBP ND33ET63!)S+0%XL*(MCDI5MZ>@U3>?1-)WWFJ;@&F@#"%4I@FE>5SHH/\-4* M8F_17Z#[&E)7DC01:8]F /TE<-7Y87/#6F%8KV37G*Z[E)2&://I\O:]NKR] M4F>CLR'^H7\S4 LU5A-UK$[4*5X:J,LLJS<&!0/OO&G'\8ZL&=@O(+S-4WMO M4Y2#N C/@.BBW7KN48=BYP,H,I<@4$&*@7Z(E,DV:!+!!)*A(UWS@Q 6P2)< MF!>=O&D!!XTK^)3 27,(S (: ]%6$">@#PDF#/7KP3@=+HP8'#J8%,".('0&J%9LI96$_$ 2*B17:$ M!9+>V6G%T1D<.*"J9@9D"RQ0BM#*A74ID* D_O(WX;(Z;XD0 -3S.>@V*7XM M0P!D;HJYTZN%34C/YS'5:2&! 5%NLBW)C,<1)]K8!H_1VH>I"?;7S L.\).% M-?=LEUJN<_HO0^4=)MC*@@@NP(#@8V"2X9&!.#=@!^:)F>.@IU\;B/O(\GK2"OR?N?8!7.%R"F8MU$,49 T9D ^3X;J MEB"CA1#SYT.L2,G!FK0!!>J!K# HSL7QCW3RBXL?2:GPV8T!NVZP>M.Q'VXT M8&-;9.)%6876H(V(+"G"#/=N(5)!>@!!/3M9)D0!"1*0,Z93#MB(WAG\.2S% MNW%YU.==%3:.ZI1HW@H(=N8A#H:S>OCL9Q:CG)(E#P3! )T C15*'@(%B4TI M4Z!BH;A79P)@9+_!_(GK"\&O%-.2TH.DI@3>)^-3VQY:YXQ$2> V9U4V@SB M:"#[;3!]B#D!D'-)'H(AL4+$;8?J1F_89 83R,BRB&7 48H$0&"3A4GN!BH! M.>V MF:/0+#@?BKO(W8 'H\ JXVZ5 [+I:P9^ !DJX9WP7\] <'K&!"\?JQ8!A%@ M*5G!5^N! %=, /[RO-2E=[/NH"#&'2@"?X(2 37:6'TK2C"@=:P-'/[\^U6( MK:..[56][NN0'B%=]RV"S'SW'K+/F=T;\'RY+OKX<1'Y2O!=> M-\DO0]C3V(T2QE:J\*&HIB5HGXJ/8W"SI]#4D7K$NH3U=>6@0$U*3>,Q3R6$ MM#-[(45EYQTL$OJ\^P)B\9B'D4)UU0QSGBH0_6COJV'_[]"\SM72 M:,_:V8P50DP3,N)6$+==6<5]RXQ%1F-@YL@,:G8?D=(Z&OJV:2WU'14-<37+ M5:N"94(8#2#OPS%:^(#+JR X>?S!D*4/(,((I<2K D+J,.$N" XAI""B\.$+T4*[(X M-/(RLRI/\6@4"5*XP9&=0M8PET$H(#H-83DCN0EA.^<0DI_[P(,M+[45S,>T M> \!N=R,2Y8%J&]F[RA!8>U>&LB#4T%,ZBIUG!T"L"V.E%2+D=QO:EK"M%Z8 M?#L&"6(12(@%>''X3JQ6(Z3P$1N'D';=FT#HT1(1+D6!F'3(@9$L9C1B,(]8("=4\H")+NU+JF6OD3GT'8- MBZ@U4BYK);0=!!;=\PW\)%W"^ ND"(M*M%+P%<'I/A8<(:DRJ:D+";6,*M(;2Q9YQ(;$3H/(8^),W"=C'G C H$ER$@0@8(.K'5()L*7!E<\ M7*'R0[--U@S94LMM:84,4$)C0 M*IYQ?8U:*U+9X((-4#+;#-5E;+JT8^N6:LR$ETTN46Y32W,)@I@RB&#+6E4: MTH0@WEAKQ@Y$5VX_1'>P+'(+D"G#!HZ'I@;@[+'&B8Z RI +D\V 8C/VF2W% M376IF1QK8^Y NJ64>#W#5+*N@-1%',3901Q/W*5Z9K#9<"/B'DXU0#!42C4M MF:EKR+XF8-T(J(- [/GX4,%%;2[N*<V@-+LY MYK"^LQA ( 9U]5^<)"AQXRY7-Y>0L'NJ.82"&U<'Z39K1L&U(I1_7!XKBD.) M0D.SY9$\>#RI&3;I9QA6LG!_^O 1?.(]2%)>/KM]U[_/'L;!GH..G1&?KQ*/ M&4&MJRI+93C)MZA0EH+#\U:"Y*G.[Z3H46F(:TIC8EWZDT'WDH$N\(+K'")W MTJZKPH'3E!!MA4SZO\GI"+.P';T9DF'O5J=A\P"$9[/@1Q>V\=6-[APV9&Q9 M2:2-;L[BS N /)P:[;@*Q0$^2)ZO-#X=8'IW M'1SULV7C!8-1<3-5?P(5IK9E3(K!)*+2S$C/T-ACN40Z9Q@D8D$=*ZY(7M;U MZ"[$PW+NS'^1FU1_>G$670]KC?NGM;Z QS" V1>..YY*QQ?,:_L_&(-G M_$Q'"XA*E97E*T 4[ :]/IE$Q/N(40])C?NGI&ZDOPIBE6DI;7RLVZS/E+47 MC$7=-!N\<6=UT]GWE2@M%F=(]#C1Y]XQRB=& $2\.E:NO,&R4NPJE_584YT* MXG A>IU#<@.Y(@'S[46Y<8S@#XQ\<>2%B@DF M)Q%E[XL==:B6#7V9A[&83G,Q"(NL$(>"!5XFQ$HE>V#-LB+QP-\^#T M33=W*\];QLRJEHTZ] \=/B;IWC$##FA15ZD&\@O.MY@R]+W0_30@'T%$0>(A M^1?/,;T"Q<9>C?]9?8+PT%+.AIO,[ -^]NI8_3&;8916;WO,*KXK7Z?-80!) M4" HAQ03AZ+C*0;-(\3X)H,DX#"C!$?$D$<7("Y">UT/0R"A2=$0*L_((7/R MBAH0L&9)=1[,XKG:9($;]ZP KCD^UTZ[L?6)29CPZ+CW3(+Y@L*JQ*:+UI>8:X]#$ M*LPB;=6LHUD,!BM]Q,Q%PV7='KUJ&\)=T6OQM+8=33LHMI>>K!EW#_9\ICT?([S1,\4FA?,N41< MFES"]F CYJ(J#,2G"YH%17G(PH@9,JT"X\06H7+H2-@NH*/(\?W8E/"8A>,1ZLSTZP.5U[F%);: MW8&UH68[%E):TC8#; 5B+-DV2<459YXW$ZG&+!/[YSS6Y2ES6.(:3?,CC=E; M&@>L-PB^BIH U]WM+H;*^Z$[==80*7SC/1&^B^)X7V35LCWN.N#J;F1?4FZC ML>><,C,!IX$8A7QK/>[6X"I6BKDD*7.'P_^!,M9-Y7%_5_E]F/:[:DS[/5?Q M7M!+ODS TWI;OU30C4@KBN3111'"-OUC*6.K4\65ZAV[GU ='6*IUM@AC@&& M ,OS "ZV-P <,(TF+78M;0!55]NVO4&-J#@#\Y#(L-.3SQ'CXP:P.C@.".HF M7EMCMJT$H#8QTCOC(2ZBN/08NJ:'FRJS=X(22^U8K:28A_(Q1Q<(S []8/]. MH(UIS]!.V:5]9SLOF+'0NNO3DKK5/^[O]5]S6O!-/SS;*;V@Z5_OUIL$\U,E M/551&RH./WXK5C91YR7.4[2*4F=#8_,BY33\RBA<8!7JKZ[,[P MQ>B"DDR*<*4M2",_N$G'< :7)1ZI"$[J!O^DO\'_43LLR8/A@EUN(7\RS^53 M_P;=?/K=E(&\<5_U'OQR0NF@,&B%;6*Z)=7<2KIQ-%"*$MYX6$I]:RKCHJK* MBQ]Y102DJA$[2X0(-J JT;<3F)"=AG[!W>EXXF(382,(0RQLT>0$A%,.3\SHH,@1LA*MMLZEZ+,^#W*BBT*6U MDKU!1%D>0B<0]LPV]6UO()ULV')J"O+[,JDPNEOHV,V8!^,2&R;]/0<77(J, MK^L$[I&3D2 O>J;V\1MO2]1A3Q \5@$>GV7,@H _YJ;KL(M!X?*XF%[V6M&Z&3?J;89^0]W\2TW\CA3 O*6CV;[+G/<_. MG=L.D%(0'*;I-)#NRY _Q"BK&QDBVG M#.4Y05P,2[W[<-OYOYZ BV_0E,VKQZ% ML%U\\NUWT_:]&N8QPM32^8J3Z*;9/'/MOM.@>\(0#42XOM(;>6FJ'OG>(0J^ M>9KHRL<4C0K#<)P23>FF$4'7[Q(-VR=M21'0QL2M>W=NI0/!EH9VF+P5&WZ8V"IIC& M"+#CPB3:JU>8R$]&OZJOM]\])RNX@,L9J-/A?3[,6>)L24S\:%0.GM+RIF"< M3!48])8A)"&(]R'S;!6&T'%,GRK,.*'/8TH%?C3+559LC*E? *HR+%5XF6_! M_ EQJ,?EPSMI[+=R2$T"B% E".\/SIT6O0J/2#Q2A.PJU"SEM44Q.IWO2&ZE MI 2;7ZMLJDA'!XW2A/'K08N3AQW,[1/9ND4[Z6_1WIHYI9E?0R#Q;$E]0:M6 M-FV[%W[3F&F"^>/D-=C0'?3H5M_)ZX[JI+^C^KM9MWZCQ!5Y@6_P+%\RS-"_ MU[[7_'#>9C\..#KV]PHI,1J?#>BO&D/Z5KO$Z\9;F/(VPA=^H?P5^Z'CR1G( MT_>P-OY_]?'JR\[%&):-3VFWBZ'Z'9LX> F_\D4U'@WV+8'8ZN\ZK[#'%B<> M>(P-&+DJ RC,/NGAT_0=02P,$% @ -XI]6,F^DB4M P +P< !D !X;"]W;W)K&ULC55M;]LV$/XK!PTH6B"+9-EJFLPV8"*;W?W/(_NCO.]L0^N0?1P4%*[1=)X MW]ZDJ>,-*N8N38N:3BIC%?.TM'7J6HNLC$9*IGF6O4T5$SI9SN/>QB[GIO-2 M:-Q8<)U2S#ZM49K](IDDIXTOHFY\V$B7\Y;5N$7_K=U86J6#EU(HU$X8#1:K M1;*:W*R+<#]>^%/@WCV;0V"R,^8A+#Z6BR0+@% B]\$#H\\CWJ*4P1'!^'[T MF0PA@^'S^S_X!'/A$@-]+%$?;' MNUD"O'/>J*,Q(5!"]U]V..KP$H/\:)!'W'V@B/*.>;:<6[,'&VZ3MS")5*,U M@1,Z_)2MMW0JR,XO?S<>(8=?8=O_%3 5;$6M124XTQY6G)M.>Z%KV!@IN$ ' MK[^RG43W9IYZ0A#\I/P8;=U'R_\GVB2'ST;[QL&]+K'\V4%*T ?\^0G_.A_U M>(?\$J:3"\BS?#KB;SKH,8W^IB-Z..@)GN/76\_.6X<*NG$MX[A(J$06:M'ZIPO8R/!OF"[A_GLG6BH2?P'?'%:=A$^B M0O@[,H"O>/"PEH8__'..S&BX\V16SE&GX,QC;2A;[I".N&"QPE)8*6.]^-$O M":LP);P6&IZ06?<&WG=6"]]9C- K<0AS!U/XHZ)T0\ 3&=KZA%1KC9$E"-5: M\XAAWT$!(T(6@Y#%J)!;:FUE1_I0LJ\HN4LAN] <8(N\L\*')+\_<-E1CD)E MC8);H]K.][S(Z)X1$5T[V*"%;<N M0RC9(UIJHN "& ?4?ITGD4/=SBYFUQF-13&%NQ-3K"KJBX%+2QE/&C )W"A% M_(XN9I,"9A0HFE"$EX6ZSHHP7A4_"VO:()V#R>0*\NNS_S!]UL04VCJV:@>Q M_?3];-@=7H-5WP3_N]X_)9^9K05%DUB1:79Y1;+;OCWW"V_:V!)WQE.#C=.& M7C2TX0*=5X9$.2Y"@.&-7/X+4$L#!!0 ( #>*?5C9L]0#^@( /X& 9 M >&PO=V]R:W-H965T53I/V)?'9=\\]SSEW&6^D M>M K1 -/I:CTQ%L9LS[U?9VML&3Z1*ZQHI-"JI(9,M72UVN%+'=!I?"C(!CX M)>.5EX[=WHU*Q[(V@E=XHT#79LR7>H;E? MWRBR_ XEYR56FLL*%!83;QJ>SA+K[QR^CWB&0E@@HO&SQ?2ZE#9P>_V"_MEI)RT+IO%,BF\\-ZN)-_(@QX+5PMS* MS1=L]?0M7B:%=D_8-+Z#R(.LUD:6;3 Q*'G5O-E36X>M@%'P1D#4!D2.=Y/( ML3QGAJ5C)3>@K#>AV863ZJ*)'*_LI=P91:>S%G36@$9O@(817,G*K#1\JG+,_P3PB6%',WJA.8OV M(IYC=@)Q> 11$,5[\.).=NSPXCVR-30"=^EKHI/=T;913O6:93CQJ!,TJD?T MTO?OPD'P<0^WI..6[$-/[ZCQ\IKN018[;H55.5Q(F6^X$/#=*8 Y/AF8"9D] M_-@E9F^ZW6*FVF:GJF.Y0-55'BZ4U,2AE'5E8)IE=5D+9C"W6\KP7\RUVC4- M$]N(\,A$C7"OL:@%"%X@])Z1*7T(,T5"-!Q -#B*@I 6QZ_&)7TU!:\X?9IG M@B.E4B@FQA?\.%MN\PA%X84$Q(G3"7A@G@.67E!7?E94WE';V$< _(/8S)W^W$P0?8 M7:[H_Y7KS3+$"?%(!KO*$%M)2?!/91C:D+]5(;+7U1N&K@)A/X!='[V_-9-* M5$LW>35DMA3->.IVN^$^;6;:JWOS9[AB:LE)E,""0H.38=\#U4S;QC!R[2;< M0AJ:EVZYHA\4*NM YX6D=F\-FZ#[Y:6_ 5!+ P04 " WBGU8HBX]S7," M !3!0 &0 'AL+W=OU!L)C8JBYXD)^W?CY)3+P72O)BB1!Z= M0XN<;DD_F0+1PG,EE9D%A;7U11B:K,!*F#.J4?')BG0E++MZ'9I:H\A]4B7# M)(I&825*%:13OW>GTRDU5I8*[S28IJJ$?IFCI.TLB(/7C?MR75BW$:;36JSQ M >V/^DZS%W8H>5FA,B4IT+B:!9?QQ7S@XGW SQ*W9F\-3LF2Z,DY-_DLB!PA ME)A9AR#8;'"!4CH@IO%WAQET5[K$_?4K^K77SEJ6PN""Y*\RM\4L& >0XTHT MTM[3]AON] P=7D;2^"]LV]AA%$#6&$O5+ID95*5JK7C>U6$O8?Q>0K)+2#SO M]B+/\DI8D4XU;4&[:$9S"R_59S.Y4KF?\F UGY:<9]/O9!$&\!ENU :5)5VB M@9-'L91H3J>AY2M<8)CMX.8M7/(.7)S +2E;&/BJ?!*Y+5?(SRV%-E!OX".->,DF\[0_.84%538I9 M&IB,8AB/AG IN>.%RA!X=@ M#7'),W0;)_$H@5,VT3F;1[)",M*D%TUB;^-H M"(?J&>X]] KUVK>S@8P:9=LWW^UV$^.R;93_X>VXN15Z72H#$E><&IV=#P/0 M;0NWCJ7:M\V2+#>A7Q8\]5"[ #Y?$;^DG>,NZ.9H^@]02P,$% @ -XI] M6&=UE+!9 @ .@4 !D !X;"]W;W)K&UL?53? M3]LP$/Y73MXT@<2:'TU+86TD"DS; U,%;'N8]N FUR;"CH/MT/+?[^RD69%* M7VR??=]WWYU]GFZ4?C(%HH6M%)69L<+:^C((3%:@Y&:@:JSH9*6TY)9,O0Y, MK9'G'B1%$(?A.)"\K%@Z]7L+G4Y58T59X4*#::3D^G6.0FUF+&*[C?MR75BW M$:33FJ_Q >W/>J')"GJ6O)18F5)5H'$U8U?1Y3QQ_M[A5XD;L[<&E\E2J2=G M?,]G+'2"4&!F'0.GZ06O40A'1#*>.T[6AW3 _?6._:O/G7)9"'NO-M^PRV?D^#(EC!]AT_HF%PRRQE@E.S ID&75SGS;U6$/, G? M <0=(/:ZVT!>Y0VW/)UJM0'MO(G-+7RJ'DWBRLI=RH/5=%H2SJ8_E$48P6=8 M:+IH;5^!5SGZWQ3NL\/LIX@]D AM$9Q&$\/,(W[',?>K[AD=P-M D>RJ]%)X?1 MKELN3-%PR-N M+E26"X)$PW,:DS$_BIW7*_+RH# %4'#P?F(@6X[M36LJGUW+)6E7O/+@CXWU,Z! MSE>*7DEGN #]=YG^ U!+ P04 " WBGU8.I^E!L]VF9>HB^)+/+:"W5@UXB&G@J MN=#C8&G,ZCP,=;;$DNF.7*$@SURJDAE2U2+4*X4L=TDE#Y,H&H0E*T20CIQM MJM*1K PO!$X5Z*HLF7J>()?K<1 '6\--L5@::PC3T8HM\!;-_6JJ2 MKE+PH M4>A""E X'P<7\?FD;^-=P-<"UWI/!MO)3,H'JWS*QT%D"2''S%@$1J]'O$3. M+1#1^+7!#.J2-G%?WJ)_<+U3+S.F\5+R;T5NEN-@&$".]K,82]A^%I"LDE('&]?R+&\8H:E(R77 MH&PTH5G!M>JRB5PA[*'<&D7>@O),^D4:A &<@!4T3-DSFW&$UIU]Z>-1:*B( M#0VS#>#$ R:O ,8)7$MAEAK>BQSSOP%"8E=33+84)TDCXA5F'>C&;4BBI-N MUZU;[CJ\;D/+&GR#A_KSV;W#V?:2G.L5RW 8AR(^AARC15+&>HZLG"2TM" M554)7#(!%]""82>)X0CBJ#U(^B2<[/DG6_]9NQ]%Y+H7K)3*%+\QITM"C11: M5TQD")G41D,KC@=P;#&D89S*M:/HS(%>5DJA,-#J.2@;\UF*A2]&Y?MD]I$- M\^[7\^[_\[ROF:E480KZ.$BS-4]4&G5.:4#*[TFO&+ERNVDF#6TZ M)R[IUX+*!I!_+NFR;A1;H/Y9I7\ 4$L#!!0 ( #>*?5B3VZUQ3P, #0( M 9 >&PO=V]R:W-H965T2IJY/4J6EUBI7%0@<3USKOS+16SB;<#G''?J8 RFDI40#V;R(9LY MGA&$!:;:('!Z/.);+ H#1#*^=YA.3VD2#\=[]/>V=JIEQ16^%<67/-/;F9,X MD.&:-X6^%;M_L*O'"DQ%H>PO[+I8SX&T45J473(I*/.J??*G;A]^)R'H$@*K MNR6R*M]QS>=3*78@332AF8$MU6:3N+PRAW*G);W-*4_//PF-,(8+N/[>Y/H9 M3N_YJD!U-G4UH9L8-^V0%BU2\ J2'\!'4>FM@NLJP^Q' )=D]=J"O;9%,(CX M#E,&H7\.@1>$ WAA7VMH\<*!6A6T!1ZKK\V.CF>;K^-2U3S%F4/V5R@?T9G_ M_9<_\MX,:(MZ;=$0^OQNRR5>+,A?&2SY,]E>PY64O-J@&9_#36UGS0L"I$^?#M6TR#K\9H^->4*)8@U?+&>)D7\$25]HH!/*--T/!X+/2'>4*(DHAX1BP)(&(Q#)@D M[DT2_QF3[$N I=W_6Q/QFX895'#<, ?[L&>V3+V*U@4U;8XR%<"]T+R JO?9 MWBV_1Z_[LF5ZO@^BV,*),L$9- PILB164]8/((H,,,Q&[4N:$&L$\*X-5]RW!#NP4U>HMS8 M?J4@%4VEVTN]7^U;XE7;"5["VW[ZD&ULC55M;]LV$/XK!ZW8 M4D"U)%J2[ M>^Z%=].MTD]F@VAA5\G:S(*-M-J%EPEEXO,R7N!/P5NS=$:G"=+I9[/U'OV3]YU\67*#UTK^)4J[F07C M $I<\5;:![7]'7M_/,%"2>._L.UEXP"*UEA5][/@X_HL!Z!>9Y M=X8\RQMN^7RJU1:TDR8TM_"N>FTB)VJ7E$>KZ5:0GIU_419A#!_@JOC6"B-\ MJ-0*[D0E?C'PH(HGN%:Z@8NO?"G1O)]&ELPZY:CH32PZ$^P[)A(&=ZJV&P,? MZQ++MP 1\3V09GO2"W86\0:+ 0R3$%C,AF?PAH<@##W>\$P0#'0.GO*OTTY/ M:[MG4!RS4NA;_ M80FW)=96K 0MKXQ!:[H$:MKSNH3/@B^%I&R27W3?5G3^CW<0ON+.PD)28O\] MY>M9-J=]_81+W=*+!C;N4K*GQ'M*ET2N4&U-1QH+%,^>R#M@60RW]3-YHK1C MFH1)GL.]QH:+$G!'G<>@]T?9#6K@'2QC,3QRRA58OCM&'.<,?%MQP6J=JE. MR9@PJ8UI^^+!D%@UU%@L#!G9M[Q>"Z?>PX_"?!C#;TJ56R$E)"PFK!PU_ M\<8<$B\*W>(KU0L6YI,4WA-JH2KT_/;R%WF6T TQ*=O"$FW;ZMJ0RI!./R-U M%I!'6;M($B=^@RO4+JL.ZLT]"]/4F?I"'O*W\:;0)J,PGDS@3 %FAP+,SA;@ MHC5T8LQQAPB=&^#;(KG:C0;7.'ZLQ,[:.UUB?R/7@*Y]P-&2^@!62RH,UPO> M;'P5TH?J :F^6E=MV2@<99E;C,,T&_G B2Y/[RCI\2BG?QIFE.P;(5M+!NI7 M$2H?,!NNG7 R2$?TBP<3=C+"T5$_KE"O_=0QX NH:\V'T\-@N^KZ^:MX-Q7O MN%X+*A.)*U*-!R,*GNXF3;>QJO'=?:DLS0J_W-!P1NT$Z'ZEJ+GU&V?@,.[G M_P-02P,$% @ -XI]6."^TQ6U! P !D !X;"]W;W)K&ULK591;]LV$/XK!R\;'$"V)4JR["PQT"0M%J!-@R3M, Q[ MH*6SS54B79*JTW^_(R4K*>JJ?AALD.*)/-[=]]WISG=*?S(;1 M/52G-Q6!C M[?9L,C'Y!BMNQFJ+DMZLE*ZXI:5>3\Q6(R_\H:JG&N M:EL*B7<:3%U57'^]Q%+M+@;18"^X%^N-=8+)XGS+U_B ]L/V3M-JTFDI1(72 M""5!X^IB\"HZN\S?$,SI.E4I_)@LJ(9N9/[5Q>'%@%O[@ &L/,&]W"SMG%K;((40@CN)&YJA >^1,:&#[R M98GF]'QBZ1*W=9*W"B\;A>P'"B,&[Y2T&P.O98'%MPHF9%UG(MN;>,EZ-5YC M/H8X"H"%+.[1%W*W M7Z)I^'N/;4EG6]*G??% 25?4)8):P96JMDJBM,:MGN&!UT^4D@9A>(D25\*> MPM_>&WC$)PN7IH."NAYR>"JUIIL!TL& MX][@Y=[@:_+%6)'#"0RS#$YICN9SH$2C-)*0I2DQ\AI72$J*G^F(@C"=TAC- MDT[#D#FM([C3ZHOP%80*&(@FB-9SG*X,LC#S^M(,O/1J^UZL5^I+S M$KI[3NEVC[F2N2@%]X7I./!Z+_XI>+TX?@_>G<:1"[JDKT(;LQ/(@C",:4Z# M&6UY@P5J7KX(*6CG'&/C&'X%EHQ#FGK"[VII ?3&6&YKJ_371D$4I%/F(JM V^K!=F[19H*&,ZFGDOO[8:"E*4P3&C] M_S!KVC%K>C2SNKQPC'IE#%*%X+* MX(OB556D G'D:KWSL.D.H8^WR0N;PP< MEL_6G<);90SD7!/H%+T=UX4A7H4$.0O"."'/Y-K#N3_-4@_!C;3?O0G2)/PV MUYMPM"8;2.8A1&G6XA=1I8F/,#$.G',LB&<)?.1EW20K+ZF-X8Y/PR28)HX( MPS1VM>:6\X##\\'!]"H_*DH@Y1,GA,*)QU#Z1 M,(5YZCH/-])R2L&>4\A'[4RBS"W"YA_/8!JE! MC"8VS>.Z$<[]]1DG9CF$2 M>A&+TOT8)A&)*-ZDHAE)Q$B4!#%=W8PDBOVN,)NWXPW5RY60@HK2R/].:&\Z MFSL/TF#JW6$A?7;"@S!.7G1E%>JU[SV)]:J6MFG0.FG7WKYJNKKG[4UO_([K MM2!:E[BBH^$XHZ^!;OK-9F'5UO=X2V6I8_2/&VK14;L-]'ZEJ.EI%^Z"KNE? M_ =02P,$% @ -XI]6"7^L.G=! "!X !D !X;"]W;W)K&ULO9EM;]LV$(#_"J$610IDT8OMV$EM XFEO0!S9\1)]V'8 M!T8ZQT0DT26I. 7VXT=2LBPE#A.M[+[8(L5[CKSCG73B>$O9/5\#"/28I3F? M.&LA-N>NR^,U9)B?T WD\LZ*L@P+V61W+M\PP(D6RE(W\+Q3-\,D=Z9CW;=@ MTS$M1$IR6##$BRS#[-LEI'0[<7QGUW%%[M9"=;C3\0;?P1+$S6;!9,NM*0G) M(.>$YHC!:N)<^.>1/U(">L07 EO>N$9J*;>4WJO&;\G$\=2,((58* 26?P\P M@S15)#F/KQ74J74JP>;UCOZS7KQ$ @J@>"M KU*H/=$ MH-=[0:!?"?3?*C"H!/32W7+MVG A%G@Z9G2+F!HM:>I"6U]+2WN17&V4I6#R M+I%R8OJ9"D ^^@F%P&-&-MI[=(4N"RY'?@!FM-A(;H&$IBEF'&UDKY['1_2/>9F7QCFH1'G.-SB&B2,S M(0?V ,[TPSO_U/MTR)DV86$)&VJ8RK@/4^_$\\?N0]-+KPQJ&;Y?&[YO-/P% MYR"XBL-YP>,4%M)X&9I1MJ$,ZQ#]:P[9+;"_#QG4R.YJ4)NPT"8LL@1K.6A0 M.VA@C@S\33XMI8L$11?QUX+([;]@-"GTFAF5 M=S6Z35AD"=8R^FEM]%.CT:]!!L'O%.?HLM[_,KM\7[ 8578-%INPT"8LL@1K M^6U8^VWX8X)E^#Q8/.]9L!B5=S6Z35AD"=8R^J@V^LAH]#G)R(=WH\ ??N+H M2CZ]=4080\$([!H*-F&A35AD"=;RREGME3.C5^K7ZAG-;DFNT].Q;,C"*X$J M6UTSG//RO>N0EXP*NGKI['F$#;VSLW:$A3951I9@+?/[WK[<\3KGHIU30-8Q MOS#*#^8B,[>KW:W2PHKVBANC \.\P^^I?J-\]+\GST5FH/GA6,H56ED2U: MV_3[VMHW%]=+8 2X#(0GWY_,@6&SS)U9I856:9$M6ML[^R+<-U?A_\]'0?,D M.KO3:F%>T5[Y+FA+9]M-^YK;-Q?=;%;",ZNT MT"HMLD5K.VI?I_OF0OUSH7R@/E_)>'HI&JR6YE9I845KOL[)XN/I$RJRI;2T MLMLX\FC1HYB6N2B/"*J>^OCS M]B/>D/U3'G/HD;8\ISTCGF-V1G*,4 M5A+IG0QEVF7EL6/9$'2CS]5NJ1 TTY=KP+*,5P/D_16E8M=0"NK#W^F_4$L# M!!0 ( #>*?5C-UZ.5804 /4< 9 >&PO=V]R:W-H965T]& ..*1PE;L?$91*G/&GJ*+Z\6@5H\8@0>.C""(^K>!,7A>A*1X M_$I!:]EO1@-W/[^B?X^35\G,B8 Q\_ZB"^D.:MT:6L"2A)Z\9]L_(4VH%>$Y MS!/Q7[1-8^LUY(1",C\=K!CX-$C^D^>T$#L#,#XP *<#\+$#&NF 1IQHPBQ. MZXI(,NQSMD4\BE9HT8>X-O%HE0T-(AFGDJMOJ1HGA[=, L+H*YHF.B*V1%.Z M"NB2.B20:.0X+ PD#59HPCSJ4!#H\Q5(0CV!9O L0^)]09\0#=#,9:$@P4+T M+:F81?B6D[*X3%C@ RQLC&Y8(%V!O@4+6!0!+)52EA=^S>L2&Q&OP#E'#?L, MX3INH(?I%?K\Z8N&V/AX&*R'*=!K9&5OQ+C- [AI606Z!P?HALP].$,C3S45 M"1Q JCW1F,."2O23"6U!$_Q6C!_UZF9H=_K69C>U_9!6/0LIT&YFM)M&VF,E M$E>=IR:I=-$XGI[ SU06RS!8H)^4S*E'Y8N.<(+66 MD?)UL(% ,C6S'XD7DGCMN 7@1'A>'Y)LA6!%9+M9LEVS4U!A'N&OE]= MC]%U($+5MFCD1]VMR[J[-W7P3E,FR1A_[IW)]+)D>N9DTIY&JM4=B+H]Z1@J MGC(UT;^J@U17A6K-2NJ:*9PJ;U5HQ8+AO&"X:GVQ1KG&GKZZJ/:!7<7.?89M-AI'ZJOQ(RV.;_S[Y=H>EL-/LVU:9H9'&RPA6A%6N6>RW;;+;>H7!;(UYO3V)M5.^ Q+F9 MLLUN:AJNUQX]OH*XQ]7*DIJPJM6+;YJ M]&N5C;4VJG-H)\Z-EVUV7OD30"*4_C&Z]Z;O-X84GZ5S4X/-IN;(&9@]:WWE MX!&IC/ DY(Y+Q([]4V$SE\/K=#3[0C.M4^=C56C%(N96"YNMUE$"IQB[ZI57 M&?//O#>-W !ALP&J=BZDBU*T/ADG@I'3R1.A(K1B!7-/AM_P9"$HM4'V M@8T(Y^X(F]W1Q^@=K_E&Q2MZ8976YB->?^',R=>+Z >RD\[A?U!+ P04 " W MBGU8+\I^1&4" #Q!@ &0 'AL+W=O8(T229QS;B,LIF?6^ALIEHKN,2%!M/6-=./)RC49AX-HJ>) M:[ZNK)N(LUG#UKA$>],L-%EQCU+P&J7A2H+&;1YP@*+%DK[+7:?,,NG['#RY4P_@N;SC>)(&^-57473 QJ+K=_]M#I ML!,P&.T)2+N U//>;N19GC'+LIE6&]#.F]#M?R MANIDX<9@V0JXY"7"P1E:QH7Y,(LM\72[Q7G'Z63+*=W#Z0SS0Q@./D*:I,/G MX3&EU^>8]CFF'F^T!^^\U9+;5J.G>\X?W-C GRNL5ZC_OD0P".@NRI%I6([S MB&Z"07V/4?;^W6"2? G0'?9TAT&ZS\3%7MR#W\CTBVJ&X8;P2($F0&S4$QL% MD7Z4="API]XA!8-0KU1PW!,=OZV"8;C_*SCIB4V"2)=(#:12HH"+NM'J'AVO M\$D, KY2QVE/=_JV.H;AQOMUC'&4*J2W#79K6-7X MIK92EEJD'U;T)J%V#K1>*FILG>'Z9/_*9?\ 4$L#!!0 ( #>*?5C7 ]UQ M"P, %T( 9 >&PO=V]R:W-H965T1@+;:'KJAHFT/TQY,^KY,E%%1?RA($OLFD*JC!K/'1G,Q4/Y9*Z[B[WJ+?.>VH94$U3"7_R5*S''D? M/9)"1E?(KEVOV13VP8>25;:R*)V1@8%$]63/M5QV'$(^T<< MHMHAVG?H'G'HU X=)[1BYF3=4$/CH9(;HJPUHMF%BXWS1C5,V"S.C<*W#/U, M_%4:(!&Y(/,JC41F9,YRP3*64&'(.$GD2A@F!-M2&RI2FYXS)NKC M\[8X5M?TW36VM==QMWL5#/WUKK86HUZOTQB]4-!M%'1/*FAJ!;(,>]<66(E% MAS5%.4ED4<@M[]NH=]HZ)_4X#KN HL)Z<_H,WZ&L;65HB('N_Y OI6N77_=0[$ ];N-_,D; M[+2YUB5-8.3A.-&@UN#%[]^%_>!36Q>]$=B+8 R:8 Q.!F.,M9=NJU(ZX:_6 MWN @*6$XV$O*?5@\!(61'P( ,$$ 9 >&PO=V]R:W-H M965TU9LVA:JBR?12=:OGR0[7M8UP5YLD>(YY*%)ISNE7TP-@&0ON#33H$9L[L+0 MY#4(:D:J 6EO2J4%16OJ*C2-!EIXD.!A'$4WH:!,!EGJ?2N=I:I%SB2L-#&M M$%3_F@-7NVDP#@Z.1U;5Z!QAEC:T@C7@<[/2U@H'EH()D(8I2324TV VOELD M+MX'?&>P,T=GXI1LE'IQQGTQ#2)7$'#(T3%0^]K" CAW1+:,GSUG,*1TP./S M@?V+UVZU;*B!A>(_6('U-/@4D )*VG)\5+NOT.NY=GRYXL8_R:Z+O8T"DK<& ME>C!M@+!9/>F^[X/1X#QS0E W /BMX#)"4#2 WSGPJXR+VM)D6:I5CNB7;1E M+\GEQ16Y($R2IUJUALK"I"':4AQAF/=IYUW:^$3:<4P>E,3:D,^R M@.)O@M!J&(3$!R'S^"SC$O(12<8?2!S%R3L%+?X?'I\I)QGZFGB^R0F^F5 : MV2OULZK*?]O[7L\ZRFM/Z=9OFTUL+=MC%6=#NDK#HVD0H"N_)(;DJI78]7/P M#GLX\^/WQC^W^]FMTQ^:;KD?J*Z8-(1#:2FCT:TM2'<+TQFH&C]S&X5V@OVQ MMO\8T"[ WI?*SEUON 3#7RO[#5!+ P04 " WBGU83C2=4G $ !U&0 M&0 'AL+W=ODXZ=>7E!5=*?H"-2^)+N<,9ZAS M.)0\VE+VQ->$"/ 2A3$?6VLADFO;YO,UB3"_H@F)Y9TE91$6\I2M;)XP@A=I M4A3:R'%\.\)!;$U&Z;5[-AG1C0B#F-PSP#=1A-GK+0GI=FQ!Z^W"0[!:"W7! MGHP2O"*/1'Q+[ID\LW.411"1F ',:\O0OV&:QC@7F&RYHE"5+!E$0[_[C MEVPB2@G0:TE 60(Z-,'-$MQ4Z(Y9*NL."SP9,;H%3$5+-'60SDV:+=4$L7J, MCX+)NX',$Y._J2# !9?@"5XCF'\"*4:Z5M,/HI1BJ;9XGR/?4^,]E MYIHH!/.8"CTWI^<>3@]'E(G@)U;=H6.Y@_)+XU]"Z-9(:H+Z+22]G*1W.,E8 M+DRRF,I V2R'>=84U*,PKV'+V47BZE M9Y1RDR2,O@31CO=_7T@T(^R'CJ(11RW-USS!J]@\OQ7XNIF\4,TW74\+ PE3$7P=)-SX((V QTKJ M"*RB?9!K'W2PE T:DSYP:GUE#*E0&^;4AMW5V+!9%KU>C:(FQO7T'*%3&*7S MSNM8-F#%$NI2-#&>WR*EY/GP<"D;3I:;$(3!DH#S?PEF%UJN9D0/O,I,74E- M3\FLZBK<&IKM6FWL-EEG&[O:C'-L6W>%5E5=; +@$;N UL[.0,J%U*^WMCFF M2J^P?WB$_^_K;MAT[4MO4*>I"7+;>!;>#LWF_AOZNZ?9\M6U-&.\-BF%9\,C M3/O _C8CFOK[A,RJKL*^H=F_OY,9#^3[BK&U.W7LKM"J@@O/AEV8=@92KB$( MZW5FC*G2*WP;=FC<4./*L+$":8+Z>IJH<&[TWLZ-FJYUIPTY?\;M"JVHNMA/(O)TXL W[C>?G-XJVWVA5OV47APKS1T>8_][. M:KZ6-TB:0JH].!$W2S^0S*@2-TL,UD4W!5("\OZ14O)VH+^_Y+RV37U!+ P04 M " WBGU8\"M9/4L" #D!0 &0 'AL+W=OBB@>0#OIS@Z&M$FQ"Q\.=$(.[YZSUUH@TWB79!O_] M.6FIQN@0+VWL?)_]V9$]WJ%^,16 9:^U5&825-:NK\/0%!74W%S@&A3=+%'7 MW)*I5Z%9:^"E)]4R3*)H&-9]^#SL>XL5(H>-#,;.J:Z[=;D+B;!''P M[G@4J\HZ1YB/UWP%<[#/ZP=-5MA%*44-R@A43,-R$MS$U].!PWO 'P$[LW=F MKI(%XHLS[LM)$#E!(*&P+@*GWQ:F(*4+1#+^M3&#+J4C[I_?H]_YVJF6!3

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�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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 169 315 1 false 70 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://fitlifebrands.com/20231231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Income and Comprehensive Income Sheet http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income Consolidated Statements of Income and Comprehensive Income Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Stockholders' Equity Sheet http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 7 false false R8.htm 995452 - Disclosure - Note 1 - Description of Business Sheet http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business Note 1 - Description of Business Notes 8 false false R9.htm 995453 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 995454 - Disclosure - Note 3 - Intangible Assets Sheet http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets Note 3 - Intangible Assets Notes 10 false false R11.htm 995455 - Disclosure - Note 4 - Inventories Sheet http://fitlifebrands.com/20231231/role/statement-note-4-inventories Note 4 - Inventories Notes 11 false false R12.htm 995456 - Disclosure - Note 5 - Property and Equipment Sheet http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 12 false false R13.htm 995457 - Disclosure - Note 6 - Notes Payable Notes http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable Note 6 - Notes Payable Notes 13 false false R14.htm 995458 - Disclosure - Note 7 - Equity Sheet http://fitlifebrands.com/20231231/role/statement-note-7-equity Note 7 - Equity Notes 14 false false R15.htm 995459 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp Sheet http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp Note 8 - Acquisition of Mimi's Rock Corp Notes 15 false false R16.htm 995460 - Disclosure - Note 9 - Acquisition of MusclePharm Sheet http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm Note 9 - Acquisition of MusclePharm Notes 16 false false R17.htm 995461 - Disclosure - Note 10 - Income Taxes Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes Note 10 - Income Taxes Notes 17 false false R18.htm 995462 - Disclosure - Note 11 - Commitments and Contingencies Sheet http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies Note 11 - Commitments and Contingencies Notes 18 false false R19.htm 995463 - Disclosure - Note 12 - Subsequent Events Sheet http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events Note 12 - Subsequent Events Notes 19 false false R20.htm 995464 - Disclosure - Note 13 - Reclassifications Sheet http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications Note 13 - Reclassifications Notes 20 false false R21.htm 995465 - Disclosure - Significant Accounting Policies (Policies) Sheet http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies 21 false false R22.htm 995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies 22 false false R23.htm 995467 - Disclosure - Note 3 - Intangible Assets (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables Note 3 - Intangible Assets (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets 23 false false R24.htm 995468 - Disclosure - Note 4 - Inventories (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-4-inventories 24 false false R25.htm 995469 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment 25 false false R26.htm 995470 - Disclosure - Note 6 - Notes Payable (Tables) Notes http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables Note 6 - Notes Payable (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable 26 false false R27.htm 995471 - Disclosure - Note 7 - Equity (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables Note 7 - Equity (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-7-equity 27 false false R28.htm 995472 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables Note 8 - Acquisition of Mimi's Rock Corp (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp 28 false false R29.htm 995473 - Disclosure - Note 10 - Income Taxes (Tables) Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables Note 10 - Income Taxes (Tables) Tables http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes 29 false false R30.htm 995474 - Disclosure - Note 1 - Description of Business (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual Note 1 - Description of Business (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business 30 false false R31.htm 995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables 31 false false R32.htm 995476 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details) Details 32 false false R33.htm 995477 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details) Details 33 false false R34.htm 995478 - Disclosure - Note 3 - Intangible Assets (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual Note 3 - Intangible Assets (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables 34 false false R35.htm 995479 - Disclosure - Note 3 - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details Note 3 - Intangible Assets - Schedule of Intangible Assets (Details) Details 35 false false R36.htm 995480 - Disclosure - Note 4 - Inventories - Summary of Inventory (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details Note 4 - Inventories - Summary of Inventory (Details) Details 36 false false R37.htm 995481 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual Note 5 - Property and Equipment (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables 37 false false R38.htm 995482 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details Note 5 - Property and Equipment - Property and Equipment (Details) Details 38 false false R39.htm 995483 - Disclosure - Note 6 - Notes Payable (Details Textual) Notes http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual Note 6 - Notes Payable (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables 39 false false R40.htm 995484 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details) Notes http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details Note 6 - Notes Payable - Debt Obligations (Details) Details 40 false false R41.htm 995485 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals) Notes http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals) Details 41 false false R42.htm 995486 - Disclosure - Note 6 - Notes Payable - Maturity (Details) Notes http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details Note 6 - Notes Payable - Maturity (Details) Details 42 false false R43.htm 995487 - Disclosure - Note 7 - Equity (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual Note 7 - Equity (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables 43 false false R44.htm 995488 - Disclosure - Note 7 - Equity - Stock Option Activity (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details Note 7 - Equity - Stock Option Activity (Details) Details 44 false false R45.htm 995489 - Disclosure - Note 7 - Equity - Exercise Price Range (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details Note 7 - Equity - Exercise Price Range (Details) Details 45 false false R46.htm 995490 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual Note 8 - Acquisition of Mimi's Rock Corp (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables 46 false false R47.htm 995491 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details) Details 47 false false R48.htm 995492 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details) Details 48 false false R49.htm 995493 - Disclosure - Note 9 - Acquisition of MusclePharm (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual Note 9 - Acquisition of MusclePharm (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm 49 false false R50.htm 995494 - Disclosure - Note 10 - Income Taxes (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual Note 10 - Income Taxes (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables 50 false false R51.htm 995495 - Disclosure - Note 10 - Income Taxes - Provision for Income Taxes (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details Note 10 - Income Taxes - Provision for Income Taxes (Details) Details 51 false false R52.htm 995496 - Disclosure - Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details) Details 52 false false R53.htm 995497 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 53 false false R54.htm 995498 - Disclosure - Note 10 - Income Taxes - Operating Loss Carryforwards (Details) Sheet http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details Note 10 - Income Taxes - Operating Loss Carryforwards (Details) Details 54 false false R55.htm 995499 - Disclosure - Note 12 - Subsequent Events (Details Textual) Sheet http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual Note 12 - Subsequent Events (Details Textual) Details http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events 55 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 44 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, ecd:NonRule10b51ArrAdoptedFlag, ecd:NonRule10b51ArrTrmntdFlag, ecd:Rule10b51ArrAdoptedFlag, ecd:Rule10b51ArrTrmntdFlag, ftlf:NumberOfVendors, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:AmortizationOfIntangibleAssets, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentInterestRateStatedPercentage, us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization, us-gaap:InventoryValuationReserves, us-gaap:NumberOfOperatingSegments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:TreasuryStockCommonShares, us-gaap:UnrecognizedTaxBenefits, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued - ftlf20231231_10k.htm 8, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 ftlf-20231231.xsd ftlf-20231231_cal.xml ftlf-20231231_def.xml ftlf-20231231_lab.xml ftlf-20231231_pre.xml ftlf20231231_10k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ftlf20231231_10k.htm": { "nsprefix": "ftlf", "nsuri": "http://fitlifebrands.com/20231231", "dts": { "schema": { "local": [ "ftlf-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ftlf-20231231_cal.xml" ] }, "definitionLink": { "local": [ "ftlf-20231231_def.xml" ] }, "labelLink": { "local": [ "ftlf-20231231_lab.xml" ] }, "presentationLink": { "local": [ "ftlf-20231231_pre.xml" ] }, "inline": { "local": [ "ftlf20231231_10k.htm" ] } }, "keyStandard": 288, "keyCustom": 27, "axisStandard": 30, "axisCustom": 0, "memberStandard": 32, "memberCustom": 36, "hidden": { "total": 48, "http://fasb.org/us-gaap/2023": 34, "http://fitlifebrands.com/20231231": 4, "http://xbrl.sec.gov/ecd/2023": 4, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 169, "entityCount": 1, "segmentCount": 70, "elementCount": 498, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 626, "http://xbrl.sec.gov/dei/2023": 37, "http://xbrl.sec.gov/ecd/2023": 5 }, "report": { "R1": { "role": "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "longName": "003 - Statement - Consolidated Statements of Income and Comprehensive Income", "shortName": "Consolidated Statements of Income and Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity", "longName": "004 - Statement - Consolidated Statement of Stockholders' Equity", "shortName": "Consolidated Statement of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockOutstandingMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockOutstandingMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "longName": "995452 - Disclosure - Note 1 - Description of Business", "shortName": "Note 1 - Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "995453 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets", "longName": "995454 - Disclosure - Note 3 - Intangible Assets", "shortName": "Note 3 - Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://fitlifebrands.com/20231231/role/statement-note-4-inventories", "longName": "995455 - Disclosure - Note 4 - Inventories", "shortName": "Note 4 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment", "longName": "995456 - Disclosure - Note 5 - Property and Equipment", "shortName": "Note 5 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "longName": "995457 - Disclosure - Note 6 - Notes Payable", "shortName": "Note 6 - Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "longName": "995458 - Disclosure - Note 7 - Equity", "shortName": "Note 7 - Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "longName": "995459 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "longName": "995460 - Disclosure - Note 9 - Acquisition of MusclePharm", "shortName": "Note 9 - Acquisition of MusclePharm", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes", "longName": "995461 - Disclosure - Note 10 - Income Taxes", "shortName": "Note 10 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies", "longName": "995462 - Disclosure - Note 11 - Commitments and Contingencies", "shortName": "Note 11 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "longName": "995463 - Disclosure - Note 12 - Subsequent Events", "shortName": "Note 12 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications", "longName": "995464 - Disclosure - Note 13 - Reclassifications", "shortName": "Note 13 - Reclassifications", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Reclassifications", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Reclassifications", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies", "longName": "995465 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ftlf:PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ftlf:PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables", "longName": "995467 - Disclosure - Note 3 - Intangible Assets (Tables)", "shortName": "Note 3 - Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables", "longName": "995468 - Disclosure - Note 4 - Inventories (Tables)", "shortName": "Note 4 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables", "longName": "995469 - Disclosure - Note 5 - Property and Equipment (Tables)", "shortName": "Note 5 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables", "longName": "995470 - Disclosure - Note 6 - Notes Payable (Tables)", "shortName": "Note 6 - Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables", "longName": "995471 - Disclosure - Note 7 - Equity (Tables)", "shortName": "Note 7 - Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables", "longName": "995472 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Tables)", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables", "longName": "995473 - Disclosure - Note 10 - Income Taxes (Tables)", "shortName": "Note 10 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "longName": "995474 - Disclosure - Note 1 - Description of Business (Details Textual)", "shortName": "Note 1 - Description of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "d_2023-10-10_2023-10-10_AssetAcquisitionAxis-AssetsOfMusclepharmCorporationMember", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-10-10_2023-10-10_AssetAcquisitionAxis-AssetsOfMusclepharmCorporationMember", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details", "longName": "995476 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "ftlf:PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "ftlf:PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "longName": "995477 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual", "longName": "995478 - Disclosure - Note 3 - Intangible Assets (Details Textual)", "shortName": "Note 3 - Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "longName": "995479 - Disclosure - Note 3 - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Note 3 - Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details", "longName": "995480 - Disclosure - Note 4 - Inventories - Summary of Inventory (Details)", "shortName": "Note 4 - Inventories - Summary of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "longName": "995481 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "shortName": "Note 5 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details", "longName": "995482 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details)", "shortName": "Note 5 - Property and Equipment - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual", "longName": "995483 - Disclosure - Note 6 - Notes Payable (Details Textual)", "shortName": "Note 6 - Notes Payable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2023-10-10_CreditFacilityAxis-RevolvingCreditFacilityMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-10-10_CreditFacilityAxis-RevolvingCreditFacilityMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "longName": "995484 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details)", "shortName": "Note 6 - Notes Payable - Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DebtInstrumentAxis-TermLoanAMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R41": { "role": "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "longName": "995485 - Disclosure - Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals)", "shortName": "Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "41", "firstAnchor": null, "uniqueAnchor": null }, "R42": { "role": "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details", "longName": "995486 - Disclosure - Note 6 - Notes Payable - Maturity (Details)", "shortName": "Note 6 - Notes Payable - Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "longName": "995487 - Disclosure - Note 7 - Equity (Details Textual)", "shortName": "Note 7 - Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2021-02-01_2021-02-28", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2021-02-01_2021-02-28", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details", "longName": "995488 - Disclosure - Note 7 - Equity - Stock Option Activity (Details)", "shortName": "Note 7 - Equity - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R45": { "role": "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details", "longName": "995489 - Disclosure - Note 7 - Equity - Exercise Price Range (Details)", "shortName": "Note 7 - Equity - Exercise Price Range (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "longName": "995490 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp (Details Textual)", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2022-12-04_2022-12-04_BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R47": { "role": "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "longName": "995491 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details)", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-02-28_BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R48": { "role": "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "longName": "995492 - Disclosure - Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details)", "shortName": "Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_BusinessAcquisitionAxis-MimisRockCorpMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual", "longName": "995493 - Disclosure - Note 9 - Acquisition of MusclePharm (Details Textual)", "shortName": "Note 9 - Acquisition of MusclePharm (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-10-10_2023-10-10_AssetAcquisitionAxis-AssetsOfMusclepharmCorporationMember", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R50": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual", "longName": "995494 - Disclosure - Note 10 - Income Taxes (Details Textual)", "shortName": "Note 10 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ftlf:EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ftlf:EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details", "longName": "995495 - Disclosure - Note 10 - Income Taxes - Provision for Income Taxes (Details)", "shortName": "Note 10 - Income Taxes - Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R52": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "longName": "995496 - Disclosure - Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details)", "shortName": "Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "unique": true } }, "R53": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details", "longName": "995497 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "shortName": "Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "longName": "995498 - Disclosure - Note 10 - Income Taxes - Operating Loss Carryforwards (Details)", "shortName": "Note 10 - Income Taxes - Operating Loss Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "longName": "995499 - Disclosure - Note 12 - Subsequent Events (Details Textual)", "shortName": "Note 12 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "d_2024-01-01_2024-03-22_DebtInstrumentAxis-TermLoanMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-03-22_DebtInstrumentAxis-TermLoanMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ftlf20231231_10k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r665" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r625" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance of doubtful accounts of $17 and $50, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r266", "r267" ] }, "ftlf_AccruedExpenseAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "AccruedExpenseAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "ftlf_AccruedExpenseAndOtherLiabilitiesCurrent", "terseLabel": "Accrued expense and other liabilities", "documentation": "Amount of accrued expense and liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedIncomeTaxesCurrent", "terseLabel": "Income taxes payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r95", "r136" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r61", "r168", "r498" ] }, "us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the noncontrolling interest." } } }, "auth_ref": [ "r4", "r15", "r31", "r460", "r466", "r707", "r708", "r709" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r98", "r665", "r796" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r401", "r402", "r403", "r538", "r718", "r719", "r720", "r776", "r798" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r399", "r404" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r177", "r268", "r272", "r273", "r275", "r792" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Allowance of doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r177", "r268", "r272" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ftlf_AmortizationOfDeferredFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "AmortizationOfDeferredFinanceCosts", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of deferred finance costs", "documentation": "In reference to the amortization of deferred finance costs." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r54", "r59" ] }, "ftlf_AmortizationOfInventoryStepup": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "AmortizationOfInventoryStepup", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of inventory step-up", "documentation": "in reference to the amortization of inventory step-up" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive options (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r228" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r42" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r42" ] }, "ftlf_ApplicableRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "ApplicableRateMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Applicable Rate [Member]", "documentation": "Related to applicable rate." } } }, "auth_ref": [] }, "ftlf_ApproximationMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "ApproximationMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Approximation [Member]", "documentation": "Related to approximation." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r772" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetAcquisitionConsiderationTransferred", "terseLabel": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r664", "r773", "r774", "r775" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r772" ] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r772" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r134", "r171", "r203", "r234", "r254", "r260", "r269", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r440", "r442", "r454", "r490", "r576", "r665", "r677", "r737", "r738", "r781" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r163", "r180", "r203", "r269", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r440", "r442", "r454", "r665", "r737", "r738", "r781" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "ftlf_AssetsOfMusclepharmCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "AssetsOfMusclepharmCorporationMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Assets of MusclePharm Corporation [Member]", "documentation": "Represents the assets of MusclePharm Corporation." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r681", "r682", "r683" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r681", "r682", "r683" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r681", "r682", "r683" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "ftlf_BrandsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "BrandsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Brands [Member]", "documentation": "In reference to brands associated with the company." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r437", "r659", "r660" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r79", "r81", "r437", "r659", "r660" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted net income per share (in dollars per share)", "label": "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r695", "r696" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r695", "r696" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income", "label": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r435", "r436" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "us-gaap_BusinessAcquisitionsProFormaRevenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r435", "r436" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "terseLabel": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r12" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r131", "r438" ] }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationIntegrationRelatedCosts", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Merger and acquisition related", "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r80" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r80" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "negatedTerseLabel": "Lease liabilities", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expense and other assets", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsSalesTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsSalesTaxReceivable", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales tax receivable", "label": "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsSalesTaxReceivable", "documentation": "In reference to the sales tax receivable in relation to a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "negatedTerseLabel": "Accounts payable and accrued expense", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "negatedTerseLabel": "Deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "label": "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable", "negatedTerseLabel": "Income tax payable", "documentation": "The amount of income tax payable which has been recognized as of the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r82", "r83" ] }, "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductReturns", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "label": "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedProductReturns", "negatedTerseLabel": "Product returns", "documentation": "The amount of product returns which has been recognized as of the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r82", "r83" ] }, "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use asset", "label": "ftlf_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset", "documentation": "The amount of right of use asset recognized as of the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Net assets acquired", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r77" ] }, "us-gaap_CanadaRevenueAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CanadaRevenueAgencyMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Canada Revenue Agency [Member]", "documentation": "Designated tax department of the government of Canada." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r144", "r492", "r549", "r571", "r665", "r677", "r700" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r166" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "CASH, BEGINNING OF PERIOD", "periodEndLabel": "CASH AND RESTRICTED CASH, END OF PERIOD", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r37", "r114", "r199" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "CHANGE IN CASH AND RESTRICTED CASH", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r114" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashFDICInsuredAmount", "terseLabel": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r166" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r725" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r159", "r174", "r175", "r176", "r203", "r222", "r223", "r225", "r227", "r231", "r232", "r269", "r308", "r310", "r311", "r312", "r315", "r316", "r345", "r346", "r348", "r351", "r357", "r454", "r532", "r533", "r534", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r563", "r585", "r604", "r618", "r619", "r620", "r621", "r622", "r690", "r714", "r722" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r358" ] }, "ftlf_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_ClassOfWarrantOrRightExpiredDuringPeriod", "terseLabel": "Class of Warrant or Right, Expired During Period (in shares)", "documentation": "The number of warrants or rights expired during period." } } }, "auth_ref": [] }, "ftlf_ClassOfWarrantOrRightIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_ClassOfWarrantOrRightIssuedDuringPeriod", "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)", "documentation": "The number of warrants or rights issued during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r122", "r302", "r303", "r626", "r734" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r668", "r669", "r670", "r672", "r673", "r674", "r675", "r718", "r719", "r776", "r795", "r798" ] }, "ftlf_CommonStockOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "CommonStockOutstandingMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Common Stock Outstanding [Member]", "documentation": "Represents common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r97" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r97", "r563" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "terseLabel": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r97" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r97", "r563", "r582", "r798", "r799" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.01 par value, 60,000 shares authorized; 4,598 and 4,507 issued and outstanding as of December 31, 2023 and 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r97", "r494", "r665" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r32", "r183", "r185", "r192", "r486", "r503" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "COMPREHENSIVE INCOME:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r44", "r47", "r87", "r88", "r265", "r625" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r44", "r47", "r87", "r88", "r265", "r529", "r625" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r44", "r47", "r87", "r88", "r265", "r625", "r694" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r92", "r149" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r44", "r47", "r87", "r88", "r265" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r44", "r47", "r87", "r88", "r265", "r625" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r86", "r642" ] }, "us-gaap_ContractWithCustomerRefundLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRefundLiability", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerRefundLiability", "terseLabel": "Contract with Customer, Refund Liability", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer." } } }, "auth_ref": [ "r742" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r110", "r481" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r699" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Current tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r130", "r424", "r430", "r717" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r45", "r265" ] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Product returns", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r85" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r123", "r201", "r317", "r323", "r324", "r325", "r326", "r327", "r328", "r333", "r340", "r341", "r342" ] }, "ftlf_DebtInstrumentAdditionalInterestRateDefault": { "xbrltype": "percentItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "DebtInstrumentAdditionalInterestRateDefault", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_DebtInstrumentAdditionalInterestRateDefault", "terseLabel": "Debt Instrument, Additional Interest Rate, Default", "documentation": "The percent additional interest rate of debt instrument in the event of default." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r94", "r95", "r135", "r137", "r205", "r318", "r319", "r320", "r321", "r322", "r324", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r469", "r650", "r651", "r652", "r653", "r654", "r715" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ftlf_DebtInstrumentCovenantCashFlowLeverageThreshold": { "xbrltype": "pureItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "DebtInstrumentCovenantCashFlowLeverageThreshold", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_DebtInstrumentCovenantCashFlowLeverageThreshold", "terseLabel": "Debt Instrument, Covenant, Cash Flow Leverage Threshold", "documentation": "Rate of cash flow leverage threshold under covenant of the debt instrument." } } }, "auth_ref": [] }, "ftlf_DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow": { "xbrltype": "percentItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_DebtInstrumentCovenantCashFlowLeverageThresholdPercentageOfExcessCashFlow", "terseLabel": "Debt Instrument, Covenant, Cash Flow Leverage Threshold, Percentage of Excess Cash Flow", "documentation": "Percentage of excess cash flow for rate of cash floe leverage threshold under the covenant of the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r89", "r91", "r318", "r469", "r651", "r652" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Stated percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r28", "r319" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r29", "r205", "r318", "r319", "r320", "r321", "r322", "r324", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r469", "r650", "r651", "r652", "r653", "r654", "r715" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsGross", "negatedLabel": "Unamortized debt issuance costs", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r90" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r410", "r411" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense (benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r130", "r155", "r429", "r430", "r717" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r410", "r411", "r491" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets (liabilities)", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r419" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax asset", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r770" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Loss carry forwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r76", "r771" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsOther", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r76", "r771" ] }, "ftlf_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsBadDebtAndInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsBadDebtAndInventory", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Provisions and reserves", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns, bad debt and inventory." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r420" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r73", "r770" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "negatedLabel": "Intangible assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r76", "r771" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Tangible assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r76", "r771" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r60" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r60" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_DepreciationDepletionAndAmortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r239" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes", "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r681", "r682", "r683" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r681", "r682", "r683", "r685" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r684" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "NET INCOME PER SHARE" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r193", "r211", "r212", "r213", "r214", "r215", "r220", "r222", "r225", "r226", "r227", "r229", "r452", "r453", "r487", "r504", "r644" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r193", "r211", "r212", "r213", "r214", "r215", "r222", "r225", "r226", "r227", "r229", "r452", "r453", "r487", "r504", "r644" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r42", "r43" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Foreign currency impact on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r778" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Federal income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r204", "r413", "r431" ] }, "ftlf_EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, Federal, State, and Foreign Statutory Income Tax Rate", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to federal, state and local, and foreign income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r400" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r679" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables", "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables", "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual", "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r679" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r679" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r688" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r679" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r679" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r679" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r679" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r689" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r160", "r187", "r188", "r189", "r206", "r207", "r208", "r210", "r216", "r218", "r230", "r270", "r271", "r359", "r401", "r402", "r403", "r425", "r426", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r460", "r462", "r463", "r464", "r465", "r466", "r473", "r524", "r525", "r526", "r538", "r604" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangibles, useful life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangibles amortization", "negatedLabel": "Intangibles, amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r170", "r296" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r293", "r295", "r296", "r298", "r482", "r483" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r55", "r58" ] }, "ftlf_FixedChargeCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "FixedChargeCoverageRatio", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_FixedChargeCoverageRatio", "terseLabel": "Fixed Charge Coverage Ratio", "documentation": "The fixed charge coverage ratio." } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "negatedLabel": "Foreign exchange gain", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r456", "r457", "r458", "r459", "r601" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r455" ] }, "ftlf_FormulationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "FormulationsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Formulations [Member]", "documentation": "Information related to formulations." } } }, "auth_ref": [] }, "ftlf_FundedDebtToEBITDARatio": { "xbrltype": "pureItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "FundedDebtToEBITDARatio", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_FundedDebtToEBITDARatio", "terseLabel": "Funded Debt to EBITDA Ratio", "documentation": "The Funded Debt to EBITDA Ratio." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "ftlf_GNCMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "GNCMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "GNC [Member]", "documentation": "Information related to GNC." } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r46", "r625" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r169", "r281", "r484", "r649", "r665", "r731", "r732" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r280", "r291", "r649" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r11" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r109", "r203", "r234", "r253", "r259", "r261", "r269", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r454", "r646", "r737" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r681", "r682", "r683" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Pre-tax net income", "totalLabel": "INCOME BEFORE INCOME TAXES", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r107", "r139", "r234", "r253", "r259", "r261", "r488", "r500", "r646" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r204", "r405", "r414", "r417", "r422", "r427", "r432", "r433", "r434", "r537" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "PROVISION FOR INCOME TAXES", "totalLabel": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r143", "r156", "r217", "r218", "r242", "r412", "r428", "r505" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r186", "r408", "r409", "r417", "r418", "r421", "r423", "r531" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Difference in jurisdictional tax rates", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r407", "r413" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes based on statutory rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r413" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r769" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r769" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "True up of prior period", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r769" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable - trade", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Income taxes payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities and other liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r712" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Product returns", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r479", "r712" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes", "negatedLabel": "Deferred taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r697", "r712" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expense and other assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r294", "r297" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r56", "r119" ] }, "ftlf_IndefiniteMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "IndefiniteMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Indefinite [Member]", "documentation": "In relation to an indefinite time period." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r686" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r292" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangibles, gross", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r169" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangibles, net of amortization of $113 and $71, respectively", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r53", "r57" ] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndOtherIncome", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestAndOtherIncome", "negatedLabel": "Interest income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r90", "r141", "r190", "r238", "r468", "r588", "r676", "r797" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest, net of amounts capitalized", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r195", "r197", "r198" ] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InternalRevenueServiceIRSMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-4-inventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r276" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r703" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual" ], "lang": { "en-us": { "role": { "label": "Inventories, net of allowance for obsolescence of $162 and $107, respectively", "terseLabel": "Inventory, Net", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r179", "r641", "r665" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r145", "r165", "r178", "r276", "r277", "r279", "r480", "r643" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Components", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r704" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Allowance for obsolescence", "terseLabel": "Inventory Valuation Reserves", "negatedLabel": "Allowance for obsolescence", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r51", "r705" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Allowance for inventory obsolescence", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r278" ] }, "ftlf_InventoryrelatedPurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "InventoryrelatedPurchasesMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Inventory-related Purchases [Member]", "documentation": "Related to inventory related purchases." } } }, "auth_ref": [] }, "ftlf_IsatoriProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "IsatoriProductsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "iSatori Products [Member]", "documentation": "Represents iSatori products." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Stock compensation expense", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r8" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r121" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables", "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables", "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual", "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r472" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r203", "r269", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r441", "r442", "r443", "r454", "r562", "r645", "r677", "r737", "r781", "r782" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r102", "r138", "r496", "r665", "r716", "r730", "r777" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r164", "r203", "r269", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r441", "r442", "r443", "r454", "r665", "r737", "r781", "r782" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r22", "r137", "r790" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r25" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details" ], "lang": { "en-us": { "role": { "label": "Term loan (8.21% as of December 31, 2023)", "totalLabel": "Total balance outstanding as of December 31, 2023", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r137", "r330", "r343", "r651", "r652", "r790" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details" ], "lang": { "en-us": { "role": { "label": "Term loan \u2013 current portion", "negatedLabel": "Current", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r172" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r205", "r335" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r205", "r335" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r205", "r335" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r205", "r335" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r205", "r335" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details" ], "lang": { "en-us": { "role": { "label": "Term loan, net of current portion and unamortized deferred finance costs", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r173" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r265", "r658", "r741", "r793", "r794" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r371", "r478", "r523", "r554", "r555", "r609", "r611", "r613", "r614", "r616", "r636", "r637", "r648", "r655", "r661", "r667", "r739", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "ftlf_MimisRockCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "MimisRockCorpMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Mimi\u2019s Rock Corp [Member]", "documentation": "Relating to Mimi\u2019s Rock Corp." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r371", "r478", "r523", "r554", "r555", "r609", "r611", "r613", "r614", "r616", "r636", "r637", "r648", "r655", "r661", "r667", "r739", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r687" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r265", "r658", "r741", "r793", "r794" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r146", "r157" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r196" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r196" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r114", "r115", "r116" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Net income", "totalLabel": "NET INCOME", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r108", "r116", "r140", "r162", "r181", "r184", "r189", "r203", "r209", "r211", "r212", "r213", "r214", "r217", "r218", "r224", "r234", "r253", "r259", "r261", "r269", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r453", "r454", "r501", "r584", "r602", "r603", "r646", "r676", "r737" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r687" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r687" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "negatedTotalLabel": "Total other expense (income)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r112" ] }, "ftlf_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "ftlf_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r724" ] }, "us-gaap_NumberOfStores": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfStores", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfStores", "terseLabel": "Number of Stores", "documentation": "Represents the number of stores." } } }, "auth_ref": [] }, "ftlf_NumberOfVendors": { "xbrltype": "integerItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "NumberOfVendors", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_NumberOfVendors", "terseLabel": "Number of Vendors", "documentation": "The number of vendors." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "ftlf_OneVendorMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "OneVendorMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "One Vendor [Member]", "documentation": "Related to one vendor." } } }, "auth_ref": [] }, "ftlf_OnlineSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "OnlineSalesMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Online Sales [Member]", "documentation": "Information related to online sales." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expense", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSE:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "OPERATING INCOME", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r234", "r253", "r259", "r261", "r646" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Lease liability - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r471" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Long-term lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r471" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r470" ] }, "ftlf_OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ftlf_OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability", "negatedLabel": "Right of use asset", "documentation": "Amount of right-of-use asset net of amortization and lease liability from operating lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Operating loss carry forwards, 2034", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r75" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustment", "label": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r6", "r14", "r133" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Comprehensive (loss) income", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r20", "r182", "r185", "r191", "r460", "r461", "r466", "r485", "r502", "r707", "r708" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE (INCOME)" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchases of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireBusinessesGross", "terseLabel": "Payments to Acquire Businesses, Gross", "negatedLabel": "Cash paid for acquisition", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r33", "r439" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireProductiveAssets", "terseLabel": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r142", "r773", "r774", "r775" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r113" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r96", "r345" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r96", "r563" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r96", "r563", "r582", "r798", "r799" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of December 31, 2023 and 2022", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r96", "r493", "r665" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expense and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r706" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Borrowings on term loan", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r34", "r532" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options and warrants", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r5", "r19" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r710" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r262", "r481", "r517", "r518", "r519", "r520", "r521", "r522", "r639", "r656", "r666", "r698", "r735", "r736", "r741", "r793" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r262", "r481", "r517", "r518", "r519", "r520", "r521", "r522", "r639", "r656", "r666", "r698", "r735", "r736", "r741", "r793" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r120", "r150", "r153", "r154" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r121", "r167", "r499" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r489", "r499", "r665" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r150", "r153", "r497" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r121" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ftlf_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life [Table Text Block]", "documentation": "Tabular disclosure of useful life of physical assets used in the normal conduct of business and not intended for resale." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r194", "r274" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r370", "r371", "r395", "r396", "r397", "r477", "r478", "r523", "r554", "r555", "r609", "r611", "r613", "r614", "r616", "r636", "r637", "r648", "r655", "r661", "r667", "r670", "r733", "r739", "r784", "r785", "r786", "r787", "r788" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r370", "r371", "r395", "r396", "r397", "r477", "r478", "r523", "r554", "r555", "r609", "r611", "r613", "r614", "r616", "r636", "r637", "r648", "r655", "r661", "r667", "r670", "r733", "r739", "r784", "r785", "r786", "r787", "r788" ] }, "ftlf_RangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "RangeOneMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Range One [Member]", "documentation": "Information related to range one." } } }, "auth_ref": [] }, "ftlf_RangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "RangeTwoMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Range Two [Member]", "documentation": "Information related to range two." } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r726", "r727", "r728", "r729" ] }, "us-gaap_Reclassifications": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Reclassifications", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications" ], "lang": { "en-us": { "role": { "label": "Reclassifications [Text Block]", "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted." } } }, "auth_ref": [ "r93" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "terseLabel": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r711" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Payments on term loan", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r36", "r535" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r700", "r713", "r789", "r791" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r166" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r99", "r125", "r495", "r527", "r528", "r536", "r564", "r665" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r160", "r206", "r207", "r208", "r210", "r216", "r218", "r270", "r271", "r401", "r402", "r403", "r425", "r426", "r444", "r446", "r447", "r449", "r451", "r524", "r526", "r538", "r798" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r235", "r236", "r252", "r257", "r258", "r262", "r263", "r265", "r368", "r369", "r481" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r158", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r638" ] }, "ftlf_RevenueFromContractWithCustomerProductReturnsSalesIncentivesAndOtherFormsOfVariableConsiderationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "RevenueFromContractWithCustomerProductReturnsSalesIncentivesAndOtherFormsOfVariableConsiderationPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product Returns, Sales Incentives and Other Forms of Variable Consideration [Policy Text Block]", "documentation": "Disclosure of accounting policy for product returns, sales incentives and other forms of variable consideration." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r687" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r687" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r265", "r693" ] }, "us-gaap_SalesRevenueSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueSegmentMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue, Segment Benchmark [Member]", "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r693" ] }, "ftlf_SalesTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "SalesTaxesReceivable", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Sales tax receivable", "documentation": "The amount of sales taxes receivable." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r219", "r372", "r691", "r721" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r129" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r128" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r127" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r52" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r23", "r103", "r104", "r105" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r132" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r66" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r678" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r680" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r265", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r300", "r301", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r649", "r698", "r793" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r263", "r264", "r551", "r552", "r553", "r610", "r612", "r615", "r617", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r640", "r657", "r670", "r741", "r793" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r263", "r647" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r111" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r701", "r702", "r740" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r662" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r387" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r391" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r396" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r395" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, number of options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Issued, number of options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Outstanding, number of options (in shares)", "periodEndLabel": "Outstanding, number of options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r376", "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r376", "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Forfeited, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Issued, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Lower range limit (in dollars per share)", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Number of vested options (in shares)", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Total number of options (in shares)", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Upper range limit (in dollars per share)", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "ftlf_ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "ShareRepurchaseProgramMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Member]", "documentation": "Information related to the Share Repurchase Program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r663" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r394" ] }, "ftlf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value", "documentation": "Fair value of options granted." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, weighted average remaining life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r126" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r68" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r67" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining life (Year)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r126" ] }, "ftlf_SharesForfeitedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "SharesForfeitedDuringPeriodValue", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_SharesForfeitedDuringPeriodValue", "terseLabel": "Shares Forfeited During Period, Value", "documentation": "Represents the value of shares forfeited during period." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r117", "r200" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r161", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r265", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r299", "r300", "r301", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r649", "r698", "r793" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r159", "r174", "r175", "r176", "r203", "r222", "r223", "r225", "r227", "r231", "r232", "r269", "r308", "r310", "r311", "r312", "r315", "r316", "r345", "r346", "r348", "r351", "r357", "r454", "r532", "r533", "r534", "r535", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r563", "r585", "r604", "r618", "r619", "r620", "r621", "r622", "r690", "r714", "r722" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r30", "r160", "r187", "r188", "r189", "r206", "r207", "r208", "r210", "r216", "r218", "r230", "r270", "r271", "r359", "r401", "r402", "r403", "r425", "r426", "r444", "r445", "r446", "r447", "r448", "r449", "r451", "r460", "r462", "r463", "r464", "r465", "r466", "r473", "r524", "r525", "r526", "r538", "r604" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r263", "r264", "r551", "r552", "r553", "r610", "r612", "r615", "r617", "r624", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r640", "r657", "r670", "r741", "r793" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables", "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables", "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual", "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206", "r207", "r208", "r230", "r481", "r530", "r550", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r566", "r567", "r568", "r569", "r570", "r572", "r573", "r574", "r575", "r577", "r578", "r579", "r580", "r581", "r583", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r604", "r671" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r219", "r372", "r691", "r692", "r721" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-provision-for-income-taxes-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables", "http://fitlifebrands.com/20231231/role/statement-note-11-commitments-and-contingencies", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-13-reclassifications", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-summary-of-inventory-details", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-details", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-maturity-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables", "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-exercise-price-range-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm", "http://fitlifebrands.com/20231231/role/statement-note-9-acquisition-of-musclepharm-details-textual", "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r206", "r207", "r208", "r230", "r481", "r530", "r550", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r566", "r567", "r568", "r569", "r570", "r572", "r573", "r574", "r575", "r577", "r578", "r579", "r580", "r581", "r583", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r604", "r671" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Shares surrendered by former employee (in shares)", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options (in shares)", "negatedLabel": "Exercised, number of options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r96", "r97", "r125", "r381" ] }, "ftlf_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants (in shares)", "documentation": "In reference to shares of warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r70", "r96", "r97", "r125" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r16", "r30", "r125" ] }, "ftlf_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "In reference to Warrants exercised in period." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "ftlf_StockRepurchaseProgramExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "StockRepurchaseProgramExpirationPeriod", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "ftlf_StockRepurchaseProgramExpirationPeriod", "terseLabel": "Stock Repurchase Program Expiration Period (Year)", "documentation": "Expiration period for the purchase of an entity's own shares under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "negatedPeriodEndLabel": "Balance", "label": "us-gaap_StockholdersEquity", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r97", "r100", "r101", "r118", "r565", "r582", "r605", "r606", "r665", "r677", "r716", "r730", "r777", "r798" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r124", "r202", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r450", "r607", "r608", "r623" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r467", "r475" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r467", "r475" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r467", "r475" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r474", "r476" ] }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Operating Loss Carryforwards [Table Text Block]", "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r74" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow disclosure" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r45" ] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-tables", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-tables", "http://fitlifebrands.com/20231231/role/statement-note-4-inventories-tables", "http://fitlifebrands.com/20231231/role/statement-note-5-property-and-equipment-tables", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-tables", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-tables", "http://fitlifebrands.com/20231231/role/statement-note-8-acquisition-of-mimis-rock-corp-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [] }, "ftlf_TaxYear2034Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2034Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2034 [Member]", "documentation": "In relation to tax year 2034" } } }, "auth_ref": [] }, "ftlf_TaxYear2035Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2035Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2035 [Member]", "documentation": "In relation to tax year 2035" } } }, "auth_ref": [] }, "ftlf_TaxYear2036Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2036Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2036 [Member]", "documentation": "In relation to tax year 2036" } } }, "auth_ref": [] }, "ftlf_TaxYear2037Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2037Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2037 [Member]", "documentation": "In relation to tax year 2037" } } }, "auth_ref": [] }, "ftlf_TaxYear2038Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2038Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2038 [Member]", "documentation": "In relation to tax period 2038" } } }, "auth_ref": [] }, "ftlf_TaxYear2039Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2039Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2039 [Member]", "documentation": "In relation to tax period 2039." } } }, "auth_ref": [] }, "ftlf_TaxYear2040Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2040Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2040 [Member]", "documentation": "In relation to tax period 2040." } } }, "auth_ref": [] }, "ftlf_TaxYear2041Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2041Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2041 [Member]", "documentation": "In relation to tax period 2041." } } }, "auth_ref": [] }, "ftlf_TaxYear2042Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2042Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2042 [Member]", "documentation": "In relation to tax period 2042." } } }, "auth_ref": [] }, "ftlf_TaxYear2043Member": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TaxYear2043Member", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-operating-loss-carryforwards-details" ], "lang": { "en-us": { "role": { "label": "Tax Year 2043 [Member]", "documentation": "In relation to tax period 2043." } } }, "auth_ref": [] }, "ftlf_TermLoanAMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TermLoanAMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Term Loan A [Member]", "documentation": "In relation Term Loan A" } } }, "auth_ref": [] }, "ftlf_TermLoanBMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TermLoanBMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business", "http://fitlifebrands.com/20231231/role/statement-note-1-description-of-business-details-textual", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details-parentheticals", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Term Loan B [Member]", "documentation": "Represents term loan B." } } }, "auth_ref": [] }, "ftlf_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TermLoanMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events", "http://fitlifebrands.com/20231231/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "Related to term loan." } } }, "auth_ref": [] }, "ftlf_TermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TermLoansMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-debt-obligations-details", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Term Loans [Member]", "documentation": "In reference to the Term Loans." } } }, "auth_ref": [] }, "ftlf_ThreeVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "ThreeVendorsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Three Vendors [Member]", "documentation": "Related to three vendors." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r725", "r780" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r84" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax", "crdr": "credit", "calculation": { "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount of cumulative translation gain (loss), after tax, from translating foreign currency financial statements into the reporting currency." } } }, "auth_ref": [ "r106", "r779" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r63" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockCommonShares", "terseLabel": "Treasury Stock, Common, Shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r63" ] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockRetiredCostMethodAmount", "negatedLabel": "Retirement of treasury shares", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r16", "r62", "r97" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockSharesAcquired", "negatedTerseLabel": "Repurchase of common stock (in shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r16", "r97", "r125" ] }, "ftlf_TreasuryStockValueAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TreasuryStockValueAcquired", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "ftlf_TreasuryStockValueAcquired", "negatedLabel": "Repurchase of common stock", "documentation": "Represents the value of treasury stock acquired during the period." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statement-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedTerseLabel": "Repurchase of common stock", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r16", "r63", "r125" ] }, "ftlf_TwoVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "TwoVendorsMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Two Vendors [Member]", "documentation": "Related to two vendors." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r406", "r416" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-10-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r415" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r48", "r49", "r50", "r147", "r148", "r151", "r152" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable", "http://fitlifebrands.com/20231231/role/statement-note-6-notes-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ftlf_VendorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "VendorOneMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Vendor One [Member]", "documentation": "Related to vendor one." } } }, "auth_ref": [] }, "ftlf_VendorThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "VendorThreeMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Vendor Three [Member]", "documentation": "Related to vendor three." } } }, "auth_ref": [] }, "ftlf_VendorTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "VendorTwoMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Vendor Two [Member]", "documentation": "Related to vendor two." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-7-equity", "http://fitlifebrands.com/20231231/role/statement-note-7-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768" ] }, "ftlf_WebsiteMember": { "xbrltype": "domainItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "WebsiteMember", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-3-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Website [Member]", "documentation": "Information related to website." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Dilutive effect of potential common shares (in shares)", "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r723" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income", "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Diluted weighted average common shares (in shares)", "totalLabel": "Diluted weighted average shares outstanding (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r221", "r227" ] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "calculation": { "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://fitlifebrands.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic weighted average shares outstanding (in shares)", "label": "us-gaap_WeightedAverageNumberOfSharesIssuedBasic", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://fitlifebrands.com/20231231/role/statement-consolidated-statements-of-income-and-comprehensive-income" ], "lang": { "en-us": { "role": { "label": "Basic weighted average common shares (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r220", "r227" ] }, "ftlf_statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-10-income-taxes-operating-loss-carryforwards-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-10-income-taxes-operating-loss-carryforwards-details", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes - Operating Loss Carryforwards (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-10-income-taxes-provision-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-10-income-taxes-provision-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes - Provision for Income Taxes (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-10-income-taxes-reconciliations-of-federal-statutory-rate-to-effective-income-tax-rate-details", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes - Reconciliations of Federal Statutory Rate to Effective Income Tax Rate (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-10-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-10-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Income Taxes" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-dilutive-shares-excluded-from-calculation-diluted-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Dilutive Shares Excluded From Calculation Diluted Earnings Per Share (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-property-and-equipment-useful-life-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Property and Equipment Useful Life (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-3-intangible-assets-schedule-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-3-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 3 - Intangible Assets - Schedule of Intangible Assets (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-3-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-3-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Intangible Assets" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-4-inventories-summary-of-inventory-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-4-inventories-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories - Summary of Inventory (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-4-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-4-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-5-property-and-equipment-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-5-property-and-equipment-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment - Property and Equipment (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-5-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-5-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-6-notes-payable-debt-obligations-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-6-notes-payable-debt-obligations-details", "lang": { "en-us": { "role": { "label": "Note 6 - Notes Payable - Debt Obligations (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-6-notes-payable-debt-obligations-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-6-notes-payable-debt-obligations-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 6 - Notes Payable - Debt Obligations (Details) (Parentheticals)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-6-notes-payable-maturity-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-6-notes-payable-maturity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Notes Payable - Maturity (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-6-notes-payable-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-6-notes-payable-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Notes Payable" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-7-equity-exercise-price-range-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-7-equity-exercise-price-range-details", "lang": { "en-us": { "role": { "label": "Note 7 - Equity - Exercise Price Range (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-7-equity-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-7-equity-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 7 - Equity - Stock Option Activity (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-7-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-7-equity-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Equity" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-8-acquisition-of-mimis-rock-corp-fair-value-of-assets-assumed-details", "lang": { "en-us": { "role": { "label": "Note 8 - Acquisition of Mimi's Rock Corp - Fair Value of Assets Assumed (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-8-acquisition-of-mimis-rock-corp-pro-forma-information-details", "lang": { "en-us": { "role": { "label": "Note 8 - Acquisition of Mimi's Rock Corp - Pro Forma Information (Details)" } } }, "auth_ref": [] }, "ftlf_statement-statement-note-8-acquisition-of-mimis-rock-corp-tables": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-note-8-acquisition-of-mimis-rock-corp-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Acquisition of Mimi's Rock Corp" } } }, "auth_ref": [] }, "ftlf_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://fitlifebrands.com/20231231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(19)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r690": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r692": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 75 0001437749-24-010119-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-010119-xbrl.zip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end XML 77 ftlf20231231_10k_htm.xml IDEA: XBRL DOCUMENT 0001374328 2023-01-01 2023-12-31 0001374328 2023-06-30 0001374328 2024-03-28 0001374328 2023-12-31 0001374328 2022-12-31 0001374328 ftlf:TermLoansMember 2023-12-31 0001374328 ftlf:TermLoansMember 2022-12-31 0001374328 2022-01-01 2022-12-31 0001374328 ftlf:CommonStockOutstandingMember 2022-12-31 0001374328 us-gaap:CommonStockMember 2022-12-31 0001374328 us-gaap:TreasuryStockCommonMember 2022-12-31 0001374328 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001374328 us-gaap:RetainedEarningsMember 2022-12-31 0001374328 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2022-12-31 0001374328 ftlf:CommonStockOutstandingMember 2023-01-01 2023-12-31 0001374328 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001374328 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001374328 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001374328 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001374328 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2023-01-01 2023-12-31 0001374328 ftlf:CommonStockOutstandingMember 2023-12-31 0001374328 us-gaap:CommonStockMember 2023-12-31 0001374328 us-gaap:TreasuryStockCommonMember 2023-12-31 0001374328 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001374328 us-gaap:RetainedEarningsMember 2023-12-31 0001374328 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2023-12-31 0001374328 ftlf:CommonStockOutstandingMember 2021-12-31 0001374328 us-gaap:CommonStockMember 2021-12-31 0001374328 us-gaap:TreasuryStockCommonMember 2021-12-31 0001374328 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001374328 us-gaap:RetainedEarningsMember 2021-12-31 0001374328 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2021-12-31 0001374328 2021-12-31 0001374328 ftlf:CommonStockOutstandingMember 2022-01-01 2022-12-31 0001374328 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001374328 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001374328 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001374328 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001374328 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2022-01-01 2022-12-31 0001374328 ftlf:MimisRockCorpMember 2023-01-01 2023-12-31 0001374328 ftlf:MimisRockCorpMember 2022-01-01 2022-12-31 0001374328 ftlf:AssetsOfMusclepharmCorporationMember 2023-01-01 2023-12-31 0001374328 ftlf:AssetsOfMusclepharmCorporationMember 2022-01-01 2022-12-31 0001374328 ftlf:IsatoriProductsMember srt:MinimumMember 2023-12-31 0001374328 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001374328 ftlf:MimisRockCorpMember 2022-12-04 2022-12-04 0001374328 ftlf:MimisRockCorpMember ftlf:TermLoanAMember 2022-12-04 2022-12-04 0001374328 ftlf:MimisRockCorpMember us-gaap:CashMember 2022-12-04 2022-12-04 0001374328 ftlf:AssetsOfMusclepharmCorporationMember 2023-10-10 2023-10-10 0001374328 ftlf:AssetsOfMusclepharmCorporationMember ftlf:TermLoanBMember 2023-10-10 2023-10-10 0001374328 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember ftlf:OnlineSalesMember 2023-01-01 2023-12-31 0001374328 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember ftlf:OnlineSalesMember 2022-01-01 2022-12-31 0001374328 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001374328 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001374328 ftlf:GNCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001374328 ftlf:GNCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001374328 ftlf:GNCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001374328 ftlf:GNCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001374328 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember ftlf:OneVendorMember 2023-01-01 2023-12-31 0001374328 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember ftlf:OneVendorMember 2022-01-01 2022-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:ThreeVendorsMember 2023-01-01 2023-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:VendorOneMember 2023-01-01 2023-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:VendorTwoMember 2023-01-01 2023-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:VendorThreeMember 2023-01-01 2023-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:TwoVendorsMember 2022-01-01 2022-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:VendorOneMember 2022-01-01 2022-12-31 0001374328 ftlf:InventoryrelatedPurchasesMember us-gaap:SupplierConcentrationRiskMember ftlf:VendorTwoMember 2022-01-01 2022-12-31 0001374328 srt:MaximumMember 2023-12-31 0001374328 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001374328 us-gaap:OfficeEquipmentMember 2023-12-31 0001374328 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001374328 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001374328 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001374328 ftlf:BrandsMember 2023-12-31 0001374328 us-gaap:CustomerRelationshipsMember 2023-12-31 0001374328 ftlf:FormulationsMember 2023-12-31 0001374328 us-gaap:TrademarksMember 2023-12-31 0001374328 ftlf:WebsiteMember 2023-12-31 0001374328 us-gaap:CustomerRelationshipsMember 2022-12-31 0001374328 ftlf:FormulationsMember 2022-12-31 0001374328 us-gaap:TrademarksMember 2022-12-31 0001374328 ftlf:WebsiteMember 2022-12-31 0001374328 ftlf:ApproximationMember 2022-12-31 0001374328 ftlf:TermLoanAMember 2023-12-31 0001374328 ftlf:TermLoanAMember 2022-12-31 0001374328 ftlf:TermLoanBMember 2023-12-31 0001374328 ftlf:TermLoanBMember 2022-12-31 0001374328 ftlf:TermLoanAMember 2023-02-23 0001374328 us-gaap:RevolvingCreditFacilityMember 2023-02-23 0001374328 ftlf:TermLoanBMember 2023-10-10 0001374328 us-gaap:RevolvingCreditFacilityMember 2023-10-10 0001374328 ftlf:TermLoansMember ftlf:ApplicableRateMember 2023-10-10 2023-10-10 0001374328 ftlf:TermLoansMember 2023-10-10 0001374328 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001374328 us-gaap:RevolvingCreditFacilityMember 2022-12-31 0001374328 2021-02-01 2021-02-28 0001374328 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001374328 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001374328 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001374328 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001374328 ftlf:ShareRepurchaseProgramMember 2019-11-06 0001374328 ftlf:ShareRepurchaseProgramMember 2019-11-06 2019-11-06 0001374328 ftlf:ShareRepurchaseProgramMember 2019-09-23 0001374328 ftlf:ShareRepurchaseProgramMember 2019-09-23 2019-09-23 0001374328 ftlf:ShareRepurchaseProgramMember 2019-10-06 0001374328 ftlf:ShareRepurchaseProgramMember 2019-10-06 2019-10-06 0001374328 ftlf:ShareRepurchaseProgramMember 2023-03-17 0001374328 ftlf:ShareRepurchaseProgramMember 2023-03-17 2023-03-17 0001374328 ftlf:ShareRepurchaseProgramMember 2023-12-31 0001374328 ftlf:ShareRepurchaseProgramMember 2023-01-01 2023-12-31 0001374328 2021-01-01 2021-12-31 0001374328 ftlf:RangeOneMember 2023-01-01 2023-12-31 0001374328 ftlf:RangeOneMember 2023-12-31 0001374328 ftlf:RangeTwoMember 2023-01-01 2023-12-31 0001374328 ftlf:RangeTwoMember 2023-12-31 0001374328 us-gaap:EmployeeStockOptionMember 2023-12-31 0001374328 us-gaap:EmployeeStockOptionMember 2023-08-01 2023-08-31 0001374328 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-08-01 2023-08-31 0001374328 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001374328 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001374328 us-gaap:EmployeeStockOptionMember 2022-12-31 0001374328 ftlf:MimisRockCorpMember 2023-02-28 0001374328 ftlf:MimisRockCorpMember 2023-02-28 2023-12-31 0001374328 ftlf:MimisRockCorpMember 2023-04-28 2023-12-31 0001374328 ftlf:AssetsOfMusclepharmCorporationMember ftlf:BrandsMember 2023-10-10 2023-10-10 0001374328 ftlf:AssetsOfMusclepharmCorporationMember 2023-10-10 0001374328 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0001374328 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001374328 us-gaap:ForeignCountryMember 2023-01-01 2023-12-31 0001374328 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0001374328 ftlf:ApproximationMember 2023-01-01 2023-12-31 0001374328 ftlf:ApproximationMember 2022-01-01 2022-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2034Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2034Member 2023-12-31 0001374328 ftlf:TaxYear2034Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2035Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2035Member 2023-12-31 0001374328 ftlf:TaxYear2035Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2036Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2036Member 2023-12-31 0001374328 ftlf:TaxYear2036Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2037Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2037Member 2023-12-31 0001374328 ftlf:TaxYear2037Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2038Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2038Member 2023-12-31 0001374328 ftlf:TaxYear2038Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2039Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2039Member 2023-12-31 0001374328 ftlf:TaxYear2039Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2040Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2040Member 2023-12-31 0001374328 ftlf:TaxYear2040Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2041Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2041Member 2023-12-31 0001374328 ftlf:TaxYear2041Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2042Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2042Member 2023-12-31 0001374328 ftlf:TaxYear2042Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:TaxYear2043Member 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:TaxYear2043Member 2023-12-31 0001374328 ftlf:TaxYear2043Member 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember ftlf:IndefiniteMember 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember ftlf:IndefiniteMember 2023-12-31 0001374328 ftlf:IndefiniteMember 2023-12-31 0001374328 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2023-12-31 0001374328 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2023-12-31 0001374328 ftlf:TermLoanMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-22 0001374328 ftlf:TermLoanAMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-22 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y utr:M 0001374328 FITLIFE BRANDS, INC. false --12-31 FY 2023 false false false false 17000 50000 162000 107000 113000 71000 0.01 0.01 10000000 10000000 0 0 0.01 0.01 60000000 60000000 4598000 4598000 4507000 4507000 1 1 3 2 1 1 42000 0.0821 0.0821 0 0.7 11.55 P5Y P3Y P5Y P5Y 0 0 10-K true 2023-12-31 false 000-52369 NV 20-3464383 5214 S. 136th Street Omaha NE 68137 402 991-5618 Common Stock, par value $0.01 per share FTLF NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 32319000 4598241 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>ITEM <em style="font: inherit;">9B.</em></b> <b> OTHER INFORMATION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c109746583"><span style="-sec-ix-hidden:c109747021"><span style="-sec-ix-hidden:c109747022"><span style="-sec-ix-hidden:c109747023">None</span></span></span>.</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 572 Weinberg & Company, P.A. Los Angeles, California 1139000 13277000 759000 0 2046000 705000 9091000 9105000 1019000 0 639000 116000 14693000 23203000 137000 46000 121000 103000 26309000 150000 13294000 358000 792000 1847000 55346000 25707000 3261000 2995000 1026000 444000 892000 187000 571000 590000 4500000 0 87000 54000 10337000 4270000 15509000 0 51000 49000 2413000 0 28310000 4319000 0 0 46000 45000 30699000 30056000 -3417000 -8713000 -292000 0 27036000 21388000 55346000 25707000 52700000 28803000 31268000 16769000 21432000 12034000 12161000 6010000 1627000 257000 94000 66000 13882000 6333000 7550000 5701000 289000 121000 1025000 0 189000 -0 -547000 121000 7003000 5822000 1707000 1393000 5296000 4429000 1.18 0.97 1.08 0.89 4490 4553 4905 4975 5296000 4429000 -292000 0 5004000 4429000 4507000 45000 0 30056000 -8713000 0 21388000 -61000 9000 0 0 6000 0 0 6000 143000 1000 0 164000 0 0 165000 473000 473000 0 0 0 0 -292000 -292000 0 0 0 5296000 0 5296000 4598000 46000 0 30699000 -3417000 -292000 27036000 4552000 46000 -2087000 32529000 -13142000 0 17346000 48 1000 771000 -0 -0 -0 772000 -0 -2858000 2865000 -0 -0 7000 3000 0 0 29000 0 0 29000 0 0 363000 0 0 363000 0 0 0 4429000 0 4429000 4507000 45000 0 30056000 -8713000 0 21388000 5296000 4429000 94000 66000 -33000 -6000 55000 51000 473000 363000 15000 0 323000 0 882000 -247000 -1026000 2636000 -957000 -1199000 178000 -204000 -83000 -55000 -2679000 115000 -356000 184000 -77000 -55000 122000 -44000 -19000 -42000 4220000 4130000 106000 -0 17099000 -0 18788000 -0 -35993000 0 171000 29000 -0 779000 22500000 0 2375000 -0 20296000 -750000 98000 0 -11379000 3380000 13277000 9897000 1898000 13277000 698000 3000 777000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">1.</em></b>  <b>DESCRIPTION OF BUSINESS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FitLife Brands, Inc. (the “<i>Company</i>”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “<i>NDS Products</i>”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "<i>iSatori Products</i>"); and (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “<i>MRC Products</i>"); and (iv) MusclePharm.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“<i>GNC</i>”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.  The Company distributes the MRC Products primarily online.  MusclePharm’s products are sold to both wholesale customers as well as online directly to the end consumer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“<i>Common Stock</i>”), trades under the symbol “FTLF” on the Nasdaq Capital Market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Developments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Acquisition of Mimi</i>’<i>s Rock Corp</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 4, 2022, </em>the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“<i>MRC</i>”), pursuant to which the Company agreed to acquire MRC. On <em style="font: inherit;"> February 28, 2023, </em>the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was $17,099, of which $12,500 was funded using proceeds from a new term loan, and $4,599 from the Company’s available cash. See Note <em style="font: inherit;">8</em> to the financial statements for additional disclosure regarding the acquisition of MRC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Acquisition of MusclePharm Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> October 10, 2023, </em>the Company acquired substantially all of the assets of MusclePharm Corporation (“<i>MusclePharm</i>”) through an asset purchase transaction under Section <em style="font: inherit;">363</em> of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed <em style="font: inherit;">none</em> of the liabilities of MusclePharm other than <i>de</i> <i>minimus</i> cure costs relating to certain assumed contracts.  Total consideration for the acquisition was approximately $18,500 cash.  Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note <em style="font: inherit;">9</em> for additional disclosure regarding the acquisition of MusclePharm.</p> 17000 0.01 17099000 12500000 4599000 18500000 10000000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE <em style="font: inherit;">2.</em></b>  <b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Significant accounting policies are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in the consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Foreign Currency Translation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The functional currency of the Company is the U.S. dollar.  The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar.  The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Use of Estimates and Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accounts for revenue in accordance with FASB ASC <em style="font: inherit;">606.</em> The underlying principle of ASC <em style="font: inherit;">606</em> is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC <em style="font: inherit;">606</em> creates a <em style="font: inherit;">five</em>-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (<em style="font: inherit;">1</em>) identifying the contract(s) or agreement(s) with a customer, (<em style="font: inherit;">2</em>) identifying our performance obligations in the contract or agreement, (<em style="font: inherit;">3</em>) determining the transaction price, (<em style="font: inherit;">4</em>) allocating the transaction price to the separate performance obligations, and (<em style="font: inherit;">5</em>) recognizing revenue as each performance obligation is satisfied. Under ASC <em style="font: inherit;">606,</em> revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are <em style="font: inherit;">no</em> performance obligations required post-shipment for customers to derive the expected value from them.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company’s products are also sold on e-commerce platforms including Amazon.  For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to <em style="font: inherit;">third</em>-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the consolidated statements of income and comprehensive income. Distribution and platform fees are <em style="font: inherit;">not</em> recorded as a reduction of revenue because the Company: <em style="font: inherit;">1</em>) owns the goods before they are transferred to the customer,   <em style="font: inherit;">2</em>) can direct Amazon, similar to other <em style="font: inherit;">third</em>-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, <em style="font: inherit;">3</em>) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, <em style="font: inherit;">4</em>) is subject to credit risk (i.e., credit card chargebacks), <em style="font: inherit;">5</em>) establishes prices of its products, <em style="font: inherit;">6</em>) can determine who fulfills the goods to the customer (Amazon or the Company) and <em style="font: inherit;">7</em>) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in selling, general and administrative expense in the consolidated statements of income and comprehensive income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company disaggregates revenue into geographical regions and distribution channels.  The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as <em style="font: inherit;">third</em>-party e-commerce platforms such as Amazon, for the year ended <em style="font: inherit;"> December 31, 2023 </em>was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same <em style="font: inherit;">twelve</em>-month period in <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Sales to customers in the U.S. were approximately 93% and 99% for the year ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively, with the balance of sales to customers primarily in Canada.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has <em style="font: inherit;">not</em> experienced any significant payment delays from customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For direct-to-consumer sales, the Company allows for returns within <em style="font: inherit;">30</em> days of purchase. Our wholesale customers, such as GNC, <em style="font: inherit;"> may </em>return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A right of return does <em style="font: inherit;">not</em> represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will <em style="font: inherit;">not</em> cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Customer and Vendor Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Total net sales to GNC during <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> were 33% and 67 % of total revenue for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively. Accounts receivable attributable to GNC as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> represented 30% and 43% of the Company’s total accounts receivable balance, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> there was <span style="-sec-ix-hidden:c109746644"><span style="-sec-ix-hidden:c109747028">one</span></span> vendor who accounted for 51% and 78% of the Company's consolidated accounts payable, respectively. For the year ended <em style="font: inherit;"> December 31, 2023, </em>there were <span style="-sec-ix-hidden:c109746647">three</span> vendors who accounted for 37%, 30%, and 10% of the Company's inventory-related purchases. For the year ended <em style="font: inherit;"> December 31, 2022, </em>there were <span style="-sec-ix-hidden:c109746651">two</span> vendors who accounted for 49% and 18% of the Company's inventory-related purchases, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Accounts Receivable and Allowance for Doubtful Accounts</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do <em style="font: inherit;">not</em> bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts, estimating losses resulting from the inability of its customers to make required payments for products. Accounts with known financial issues are <em style="font: inherit;">first</em> reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped into categories by the number of days the balance is past due, and the estimated loss is recorded based upon management’s assessment of collectability. Account balances are charged off against the allowance when it is probable that the receivable will <em style="font: inherit;">not</em> be recovered.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> the Company had provided a reserve for doubtful accounts of $17 and $50, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Product Returns, Sales Incentives and Other Forms of Variable Consideration</i> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include, but are <em style="font: inherit;">not</em> limited to, product returns and sales incentives, such as markdowns and margin adjustments. For these types of arrangements, the adjustments to revenue are recorded at the later of when (i) the Company recognizes revenue for the transfer of the related products to the customers, or (ii) the Company pays, or promises to pay, the consideration.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We currently have a <em style="font: inherit;">30</em>-day product return policy for direct-to-consumer sales, which allows for a <em style="font: inherit;">100%</em> sales price refund for the return of unopened and undamaged products purchased from us online through <em style="font: inherit;">one</em> of our websites or e-commerce platforms. Product sold to certain wholesale customers <em style="font: inherit;"> may </em>be returned from store shelves or the distribution center in the event product is damaged, short dated, expired or recalled.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GNC maintains a customer satisfaction program which allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC <em style="font: inherit;"> may </em>require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the sale of goods with a right of return, the Company estimates variable consideration using the most likely amount method and recognizes revenue for the consideration it expects to be entitled to when control of the related product is transferred to the customers and records a product returns liability for the amount it expects to credit back its customers. Under this method, certain forms of variable consideration are based on expected sell-through results, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. The product returns liability includes estimates that directly impact reported revenue. These estimates are calculated based on a history of actual returns, estimated future returns and information provided by customers regarding their inventory levels. Consideration of these factors results in an estimate for anticipated sales returns that reflects increases or decreases related to seasonal fluctuations. In addition, as necessary, product returns liability <em style="font: inherit;"> may </em>be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include, but are <em style="font: inherit;">not</em> limited to, changes in the retail environment and the Company's decision to continue to support new and existing products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Information for product returns is received on a regular basis and adjusted for accordingly. Adjustments for returns are based on factual information and historical trends for Company products and are specific to each distribution channel. We monitor, among other things, remaining shelf life and sell-through data on a weekly basis. If we determine there are any risks or issues with any specific products, we accrue sales return allowances based on management’s assessment of the overall risk and likelihood of returns in light of all information available.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total allowance for product returns, sales returns and incentive programs as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> amounted to $571 and $590, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Cost of Goods Sold</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Cost of goods sold is comprised of the costs of products, in-bound freight charges, shipping and handling costs, purchase and receiving costs, and commissions paid to Amazon and other online selling platforms. Other expense <em style="font: inherit;">not</em> related to the production and distribution of our products is classified as operating expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i></i></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Cash, Cash Equivalents, and Restricted Cash</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s cash balances on deposit with banks are guaranteed by the Federal Deposit Insurance Corporation up to $250 at <em style="font: inherit;"> December 31, 2023. </em>The Company <em style="font: inherit;"> may </em>be exposed to risk for the amounts of funds held in bank accounts more than the insurance limit. In assessing the risk, the Company’s policy is to maintain cash balances with high-quality financial institutions. The Company had cash balances more than the guarantee during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em> Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Restricted cash consists of cash on deposit with a financial institution in an interest-bearing account pursuant to a credit card agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Inventory</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventory is stated at the lower of cost or net realizable value, with costs determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (FIFO) basis. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand and/or our ability to sell the product(s) concerned and production requirements. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market conditions or other factors, which <em style="font: inherit;"> may </em>result in cancellations of advance orders or a reduction in the rate of reorders placed by customers. Additionally, our management’s estimates of future product demand <em style="font: inherit;"> may </em>be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> the aggregate allowance for expiring, slow moving and excess inventory amounted to $162 and $107, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accounts for its leases in accordance with the guidance of ASC <em style="font: inherit;">842,</em> <i>Leases</i>. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method. The Company amortizes leasehold improvements over the estimated life of these assets or the term of the lease, whichever is shorter. When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and proceeds realized. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The range of estimated useful lives used to calculate depreciation for principal items of property and equipment are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset category</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Depreciation / Amortization period (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Furniture and fixtures</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Office equipment</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Leasehold improvements</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management regularly reviews property, equipment and other long-lived assets for possible impairment. This review occurs annually or more frequently if events or changes in circumstances indicate the carrying amount of the asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Based upon management’s annual assessment, there were <em style="font: inherit;">no</em> indicators of impairment of the Company’s property and equipment and other long-lived assets as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Intangible and Long-lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Intangible assets are recorded at cost and amortized using the straight-line method over their estimated useful lives. The Company regularly reviews the carrying value and estimated lives of its long-lived assets and intangible assets to determine whether indicators of impairment <em style="font: inherit;"> may </em>exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There were <em style="font: inherit;">no</em> impairment charges incurred during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Goodwill</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test.  The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company <em style="font: inherit;">first</em> assesses qualitative factors to determine whether it is more-likely-than-<em style="font: inherit;">not</em> that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach.  The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As the Company uses the market approach to determine fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There were <em style="font: inherit;">no</em> impairment charges incurred during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Acquisitions and Business Combinations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are <em style="font: inherit;">not</em> limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results <em style="font: inherit;"> may </em>differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, <em style="font: inherit;">not</em> to exceed <em style="font: inherit;">one</em> year from the acquisition date, we <em style="font: inherit;"> may </em>record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company accounts for income taxes under FASB ASC Topic <em style="font: inherit;">740,</em> <i>Income Taxes</i> (“<i>ASC <em style="font: inherit;">740</em></i>”). Under the asset and liability method of ASC <em style="font: inherit;">740,</em> deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax assets of the Company relate primarily to operating loss carryforwards for federal income tax purposes.  The deferred tax liabilities of the Company relate primarily to intangible assets that are <em style="font: inherit;">not</em> deductible for tax purposes in the jurisdictions to which they relate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company periodically evaluates its tax positions to determine whether it is more likely than <em style="font: inherit;">not</em> that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. The Company accrues interest and penalties, if incurred, on unrecognized tax benefits as components of the income tax provision in the accompanying consolidated statements of income and comprehensive income. As of <em style="font: inherit;"> December 31, 2023, </em>and <em style="font: inherit;">2022,</em> the Company has <em style="font: inherit;">not</em> established a liability for uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Net Income Per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic and diluted weighted-average shares outstanding and antidilutive options that were excluded from diluted weighted average shares outstanding are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,553</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive effect of potential common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,905</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Antidilutive options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Fair Value Measurements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic <em style="font: inherit;">820,</em> <i>Fair Value</i>, establishes a <em style="font: inherit;">three</em>-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">1</em> – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">2</em> – Inputs other than quoted prices included within Level <em style="font: inherit;">1</em> that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are <em style="font: inherit;">not</em> active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">3</em> – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and <em style="font: inherit;"> may </em>include the Company’s own data.</p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of its notes payable approximate their fair value based on the market interest rates of these notes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock Compensation Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company periodically issues restricted share units (“<i>RSUs</i>”), stock options and warrants to employees and non-employees in non-capital raising transactions for services rendered.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Such issuances vest and expire according to the terms established at the issuance date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Stock-based payments to officers, directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC <em style="font: inherit;">718,</em> <i>Compensation-Stock Compensation</i>. Stock-based payments to officers, directors, and employees, which are generally time vested, are measured at the grant date fair value and compensation cost is recognized on a straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock-based payments is estimated using the Black-Scholes option-pricing model or other applicable valuation model such as the Monte Carlo valuation pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used could materially affect compensation expense recorded in future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates in <span style="-sec-ix-hidden:c109746715">one</span> segment for the distribution of our products.  In accordance with FASB ASC Topic <em style="font: inherit;">280,</em> <i>Segment Reporting</i>, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.  Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue.  All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.  Since the Company operates in <span style="-sec-ix-hidden:c109746717">one</span> segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments </i>–<i> Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i> (“<i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em></i>”). The amendments included in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Although the new standard, known as the current expected credit loss (“<i>CECL</i>”) model, has a greater impact on financial institutions, most other organizations with financial instruments or other assets (trade receivables, contract assets, lease receivables, financial guarantees, loans and loan commitments, and held-to-maturity debt securities) are subject to the CECL model and will need to use forward-looking information to better evaluate their credit loss estimates. Many of the loss estimation techniques applied today will still be permitted, although the inputs to those techniques will change to reflect the full amount of expected credit losses. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> was originally effective for public companies for fiscal years beginning after <em style="font: inherit;"> December 15, 2019. </em>In <em style="font: inherit;"> November </em>of <em style="font: inherit;">2019,</em> the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> which delayed the implementation of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to fiscal years beginning after <em style="font: inherit;"> December 15, 2022 </em>for smaller reporting companies. The Company has adopted this guidance beginning <em style="font: inherit;"> January 1, 2023. </em>This guidance did <em style="font: inherit;">not</em> have a significant impact on the Company’s financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> September 2022, </em>the FASB issued ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">04,</em> Liabilities-Supplier Finance Programs (Subtopic <em style="font: inherit;">405</em>-<em style="font: inherit;">50</em>): Disclosure of Supplier Finance Program Obligations. The ASU requires buyers to disclose information about their supplier finance programs. Interim and annual requirements include the disclosure of outstanding amounts under the obligations as of the end of the reporting period, and annual requirements include a roll-forward of those obligations for the annual reporting period, as well as a description of payment and other key terms of the programs. This update is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023. </em>The Company adopted ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">04</em> on <em style="font: inherit;"> January 1, 2023, </em>and there was <em style="font: inherit;">no</em> material impact on our financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosure</i>, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC <em style="font: inherit;">280,</em> <i>Segment Reporting</i>, including the significant segment expense disclosures. This standard will be effective for the Company on <em style="font: inherit;"> January 1, 2024 </em>and interim periods beginning in fiscal year <em style="font: inherit;">2025,</em> with early adoption permitted. The updates required by this standard should be applied retrospectively to all periods presented in the financial statements. The Company does <em style="font: inherit;">not</em> expect this standard to have a material impact on its results of operations, financial position or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in the consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Foreign Currency Translation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The functional currency of the Company is the U.S. dollar.  The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar.  The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Use of Estimates and Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accounts for revenue in accordance with FASB ASC <em style="font: inherit;">606.</em> The underlying principle of ASC <em style="font: inherit;">606</em> is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC <em style="font: inherit;">606</em> creates a <em style="font: inherit;">five</em>-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (<em style="font: inherit;">1</em>) identifying the contract(s) or agreement(s) with a customer, (<em style="font: inherit;">2</em>) identifying our performance obligations in the contract or agreement, (<em style="font: inherit;">3</em>) determining the transaction price, (<em style="font: inherit;">4</em>) allocating the transaction price to the separate performance obligations, and (<em style="font: inherit;">5</em>) recognizing revenue as each performance obligation is satisfied. Under ASC <em style="font: inherit;">606,</em> revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are <em style="font: inherit;">no</em> performance obligations required post-shipment for customers to derive the expected value from them.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company’s products are also sold on e-commerce platforms including Amazon.  For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to <em style="font: inherit;">third</em>-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the consolidated statements of income and comprehensive income. Distribution and platform fees are <em style="font: inherit;">not</em> recorded as a reduction of revenue because the Company: <em style="font: inherit;">1</em>) owns the goods before they are transferred to the customer,   <em style="font: inherit;">2</em>) can direct Amazon, similar to other <em style="font: inherit;">third</em>-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, <em style="font: inherit;">3</em>) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, <em style="font: inherit;">4</em>) is subject to credit risk (i.e., credit card chargebacks), <em style="font: inherit;">5</em>) establishes prices of its products, <em style="font: inherit;">6</em>) can determine who fulfills the goods to the customer (Amazon or the Company) and <em style="font: inherit;">7</em>) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in selling, general and administrative expense in the consolidated statements of income and comprehensive income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company disaggregates revenue into geographical regions and distribution channels.  The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as <em style="font: inherit;">third</em>-party e-commerce platforms such as Amazon, for the year ended <em style="font: inherit;"> December 31, 2023 </em>was approximately 63% of total revenue, compared to roughly 28% of total revenue during the same <em style="font: inherit;">twelve</em>-month period in <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Sales to customers in the U.S. were approximately 93% and 99% for the year ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively, with the balance of sales to customers primarily in Canada.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has <em style="font: inherit;">not</em> experienced any significant payment delays from customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For direct-to-consumer sales, the Company allows for returns within <em style="font: inherit;">30</em> days of purchase. Our wholesale customers, such as GNC, <em style="font: inherit;"> may </em>return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A right of return does <em style="font: inherit;">not</em> represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that product returns are immaterial, and therefore believes it is probable that such returns will <em style="font: inherit;">not</em> cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.63 0.28 0.93 0.99 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Customer and Vendor Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Total net sales to GNC during <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> were 33% and 67 % of total revenue for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively. Accounts receivable attributable to GNC as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> represented 30% and 43% of the Company’s total accounts receivable balance, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> there was <span style="-sec-ix-hidden:c109746644"><span style="-sec-ix-hidden:c109747028">one</span></span> vendor who accounted for 51% and 78% of the Company's consolidated accounts payable, respectively. For the year ended <em style="font: inherit;"> December 31, 2023, </em>there were <span style="-sec-ix-hidden:c109746647">three</span> vendors who accounted for 37%, 30%, and 10% of the Company's inventory-related purchases. For the year ended <em style="font: inherit;"> December 31, 2022, </em>there were <span style="-sec-ix-hidden:c109746651">two</span> vendors who accounted for 49% and 18% of the Company's inventory-related purchases, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.33 0.67 0.30 0.43 0.51 0.78 0.37 0.30 0.10 0.49 0.18 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Accounts Receivable and Allowance for Doubtful Accounts</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do <em style="font: inherit;">not</em> bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts, estimating losses resulting from the inability of its customers to make required payments for products. Accounts with known financial issues are <em style="font: inherit;">first</em> reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped into categories by the number of days the balance is past due, and the estimated loss is recorded based upon management’s assessment of collectability. Account balances are charged off against the allowance when it is probable that the receivable will <em style="font: inherit;">not</em> be recovered.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> the Company had provided a reserve for doubtful accounts of $17 and $50, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 17000 50000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Product Returns, Sales Incentives and Other Forms of Variable Consideration</i> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include, but are <em style="font: inherit;">not</em> limited to, product returns and sales incentives, such as markdowns and margin adjustments. For these types of arrangements, the adjustments to revenue are recorded at the later of when (i) the Company recognizes revenue for the transfer of the related products to the customers, or (ii) the Company pays, or promises to pay, the consideration.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We currently have a <em style="font: inherit;">30</em>-day product return policy for direct-to-consumer sales, which allows for a <em style="font: inherit;">100%</em> sales price refund for the return of unopened and undamaged products purchased from us online through <em style="font: inherit;">one</em> of our websites or e-commerce platforms. Product sold to certain wholesale customers <em style="font: inherit;"> may </em>be returned from store shelves or the distribution center in the event product is damaged, short dated, expired or recalled.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">GNC maintains a customer satisfaction program which allows customers to return product to the store for credit or refund. Subject to certain terms and restrictions, GNC <em style="font: inherit;"> may </em>require reimbursement from vendors for unsaleable returned product through either direct payment or credit against a future invoice. We also support a product return policy for iSatori Products, whereby customers can return product for credit or refund. Product returns can and do occur from time to time and can be material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the sale of goods with a right of return, the Company estimates variable consideration using the most likely amount method and recognizes revenue for the consideration it expects to be entitled to when control of the related product is transferred to the customers and records a product returns liability for the amount it expects to credit back its customers. Under this method, certain forms of variable consideration are based on expected sell-through results, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. The product returns liability includes estimates that directly impact reported revenue. These estimates are calculated based on a history of actual returns, estimated future returns and information provided by customers regarding their inventory levels. Consideration of these factors results in an estimate for anticipated sales returns that reflects increases or decreases related to seasonal fluctuations. In addition, as necessary, product returns liability <em style="font: inherit;"> may </em>be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include, but are <em style="font: inherit;">not</em> limited to, changes in the retail environment and the Company's decision to continue to support new and existing products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Information for product returns is received on a regular basis and adjusted for accordingly. Adjustments for returns are based on factual information and historical trends for Company products and are specific to each distribution channel. We monitor, among other things, remaining shelf life and sell-through data on a weekly basis. If we determine there are any risks or issues with any specific products, we accrue sales return allowances based on management’s assessment of the overall risk and likelihood of returns in light of all information available.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total allowance for product returns, sales returns and incentive programs as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> amounted to $571 and $590, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 571000 590000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Cost of Goods Sold</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Cost of goods sold is comprised of the costs of products, in-bound freight charges, shipping and handling costs, purchase and receiving costs, and commissions paid to Amazon and other online selling platforms. Other expense <em style="font: inherit;">not</em> related to the production and distribution of our products is classified as operating expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Cash, Cash Equivalents, and Restricted Cash</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s cash balances on deposit with banks are guaranteed by the Federal Deposit Insurance Corporation up to $250 at <em style="font: inherit;"> December 31, 2023. </em>The Company <em style="font: inherit;"> may </em>be exposed to risk for the amounts of funds held in bank accounts more than the insurance limit. In assessing the risk, the Company’s policy is to maintain cash balances with high-quality financial institutions. The Company had cash balances more than the guarantee during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em> Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Restricted cash consists of cash on deposit with a financial institution in an interest-bearing account pursuant to a credit card agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 250000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Inventory</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventory is stated at the lower of cost or net realizable value, with costs determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (FIFO) basis. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand and/or our ability to sell the product(s) concerned and production requirements. Demand for our products can fluctuate significantly. Factors that could affect demand for our products include unanticipated changes in consumer preferences, general market conditions or other factors, which <em style="font: inherit;"> may </em>result in cancellations of advance orders or a reduction in the rate of reorders placed by customers. Additionally, our management’s estimates of future product demand <em style="font: inherit;"> may </em>be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> the aggregate allowance for expiring, slow moving and excess inventory amounted to $162 and $107, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 162000 107000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accounts for its leases in accordance with the guidance of ASC <em style="font: inherit;">842,</em> <i>Leases</i>. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method. The Company amortizes leasehold improvements over the estimated life of these assets or the term of the lease, whichever is shorter. When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and proceeds realized. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The range of estimated useful lives used to calculate depreciation for principal items of property and equipment are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset category</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Depreciation / Amortization period (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Furniture and fixtures</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Office equipment</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Leasehold improvements</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management regularly reviews property, equipment and other long-lived assets for possible impairment. This review occurs annually or more frequently if events or changes in circumstances indicate the carrying amount of the asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Based upon management’s annual assessment, there were <em style="font: inherit;">no</em> indicators of impairment of the Company’s property and equipment and other long-lived assets as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset category</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Depreciation / Amortization period (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Furniture and fixtures</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Office equipment</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Leasehold improvements</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 50%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> P3Y P3Y P5Y <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Intangible and Long-lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Intangible assets are recorded at cost and amortized using the straight-line method over their estimated useful lives. The Company regularly reviews the carrying value and estimated lives of its long-lived assets and intangible assets to determine whether indicators of impairment <em style="font: inherit;"> may </em>exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There were <em style="font: inherit;">no</em> impairment charges incurred during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Goodwill</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test.  The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company <em style="font: inherit;">first</em> assesses qualitative factors to determine whether it is more-likely-than-<em style="font: inherit;">not</em> that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach.  The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As the Company uses the market approach to determine fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There were <em style="font: inherit;">no</em> impairment charges incurred during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Acquisitions and Business Combinations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are <em style="font: inherit;">not</em> limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results <em style="font: inherit;"> may </em>differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, <em style="font: inherit;">not</em> to exceed <em style="font: inherit;">one</em> year from the acquisition date, we <em style="font: inherit;"> may </em>record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company accounts for income taxes under FASB ASC Topic <em style="font: inherit;">740,</em> <i>Income Taxes</i> (“<i>ASC <em style="font: inherit;">740</em></i>”). Under the asset and liability method of ASC <em style="font: inherit;">740,</em> deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The deferred tax assets of the Company relate primarily to operating loss carryforwards for federal income tax purposes.  The deferred tax liabilities of the Company relate primarily to intangible assets that are <em style="font: inherit;">not</em> deductible for tax purposes in the jurisdictions to which they relate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company periodically evaluates its tax positions to determine whether it is more likely than <em style="font: inherit;">not</em> that such positions would be sustained upon examination by a tax authority for all open tax years, as defined by the statute of limitations, based on their technical merits. The Company accrues interest and penalties, if incurred, on unrecognized tax benefits as components of the income tax provision in the accompanying consolidated statements of income and comprehensive income. As of <em style="font: inherit;"> December 31, 2023, </em>and <em style="font: inherit;">2022,</em> the Company has <em style="font: inherit;">not</em> established a liability for uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Net Income Per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic and diluted weighted-average shares outstanding and antidilutive options that were excluded from diluted weighted average shares outstanding are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,553</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive effect of potential common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,905</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Antidilutive options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,553</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive effect of potential common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,905</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Antidilutive options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> </tbody></table> 4490 4553 415 422 4905 4975 117 29 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Fair Value Measurements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic <em style="font: inherit;">820,</em> <i>Fair Value</i>, establishes a <em style="font: inherit;">three</em>-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">1</em> – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">2</em> – Inputs other than quoted prices included within Level <em style="font: inherit;">1</em> that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are <em style="font: inherit;">not</em> active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> </td><td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td></tr> <tr style="vertical-align: top;"><td style="width: 36pt;"> </td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">3</em> – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and <em style="font: inherit;"> may </em>include the Company’s own data.</p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, restricted cash, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of its notes payable approximate their fair value based on the market interest rates of these notes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock Compensation Expense</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company periodically issues restricted share units (“<i>RSUs</i>”), stock options and warrants to employees and non-employees in non-capital raising transactions for services rendered.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Such issuances vest and expire according to the terms established at the issuance date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Stock-based payments to officers, directors, employees and consultants for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC <em style="font: inherit;">718,</em> <i>Compensation-Stock Compensation</i>. Stock-based payments to officers, directors, and employees, which are generally time vested, are measured at the grant date fair value and compensation cost is recognized on a straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock-based payments is estimated using the Black-Scholes option-pricing model or other applicable valuation model such as the Monte Carlo valuation pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used could materially affect compensation expense recorded in future periods.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates in <span style="-sec-ix-hidden:c109746715">one</span> segment for the distribution of our products.  In accordance with FASB ASC Topic <em style="font: inherit;">280,</em> <i>Segment Reporting</i>, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.  Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue.  All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes.  Since the Company operates in <span style="-sec-ix-hidden:c109746717">one</span> segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments </i>–<i> Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i> (“<i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em></i>”). The amendments included in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Although the new standard, known as the current expected credit loss (“<i>CECL</i>”) model, has a greater impact on financial institutions, most other organizations with financial instruments or other assets (trade receivables, contract assets, lease receivables, financial guarantees, loans and loan commitments, and held-to-maturity debt securities) are subject to the CECL model and will need to use forward-looking information to better evaluate their credit loss estimates. Many of the loss estimation techniques applied today will still be permitted, although the inputs to those techniques will change to reflect the full amount of expected credit losses. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> was originally effective for public companies for fiscal years beginning after <em style="font: inherit;"> December 15, 2019. </em>In <em style="font: inherit;"> November </em>of <em style="font: inherit;">2019,</em> the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> which delayed the implementation of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to fiscal years beginning after <em style="font: inherit;"> December 15, 2022 </em>for smaller reporting companies. The Company has adopted this guidance beginning <em style="font: inherit;"> January 1, 2023. </em>This guidance did <em style="font: inherit;">not</em> have a significant impact on the Company’s financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> September 2022, </em>the FASB issued ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">04,</em> Liabilities-Supplier Finance Programs (Subtopic <em style="font: inherit;">405</em>-<em style="font: inherit;">50</em>): Disclosure of Supplier Finance Program Obligations. The ASU requires buyers to disclose information about their supplier finance programs. Interim and annual requirements include the disclosure of outstanding amounts under the obligations as of the end of the reporting period, and annual requirements include a roll-forward of those obligations for the annual reporting period, as well as a description of payment and other key terms of the programs. This update is effective for annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and interim periods within those fiscal years, except for the requirement to disclose roll-forward information, which is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023. </em>The Company adopted ASU <em style="font: inherit;">2022</em>-<em style="font: inherit;">04</em> on <em style="font: inherit;"> January 1, 2023, </em>and there was <em style="font: inherit;">no</em> material impact on our financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> <i>Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosure</i>, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC <em style="font: inherit;">280,</em> <i>Segment Reporting</i>, including the significant segment expense disclosures. This standard will be effective for the Company on <em style="font: inherit;"> January 1, 2024 </em>and interim periods beginning in fiscal year <em style="font: inherit;">2025,</em> with early adoption permitted. The updates required by this standard should be applied retrospectively to all periods presented in the financial statements. The Company does <em style="font: inherit;">not</em> expect this standard to have a material impact on its results of operations, financial position or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">3.</em> INTANGIBLE ASSETS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Intangible assets are amortized on a straight-line basis over their estimated useful lives.  The following table sets forth the components of the identifiable intangible assets acquired and their estimated useful lives as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>As of December 31, 2023</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amortization </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net book </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Useful life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Brands</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><i><em style="font: inherit;">Indefinite</em></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Client relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Formulations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trademarks</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><i><i><em style="font: inherit;">Indefinite</em></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Website</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total identifiable assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>As of December 31, 2022</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amortization </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net book </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Useful life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Client relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">46</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Formulations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trademarks</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><i><i><i><em style="font: inherit;">Indefinite</em></i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Website</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total identifiable assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Amortization expense was $42 for the years ended <em style="font: inherit;"> December 31, 2023 </em>and<i> </i><em style="font: inherit;">2022</em><i>.</i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>As of December 31, 2023</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amortization </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net book </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Useful life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Brands</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,201</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><i><em style="font: inherit;">Indefinite</em></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Client relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Formulations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trademarks</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><i><i><em style="font: inherit;">Indefinite</em></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Website</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total identifiable assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>As of December 31, 2022</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>amortization </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net book </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>value</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Useful life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Client relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">46</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Formulations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trademarks</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><i><i><i><em style="font: inherit;">Indefinite</em></i></i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Website</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total identifiable assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 26201000 -0 26201000 80000 55000 25000 P4Y 70000 48000 22000 P4Y 60000 -0 60000 11000 10000 1000 P3Y 26422000 113000 26309000 80000 34000 46000 P4Y 70000 30000 40000 P4Y 60000 -0 60000 11000 7000 4000 P3Y 221000 71000 150000 42000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE <em style="font: inherit;">4.</em></b>  <b>INVENTORIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s inventories as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,292</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Components</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">961</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">865</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for obsolescence</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(162</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(107</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,292</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Components</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">961</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">865</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for obsolescence</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(162</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(107</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,105</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 8292000 8347000 961000 865000 162000 107000 9091000 9105000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">5.</em></b>  <b>PROPERTY AND EQUIPMENT</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company's property and equipment balances as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">951</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">902</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(856</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">137</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Depreciation expense for property and equipment was $52 for the year ended <em style="font: inherit;"> December 31, 2023 </em>compared to $24 for the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">951</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">902</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(814</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(856</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">137</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 951000 902000 814000 856000 137000 46000 52000 24000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">6.</em></b>  <b>NOTES PAYABLE</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Notes payable consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Term loan A (<span style="-sec-ix-hidden:c109747039">8.21</span>% as of December 31, 2023)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Term loan B (<span style="-sec-ix-hidden:c109747041">8.21</span>% as of December 31, 2023)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unamortized debt issuance costs</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,009</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Current</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Long Term</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,509</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Credit Agreements </i>–<i> First Citizens Bank</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> February 23, 2023, </em>the Company entered into an Amended and Restated Credit Agreement (the “<i>Credit Agreement</i>”) with First Citizens Bank (the “<i>Bank</i>”), amending and restating that certain Credit Agreement, dated <em style="font: inherit;"> September 24, 2019, </em>between the Company and the Bank. Pursuant to the Previous Credit Agreement, the Bank provided the Company with a term loan for the principal amount of $12,500 (“<i>Term Loan A</i>”), and a revolving line of credit of $3,500 (the “<i>Line of Credit</i>”, and collectively with the Term Loans, the “<i>Loan</i>”). The Company used the proceeds from the Loan to fund the acquisition of MRC and for general working capital purposes, including those of MRC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Second Amended and Restated Credit Agreement</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> October 10, 2023, </em>the Company entered into a Second Amended and Restated Credit Agreement (the “<i>Amended Credit Agreement</i>”) with the Bank, amending and restating the Credit Agreement, between the Company and the Bank. Pursuant to the Amended Credit Agreement, the Bank provided the Company with an additional Term Loan (“<i>Term Loan B</i>”) for the principal amount of $10,000 and extended the Line of Credit of $3.5 million to <em style="font: inherit;"> December 15, 2024. </em>The Company used the proceeds from the loan to fund the acquisition of assets of MusclePharm (discussed in further detail in Note <em style="font: inherit;">8</em>) and for general working capital purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to the Amended Credit Agreement, the Term Loans accrue interest at a per annum rate equal to 2.75% above the <em style="font: inherit;">one</em>-month secured overnight financing rate published for such day by the Federal Reserve Bank of New York (“<i>Term SOFR Rate</i>”); and the Company shall make payments on <em style="font: inherit;"> March </em><em style="font: inherit;">10th,</em> <em style="font: inherit;"> June </em><em style="font: inherit;">10th,</em> <em style="font: inherit;"> September </em><em style="font: inherit;">10th,</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">10th</em> of each calendar year, of principal plus accrued interest on the Term Loans in amounts sufficient to fully amortize Term Loan A through <em style="font: inherit;"> February 28, 2028 </em>and Term Loan B through <em style="font: inherit;"> October 10, 2028; </em>and outstanding advances under the Line of Credit (“<i>Advances</i>”) will accrue interest at the Applicable Rate and the Company will pay the interest on the Advances monthly, with all principal and any accrued interest on outstanding Advances being due and payable in full on the Line of Credit maturity date. The Company <em style="font: inherit;"> may </em>prepay amounts borrowed under the Loan, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least <em style="font: inherit;">one</em> business day prior to the proposed prepayment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Agreement contains customary events of default (each an “<i>Event of Default</i>”), which upon the occurrence of an Event of Default, among other things, interest will accrue at the Applicable Rate plus 2% per annum, and the Bank <em style="font: inherit;"> may </em>declare all obligations, with interest thereon, immediately due and payable. The Agreement further contains customary representations and warranties of the Company; customary indemnification provisions whereby the Company will indemnify Bank for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of the Company, and certain other matters; and customary affirmative and negative covenants, including covenants to maintain a Fixed Charge Coverage Ratio (as defined in the Agreement) of <em style="font: inherit;">not</em> less than 1.25 to <em style="font: inherit;">1.00</em> as tested quarterly on a trailing <em style="font: inherit;">twelve</em>-month basis, starting with the fiscal quarter ending <em style="font: inherit;"> December 31, 2023, </em>a Funded Debt to EBITDA Ratio (as defined in the Credit Agreement) of <em style="font: inherit;">not</em> more than 2.50 to <em style="font: inherit;">1.00</em> as tested quarterly on a trailing <em style="font: inherit;">twelve</em>-month basis, starting with the fiscal quarter ending <em style="font: inherit;"> March 31, 2024, </em>and to the extent the Term Loans still have a balance as of <em style="font: inherit;"> June 30, 2025 </em>and a Cash Flow Leverage threshold (as defined in the Agreement) of at least 1.15 is <em style="font: inherit;">not</em> met, the Company will be required to make a prepayment on the Term Loan equal to 50% of the Excess Cash Flow (as defined in the Agreement). The Company was in compliance with all covenants as of <em style="font: inherit;"> December 31, 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2023, </em>the borrowings outstanding on the Term Loans and Line of Credit were $20,125 and $0, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Maturities of the Company's Term Loans are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ending</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total balance outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Term loan A (<span style="-sec-ix-hidden:c109747039">8.21</span>% as of December 31, 2023)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Term loan B (<span style="-sec-ix-hidden:c109747041">8.21</span>% as of December 31, 2023)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unamortized debt issuance costs</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,009</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Current</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Long Term</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,509</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 10625000 0 9500000 0 116000 -0 20009000 0 4500000 -0 15509000 0 12500000 3500000 10000000 3500000 0.0275 0.02 1.25 2.5 1.15 0.50 20125000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ending</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total balance outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 4500000 4500000 4500000 4500000 2125000 20125000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">7.</em></b>  <b>EQUITY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company is authorized to issue 60,000 shares of Common Stock, $0.01 par value per share, of which 4,598 and 4,507 shares of Common Stock were issued and outstanding as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Common Stock Issued for Services</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In <em style="font: inherit;"> February 2021, </em>the Company granted an officer an aggregate of 160 restricted share units (“<i>RSUs</i>”) with a fair value of $468. The Company recorded $31 and $287 of stock compensation expense related to RSUs during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively. As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> there was $0 and $31 of unamortized compensation expense associated with the grant of the RSUs. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Share Repurchase Program</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> August 16, 2019, </em>the Company approved a share repurchase program, pursuant to which the Board authorized management to repurchase up to $500 of the Company's Common Stock over the subsequent 24 months (the "<i>Share Repurchase Program</i>"), as amended <em style="font: inherit;"> September 23, 2019 </em>to increase the repurchase amount to $1, and include shares of the Company's Common Stock, its Series A Convertible Preferred Stock, par value $0.01 per share ("<i>Series A Preferred</i>"), and warrants to purchase shares of the Company's Common Stock ("<i>Warrants</i>") in the Share Repurchase Program, to be repurchased over the next 24 months, at a purchase price, in the case of Common Stock, equal to the fair market value of the Company's Common Stock on the date of purchase, and in the case of Series A Preferred and Warrants, at a purchase price determined by management, with the exact date and amount of such purchases to be determined by management; further amended on <em style="font: inherit;"> November 6, 2019 </em>to increase the repurchase amount to $2,500 over the subsequent 24 months, and further amended on <em style="font: inherit;"> February 1, 2021 </em>to increase the repurchase amount to up to $5,000 over the subsequent 24 months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> March 17, 2023, </em>the Board approved an extension of the Share Repurchase Program. Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $5,000 of the Company's Common Stock over the subsequent <em style="font: inherit;">24</em> months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management. All other terms of the Share Repurchase Program remain unchanged.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company did <span style="-sec-ix-hidden:c109746818">not</span> repurchase any shares of the Company’s Common Stock under the Share Repurchase Program. As of <em style="font: inherit;"> December 31, 2023, </em>the Company <em style="font: inherit;"> may </em>purchase up to $5,000 of additional shares of Common Stock under the Share Repurchase Program.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Treasury Shares</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In <em style="font: inherit;"> January 2022, </em>the Company retired all treasury shares. All shares repurchased by the Company subsequent to <em style="font: inherit;"> January 2022 </em>were retired immediately upon acquisition.  As of <em style="font: inherit;"> December 31, 2023, </em>there are no shares held in treasury.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Information regarding options outstanding as of <em style="font: inherit;"> December 31, 2023 </em>is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35.88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 63%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price per</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>number</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>of options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>life (years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>vested</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.70</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c109746454">-</span></td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">349</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">11.55</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c109746461">-</span></td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">19.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18.56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">359</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The closing price for the Company’s Common Stock on <em style="font: inherit;"> December 29, 2023 </em>was $19.10, resulting in an intrinsic value of outstanding options of $5,155. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company granted stock options to employees to purchase 117 shares of Company Common Stock. The stock options are exercisable at an average price of $19.10 per share, expire in <span style="-sec-ix-hidden:c109746827">five</span> years and primarily vest as follows: <em style="font: inherit;">one</em>-<span style="-sec-ix-hidden:c109746829">third</span> vested immediately upon issuance, and the remainder vest equally in equal annual installments over a period of <em style="font: inherit;">two</em> years from grant date. The total fair value of these options at grant date was approximately $1,014, which was determined using the Black-Scholes option pricing model with the following average assumption: stock price of $19.10 per share, expected term of 5 years, volatility of 45%, dividend rate of 0% and risk-free interest rate of 4.1%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s Common Stock; and the expected dividend yield is based on the fact that the Company has <em style="font: inherit;">not</em> paid dividends in the past and does <em style="font: inherit;">not</em> expect to pay dividends in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>the Company granted stock options to employees to purchase 10 shares of Company Common Stock. The stock options are exercisable at an average price of $15.65 per share, expire in <span style="-sec-ix-hidden:c109746841">five</span> years and vest as follows: <em style="font: inherit;">one</em>-<em style="font: inherit;">fourth</em> vested immediately upon issuance, and the remainder vest equally in equal annual installments over a period of <em style="font: inherit;">three</em> years from grant date. The total fair value of these options at grant date was approximately $90, which was determined using the Black-Scholes option pricing model with the following average assumption: stock price of $15.65 per share, expected term of <span style="-sec-ix-hidden:c109746847">5</span> years, volatility of 67%, dividend rate of 0% and risk-free interest rate of 2.7%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s Common Stock; and the expected dividend yield is based on the fact that the Company has <em style="font: inherit;">not</em> paid dividends in the past and does <em style="font: inherit;">not</em> expect to pay dividends in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company recognized $442 and $76 of stock compensation expense related to the vesting of these options during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively.  As of <em style="font: inherit;"> December 31, 2023, </em>there was $740 of unvested stock compensation that will be recognized as an expense in future periods as the options vest.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2021, </em>143 warrants at an exercise price of $1.15 per share were outstanding. During the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> no warrants were granted and no warrants expired. During the year ended <em style="font: inherit;"> December 31, 2023, </em>143,480 shares of Common Stock were issued for the exercise of all outstanding warrants, resulting in net proceeds to the Company of $165.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Total outstanding warrants to purchase shares of Common Stock as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em><i> </i>amounted to 0 and 143,480, respectively.</p> 60000000 0.01 4598000 4507000 160000 468000 31000 287000 0 31000 500000 P24Y 1000 0.01 P24Y 2500000 P24Y 5000000 P24M 5000000 5000000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35.88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 380000 3.44 P6Y2M12D 10000 15.65 4000 8.27 7000 35.88 379000 3.09 P5Y3M18D 117000 19.1 9000 0.7 3000 30.31 484000 6.82 P4Y6M <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 63%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td colspan="4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price per</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>number</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>of options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>life (years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>vested</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.70</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c109746454">-</span></td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">349</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">317</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">11.55</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c109746461">-</span></td><td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">19.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18.56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">359</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 5.24 349000 P4Y6M 2.3 317000 2.01 19.2 135000 P4Y7M6D 18.56 42000 17.63 484000 P4Y6M 6.82 359000 3.85 19.1 5155000 117000 19.1 1014000 19.1 P5Y 0.45 0 0.041 10000 15.65 90000 15.65 0.67 0 0.027 442000 76000 740000 143000 1.15 0 0 143480000 165000 0 143480000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">8.</em> ACQUISITION OF MIMI</b>’<b>S ROCK CORP</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 4, 2022, </em>the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“<i>MRC</i>”), pursuant to which the Company agreed to acquire all of the equity interests of MRC. The acquisition closed on <em style="font: inherit;"> February 28, 2023. </em>MRC is headquartered in Oakville, Ontario, Canada. The purchase price of $17,099 was paid with proceeds from the Term Loan as well as cash on hand. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> the Company incurred $1,570 and $225, respectively, of transaction-related costs for the acquisition of MRC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accounted for the acquisition as a business combination under Accounting Standards Codification (“<i>ASC</i>”) <em style="font: inherit;">805,</em> Business Combinations. The following table summarizes the allocation of the purchase price based on the fair value of the assets acquired and liabilities assumed on the date of acquisition:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>February 28, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets acquired:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expense and other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sales tax receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">862</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable and accrued expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Income tax payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(651</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Product returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(111</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,444</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net assets acquired</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,099</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The purchase was intended to augment and diversify the Company’s product offerings and lineup.  Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Pro Forma Condensed Combined Financial Information (Unaudited) (In thousands)</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following presents the Company’s unaudited pro forma financial information for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively, giving effect to the acquisition of MRC as if it had occurred at <em style="font: inherit;"> January 1, 2022. </em>Included in the pro forma information is: fair value adjustment to inventory acquired during the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> removal of transaction-related costs related to the acquisition of MRC, removal of the interest costs from MRC’s debt prior to the closing of the acquisition, and interest on borrowings made by the Company based on the projected balance of the Term Loan for the respective periods presented in this pro forma.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ended</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ended</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,076</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted net income per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The pro forma adjustments do <em style="font: inherit;">not</em> reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does <em style="font: inherit;">not</em> purport to present what the Company’s results would actually have been had the transaction actually occurred on the dates presented or to project the combined company’s results of operations or financial position for any future period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">MRC revenue and net income for the period from <em style="font: inherit;"> February 28, 2023 </em>to <em style="font: inherit;"> December 31, 2023 </em>was $24,370 and $1,975, respectively.</p> 17099000 1570000 225000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>February 28, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets acquired:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expense and other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sales tax receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">862</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable and accrued expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Income tax payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(651</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Product returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(111</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,444</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net assets acquired</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,099</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 250000 1166000 220000 862000 98000 32000 7630000 12764000 2694000 651000 23000 111000 2444000 17099000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ended</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ended</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,076</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Diluted net income per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 57755000 58457000 7076000 4564000 1470 920 24370000 1975000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">9.</em> ACQUISITION OF MUSCLEPHARM </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> October 10, 2023, </em>the Company acquired substantially all of the assets and assumed <em style="font: inherit;">none</em> of the liabilities other than <i>de</i> <i>minimus</i> cure costs relating to certain assumed contracts of MusclePharm Corporation (“<i>MusclePharm</i>”) through an asset purchase transaction under Section <em style="font: inherit;">363</em> of the U.S. Bankruptcy Code. Total consideration for the acquisition, including legal costs, amounted to $18,788.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company accounted for the transaction as an asset acquisition under Accounting Standards Codification (“<i>ASC</i>”) <em style="font: inherit;">805.</em> The assets acquired consist of indefinite life intellectual property – brands with an estimated value of $18,593 – and inventory of $195.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 18788000 18593000 195000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">10.</em></b> <b> INCOME TAXES</b></p> <div> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Components of the total provision for income taxes are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year ended </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year ended </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Current tax expense (benefit)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax expense (benefit)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,194</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Provision for income taxes</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company is subject to income tax in the U.S., Canada, Germany and Barbados through its wholly owned subsidiaries.  The combined statutory tax rate is 22% (24% in <em style="font: inherit;">2022</em>)</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The provision for income taxes differs from the amount determined by applying the federal statutory rate as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-tax net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income taxes based on statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase (decrease) resulting from:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-deductible expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Difference in jurisdictional tax rates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">True up of prior period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Provision for income taxes</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The tax effects of significant temporary differences and credit and operating loss carryforwards that give rise to the net deferred tax assets and tax liabilities are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets (liabilities)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss carry forwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,097</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,540</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Provisions and reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">157</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">193</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets (liabilities)</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,384</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(4,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(537</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net deferred tax asset (liability)</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has assessed the realizability of the net deferred tax assets by considering the relevant positive and negative evidence available to determine whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized. In making such a determination, the Company considered all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and recent results of operations.</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Deferred income taxes have <em style="font: inherit;">not</em> been recorded on the basis differences for investments in consolidated subsidiaries as these basis differences are indefinitely reinvested or will reverse in a non-taxable manner. Quantification of the deferred income tax liability, if any, associated with indefinitely reinvested basis differences is <em style="font: inherit;">not</em> practicable.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2023, </em>the Company has the following U.S. federal losses carried forward. U.S. federal losses incurred prior to <em style="font: inherit;">2018</em> have a carry forward of <em style="font: inherit;">20</em> years, subsequent losses can be carried forward indefinitely. The Canadian non-capital loss carry forwards expire between <em style="font: inherit;">2037</em> and <em style="font: inherit;">2043.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">U.S. Federal</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Canada (USD)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2034</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2035</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2036</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2037</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2038</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,224</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2043</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Indefinite</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Utilization of net operating loss carry forwards <em style="font: inherit;"> may </em>be subject to limitations in the event of a change in ownership as defined under U.S. IRC Section <em style="font: inherit;">382,</em> and similar state provisions. An "ownership change" is generally defined as a cumulative change in the ownership interest of significant stockholders of more than <em style="font: inherit;">50</em> percentage points over a <em style="font: inherit;">three</em>-year period. Such ownership change could result in a limitation of the Company's ability to reduce future income by net operating loss carry forwards. The Company acquired a subsidiary in <em style="font: inherit;">2015.</em></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company operates in a number of tax jurisdictions and is subject to examination of its income tax returns by tax authorities in those jurisdictions who <em style="font: inherit;"> may </em>challenge any item on these returns. Because the tax matters challenged by tax authorities are typically complex, the ultimate outcome of these challenges is uncertain. The Company recognizes the effects of uncertain tax positions in the consolidated financial statements after determining that it is more-likely-than-<span style="-sec-ix-hidden:c109746909">not</span> the uncertain tax positions will be sustained.  As of <em style="font: inherit;"> December 31, 2023, </em>the Company has <span style="-sec-ix-hidden:c109746910">not</span> recorded any uncertain tax positions or any accrued interest and penalties on the consolidated balance sheet. During the year ended <em style="font: inherit;"> December 31, 2023, </em>the Company did <em style="font: inherit;">not</em> record any interest and penalties in the consolidated statement of income and comprehensive income.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> </div> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year ended </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year ended </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Current tax expense (benefit)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">755</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax expense (benefit)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,194</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Provision for income taxes</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> -77000 199000 755000 0 1056000 1194000 -27000 0 1707000 1393000 0.22 0.24 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-tax net income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income taxes based on statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,562</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase (decrease) resulting from:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-deductible expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Difference in jurisdictional tax rates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">True up of prior period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Provision for income taxes</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 7003000 5822000 0.223 0.24 1562000 1397000 28000 0 128000 0 -86000 0 75000 -4000 1707000 1393000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2023</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets (liabilities)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss carry forwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,097</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,540</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Provisions and reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">157</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">193</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets (liabilities)</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,384</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(4,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(537</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net deferred tax asset (liability)</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 5097000 2034000 25000 -0 2540000 -0 490000 157000 1000 193000 3023000 2384000 4644000 537000 1621000 1847000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">U.S. Federal</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Canada (USD)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2034</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2035</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2036</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2037</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2038</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,224</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2043</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Indefinite</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 101000 0 101000 950000 0 950000 2923000 0 2923000 0 20000 20000 615000 3224000 3839000 0 2875000 2875000 0 2215000 2215000 0 1838000 1838000 0 4350000 4350000 0 1079000 1079000 0 0 0 4589000 15601000 20190000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">11.</em> COMMITMENTS AND CONTINGENCIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are currently <em style="font: inherit;">not</em> involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is <em style="font: inherit;">no</em> action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">12.</em></b> <b> SUBSEQUENT EVENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Subsequent to the end of <em style="font: inherit;">2023,</em> the Company made a scheduled amortization payment of $1,100 on its term loans as well as a voluntary payment of $2,500 on its Term Loan A.</p> 1100000 2500000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">13.</em> RECLASSIFICATIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Certain prior year amounts have been reclassified to conform to current presentation.  These reclassifications had <em style="font: inherit;">no</em> effect on the reported operating income or net income on the Consolidated Statements of Income and Comprehensive Income.  Certain costs previously classified as selling, general and administrative expense have been reclassified to merger and acquisition related expense on the Consolidated Statements of Income and Comprehensive Income.</p>